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Natural products, compounds synthesized by all kingdoms of life, offer a wealth of 
structural diversity, giving rise to an array of biological activities. For centuries chemists looked 
to nature for the discovery of new medicines. More recently, chemists have begun to employ 
Nature’s tools for complex molecule synthesis in the generation of novel compounds. My thesis 
describes the development of new oxidative biocatalytic methods and application of these methods 
in the synthesis of biologically active molecules.  
Chapter 2 describes the substrate scope and selectivity of three wild type flavin-dependent 
monooxygenases enzymes. Together this enzyme suite provides complementary catalysts for 
asymmetric oxidative dearomatization.  
We have developed a positioning group strategy to overcome substrate scope limitations 
with one of our catalysts, described in Chapter 3. We have engineered substrates to allow for 
improved turnover, thus, enabling access to a wide array of o-quinol containing natural products. 
Pairing experimental data with computational and biophysical characterization of the substrate-
protein interactions further informed our understanding of the role of the positioning group.  
A scalable platform for biocatalytic oxidative dearomatization has been developed 
allowing for gram-scale reactions, described in Chapter 4. We have applied this method in the 
synthesis of a number of natural products in one-pot cascades from simple arene starting materials, 
using oxidative dearomatization as the key synthetic step.  
 xxx 
Chapter 5 describes our work to identify stereocomplementary homologs of these 
monooxygenases which have allowed access to enantiomeric intermediates that can be elaborated 
to various azaphilone natural products. Specifically, the total syntheses of two members, 




CHAPTER 1: Introduction 
 
 
Portions adapted with permission from “Flavin-dependent biocatalysts in synthesis” Tetrahedron 
2019, 75, 1115–1121. 
 
Chapter 1.1: Flavin Biocatalysts in Complex Molecule Synthesis 
Flavin-dependent enzymes are essential in primary metabolism in all kingdoms of life, 
performing a plethora of chemical reactions.1 The versatile flavin cofactor that defines this enzyme 
family is capable of mediating both oxidative and reductive processes depending on the form of 
the cofactor employed.1 Further diversifying the chemistry possible with flavoproteins, Nature has 
evolved flavin-dependent enzymes to carry out specialized chemistry within secondary metabolic 
pathways.2 Chemists have begun to tap into this incredible set of catalysts, exploring the chemistry 
possible with various classes of flavin-dependent enzymes. These endeavors capture the 
advantages and challenges in biocatalytic synthesis. 
Selectivity, tunability, safety and sustainability can motivate chemists to choose 
biocatalytic methods over traditional chemical catalysts and reagents.3 For flavin-dependent 
enzymes, chemo-, site- and stereoselectivity can often be achieved at a higher level or with 
orthogonal selectivity to that attainable with small molecule reagents.4 Mediating oxidation 
reactions with flavin-dependent enzymes presents the opportunity to use molecular oxygen as the 
stoichiometric oxidant, and similarly economical and abundant stoichiometric reductants in 
reductive transformations.1 Additionally, the ability to carry out reactions in water without the 
need for extreme temperatures or a controlled atmosphere adds to the procedural simplicity of 
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biocatalytic chemistry. Despite these advantages, synthetic chemists have been slow to fully 
embrace biocatalysis in preparative-scale synthesis. The barriers to incorporating flavin-dependent 
biocatalysts in a synthetic route can include access to the biocatalyst, limited or unknown substrate 
Figure 1.1: Catalytically active species of flavin (flavin-adenine dinucleotide and flavin mononucleotide) referenced 
in this review. (A) Flox can act as a one or two electron acceptor to afford the semiquinone or reduced flavin (Flred). 
(B) Flred, in the context of ene-reductases, can perform the two-electron reduction of activated olefins. Flred may also 
react with molecular oxygen to form the C4a-peroxy (D) or hydroperoxy flavin (E) which can be the source of an 





scope of an enzyme, or catalyst stability. As the biocatalysis community expands, these obstacles 
are disappearing. More enzymes are commercially available than ever, and the technology for 
evolving proteins to access variants with an altered substrate scope and increased stability has been 
established.5 
Decades of experimental and computational investigation of flavin-dependent enzyme 
mechanisms have provided a framework for understanding the reactions possible from each flavin 
state. Figure 1 illustrates a portion of the flavin states relevant to flavoprotein chemistry.6 Starting 
from the oxidized form of the cofactor flavin-adenine dinucleotide (FAD, 1.1) or flavin 
mononucleotide (FMN, 1.2) addition of a single electron affords the anionic flavin semiquinone 
 
Figure 1.2: Monoamine oxidases (MAOs) in the synthesis of enantio-enriched amines. (A) Dynamic resolution of 
amines using MAO-N variants and a reducing agent. (B) Monoamine oxidase initiated Pictet-Spengler cascade for the 




(1.3). Further one electron reduction of the semiquinone form (1.3) or two electron reduction of 
1.1 or 1.2 provides access to FADH2 (1.5) or FMNH2 (1.6), respectively. NAD(P)H is the most 
common native cofactor used for the reduction of FAD, however this substrate is costly and 
unstable. As such, a number of NAD(P)H recycling systems have been developed for reactions 
which generate FAD from FADH2. This reduced form of the cofactor can engage molecular 
oxygen to form peroxyflavin 1.7, which upon protonation yields hydroperoxyflavin 1.9. The 
protein scaffold and reaction conditions dictate the forms of the cofactor accessible and the 
chemistry that can be carried out in a given system. Presented herein are examples of flavin-
dependent enzymes in organic synthesis. Examples are organized according to the form of the 
flavin cofactor involved in each reaction. 
  
Oxidized flavin (Flox). The oxidized form of the flavin cofactor, FAD or FMN (Flox see 1 and 2), 
can participate in reduction of substrates (Figure 1.1A). In the context of complex molecule 
synthesis, the chemistry of Flox has been most widely exploited in the synthesis of imines from 
amine substrates by monoamine oxidases (MAOs).7 MAOs have been applied to the dynamic 
resolution of racemic amines as outlined in Figure 1.2A.8,9 MAOs are often selective for a single 
enantiomer of the amine substrate, enriching for the enantiomer not oxidized by the biocatalysts. 
Coupling the oxidase with a reducing reagent leads to a dynamic resolution. For example, Turner 
and coworkers have engineered a MAO from Aspergillus niger to create a panel of MAO variants 
with complementary substrate scope.9 By applying both directed evolution and rational design 




The utility of these biocatalysts has been demonstrated through the synthesis of natural 
products as well as enantioenriched precursors to active pharmaceutical ingredients (APIs). 
Notably, a number of enantioenriched alkaloid natural products were obtained through this 
deracemization approach including the neurotoxin (R)-coniine (1.22), plant alkaloid (R)-
leptaflorin (1.28) and anti-Leishmania compound (R)-harmicine (1.27) (Figure 1.2).9 This panel 
of products demonstrate the stereochemical preference of MAO-N variants for the (S)-enantiomer 
of these amine substrates, thus enriching for the (R)-enantiomer of each amine. Further studies 
have demonstrated the potential for MAO-N variants to enrich for the (S)-enantiomer with specific 
substrate classes8 or through protein engineering.9 MAO-mediated deracemization of complex 
amines provides a valuable alternative to traditional approaches, which require asymmetric 
installation of the amine moiety at an earlier stage in the synthesis. In addition to the resolution of 
alkaloid natural products, MAO deracemization has been used to access enantioenriched 
intermediates in the synthesis of amine-containing drugs. Specifically, the MAO-D11 variant can 
discriminate between two similar aryl groups to afford 4-chlorobenzhydrylamine (1.30) in 97% 
ee, which can subsequently be elaborated to the antihistamine drug, levocetirizine (1.31).8 
Similarly, solifenacin precursor (S)-tetrahydroisoquinoline 1.32 can be accessed in 98% ee. by the 
same MAO-N variant.8 Amine oxidases beyond MAO-N have also been explored for synthetic 
applications. For example, enantio-enriched tetrahyroquinolines such as 1.29 can be obtained 
through deracemization with cyclohexylamine oxidase (CHAO).12 MAOs can also be applied 
beyond simple deracemization reactions. For example, MAO-generated iminium ions such as 1.25 
can be intercepted in a Pictet-Spengler type bond forming event (Figure 1.2B),9 and cyclic amines 
can be aromatized using MAOs.13 These are just select examples of the synthetic potential of these 




Figure 1.3: Reactions with ene-reductases. (A) Chemoenzymatic synthesis of amino acid derivatives via an ene-
reductase-catalyzed hydrogenation.21 (B) One-pot three-step cascade to enantioenriched -butyrolactones.22 (C) One-
pot, two-step cascade to generate actinol (1.50).23 
 
FlSQ. Single electron reduction of Flox provides the flavin semiquinone (FlSQ, 1.3, Figure 1.1). FlSQ 
has been extensively studied in a number of flavin-dependent enzymes, including glucose 
oxidase14 and methanol oxidase.15 Despite the accessibility of the flavin radical, there have been 
few reports of synthetic methods that proceed via a single electron mechanism. Recently, Sandoval 
and coworkers reported the ene-reductase mediated radical dehalogenation of -bromo esters.16a 
They propose a mechanism in which reduced flavin (FMNH2, 1.6) performs a single electron 
transfer to the substrate; the resulting flavin semiquinone serves as a hydrogen atom donor to afford 
the dehalogenated products. Following this work, Biegasiewicz and coworkers applied this 
approach to access enantioenriched lactams from unsaturated -halo amides.16b With the 
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groundwork laid by these reports, we anticipate future biocatalytic methods will take advantage of 
radical flavin species.   
 
Flred. Ene-reductases (ERs) are a large class of enzymes characterized by their capacity to reduce 
activated olefins including enones, enals, unsaturated carboxylic acids, esters and cyclic imides.17 
Enantioenriched amino acid derivatives, important polymer precursors, and chiral building blocks 
have been synthesized using ERs as a key synthetic step.17 The Old Yellow Enzyme (OYE) family 
of flavoproteins belong to this class and have been employed in a large number of reaction cascades 
and industrially-relevant processes due to their substrate promiscuity and excellent 
stereoselectivity.18,19 The mechanism of OYEs in the asymmetric reduction of olefins has been 
well-studied,20 and is understood to involve the delivery of a hydride from flavin mononucleotide 
(FMNH2, 1.6) to the -position of the substrate which is coordinated by a strictly conserved 
histidine/asparagine or histidine/histidine pair (Figure 1.3A). To arrive at the product, tyrosine 
protonates the alpha position on the face opposite to the flavin cofactor.20  
 Stueckler and coworkers devised an approach that highlights the utility of this class of 
flavoproteins in the synthesis of stereochemically dense small moleucles.21 They reported a 
chemoenzymatic route to N-acyl amino acid derivatives in which N-acetylamino acrylic esters 
were reduced in modest yields by OYE1-3, YqjM and OPR1 to afford products in 85-95% ee 
(Figure 1.3A, see 1.38-1.40).21 Only terminal olefins (such as 1.35) were productive substrates, as 
compounds with additional substitution of the double bond gave no conversion to the 
corresponding saturated product with any of the enzymes tested. However, one exception to this 
rule was identified; diester 1.36 was converted quantitatively and with perfect stereoselectivity to 
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afford the (S)-isomer of 1.38 by OYE1 and OYE3. Sterically bulky amides were also converted to 
products in good yields and enantioselectivities.  
In 2014, Classen and coworkers reported a chemoenzymatic cascade which afforded access 
to -butyrolactones.22 Employing YqjM, a homolog of OYE involved in E. coli response to 
oxidative stress, substrates such as 1.41 were reduced to generate a substrate which could be 
intercepted by a second enzyme (Figure 1.3B). For example, in a first step, ,-unsaturated 4-oxo-
esters (1.41), which can be accessed through a Wittig olefination of commercially available 
starting materials, undergo a formal anti-addition of hydrogen by enolate reductase to afford anti- 
or syn--ketoester products (see 1.42). Whereas the (E)-isomer typically gives rise to the anti-
product and the (Z)-isomer gives rise to syn-product, this trend did not extend to all cases. Although 
a predictive model for YqjM stereoselectivity has not been reported to date, the authors employed 
deuterium-labeling and docking studies to understand the irregularities in stereoselectivity. 
Substrate activation occurs though hydrogen bonding to the most electron-withdrawing 
substituent. Umpolung selectivity was observed for substrates with particularly sterically 
demanding substituents proximal to the most electron-withdrawing substituent. Following YqjM 
reduction, intermediate 1.42 can be intercepted by an alcohol dehydrogenase (ADH) in a chemo- 
and stereoselective reduction of the ketone group and subsequent acid-catalyzed cyclization afford 
the lactone product 1.44 with high ee (>98%) and moderate to good yields. This method provides 
access to trisubstituted lactones with three contiguous stereocenters. Classic synthetic routes to 
this motif require multiple steps, and a general method for accessing various substitution patterns 




A similar strategy was employed by Horita in the chemoenzymatic synthesis of 
enantioenriched actinol (1.50) from ketoisophorone (1.47).23 (4R,6R)-actinol (1.50) is a valuable 
chiral building block that serves as an intermediate in the synthesis of carotenoids such as 
xanthoxin, zeaxathin. The biocatalytic cascade begins with the Candida macedoniensis OYE 
(CmOYE) reduction of ketoisophorone (1.47) to (6R)-levodione (1.48) followed by the reduction 
to actinol (1.50) by (6R)-levodione reductase. However, when these enzymes were implemented 
in a one-pot system, the authors noted 67% conversion to the final product with the balance of the 
material accumulating as an intermediate, (4S)-phorenol (1.49). This was attributed to the low 
activity of CmOYE on this reduced species. By obtaining crystal structures with and without 
substrate mimic p-hydroxybenzaldehyde bound, the authors identified a flexible loop that appeared 
to act as a lid on the active site when substrate was present. Modeling of (4S)-phorenol in the active 
site showed potential steric clashes with the gem-dimethyl group at C6 and Phe250, Pro295, and 
Phe296. These residues were individually mutated to Gly and each of these variants exhibited 
higher catalytic activity with phorenol, although substitution of these Phe residues also led to lower 
activity with ketoisophorone (1.47). The CmOYE(P295G) variant was used in the one-pot, two-
step biocatalytic reaction to afford actinol (1.50) in 90% yield.  
Innovations in the application of ERs continue to be reported. For example, Hartwig 
recently disclosed a ‘cooperative’ chemoenzymatic reaction in which a mixture of E/Z olefins are 
isomerized photocatalytically to the (E)-isomer preceding a stereoselective ER-mediated 
reduction.24 
 
C4a-peroxy flavin (FlOO-): Flavin-dependent monooxygenases are a large family of enzymes 
that can be grouped into classes A-H based on structure and activity.25 Monooxygenases access 
10 
 
the reactive flavin intermediate from reactions of FADH2 with molecular oxygen. The reaction 
between FADH2 and O2 can form peroxyflavin (1.7, Figure 1.1), providing a nucleophilic source 
of oxygen (Figure 1.4A). In these reactions, one atom of oxygen is incorporated into the organic 
substrate, and the second atom of oxygen from O2 is lost as water. Within this family, Baeyer-
Villiger monooxygenases (BVMOs)26 have received the most attention from the synthetic 
community. In addition to their canonical capacity to perform stereoselective oxidation of carbonyl 
containing compounds, BVMOs are also able to perform epoxidations27, sulfoxidations28,29 and 
amine oxidations30 with excellent stereocontrol. BVMOs have been employed in the 
chemoenzymatic synthesis of important pharmaceutical agents, such as modafinil31 and 
esomeprazole,32 and in the dynamic kinetic resolution of chiral building blocks employed in the 
synthesis of epothilones33 and isocoumarins.34 The process relevance of these transformations was 
highlighted in a 200 L-scale whole-cell biotransformation.35   
 BVMOs have been employed in chemoenzymatic cascades to generate enantioenriched 
products. Fink reported the chemoenzymatic synthesis of the aroma compound Aerangis lactone.36 
Rh/C hydrogenation in continuous flow of cyclopentenone 1.54 afforded selectively the cis-
cyclopentanone 1.55 (Figure 1.4B). Acid-mediated isomerization gave rise to the 
theromodynamically favored trans-isomer. Crude cell extract of cyclododecanone 
monooxygenase (CDMO) catalyzed the kinetic resolution of 1.55 with >99% ee. Cyclopentanone 
monooxygenases (CPMO) afforded the trans-lactone 1.58 in >99% ee. Using 2% w/v biocatalyst 




The utility of BVMOs to generate chiral building blocks for multistep synthesis of valuable 
complex molecules has been explored by a number of groups. Mihovilovic et al. reported the 
formal chemoenzymatic synthesis of tetrahydrofuran-based natural products using BVMOs as a 
key synthetic step (Figure 4C).37 [4+3] cycloaddition of furan and tetrabromoacetone followed by 
reductive dehalogenation afforded prochiral oxabicycloketone 1.59. This bicycle was subjected to 
fermentation with cyclopentanone monooxygenase (CPMO)-expressing E. coli. Using substrate 
feeding and product removal (SFPR) allowed for a 70% isolated yield of ester 1.60 in 95% ee. 
Subsequent chemical steps allowed the authors to intercept pivotal intermediates in the total 
syntheses of showdomycin (1.62), trans-kumausyne (1.66), and goniofufurone (1.64) analogs. 
Upjohn dihydroxylation of intermediate 1.60 and subsequent protection afforded acetal 1.61. In a 
separate synthesis, the chiral intermediate also underwent epoxidation to afford the goniofufurone 
precursor 1.63. The hydrolysis of the lactone followed by halolactonization gave access to the 
trans-kumausyne precursor 1.65. This work demonstrated complexity-generating potential of the 
biooxidative desymmetrization of the simple ketone 1.59.  
Figure 1.4: Reactions with BVMOs. (A) General mechanism for BVMOs. (B) Aerangis lactone synthesis featuring a 
stereoselective BV oxidation by cyclododecanone monooxygenase (CDMO) or cycopentanone monooxygenase 
(CPMO). (C) Chemoenzymatic synthesis of tetrahydrofuran-based natural products via a chiral intermediate generated 
by CPMO-mediated Baeyer-Villager oxidation a) OsO4, NMO, DCM, rt, then acetone–AlCl3, 0 °C to 40 °C, 47%; b) 
mCPBA, DCM, reflux, 98%; c) MeCN, H2O, KOH, rt, then I2–KI, 40 °C, dark, 75%. 
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 BVMOs have also been employed for in vivo enzymatic cascades. Engineered E. coli 
harboring three biocatalytic enzymes allowed for the in vivo cascade starting from 2-cyclohexenol 
to caprolactone, featuring CHMO catalyzed Baeyer-Villager oxidation as the final step.38 In 
addition to this canonical reactivity, CHMO has been reported to perform hydroxylation of boronic 
acids, and the stereoselective epoxidation of dimethyl and diethyl vinyl phosphonate.27 
Interestingly, CHMO has also been demonstrated to perform heteroatom oxidation, presumably 
from the hydroperoxy flavin.27   
 
C4a-Hydroperoxy flavin (FlOOH): While BVMOs use peroxyflavin (1.7) to oxidize organic 
substrates, group A flavin-dependent monooxygenases perform hydroxylation on electron-rich 
substrates using the hydroperoxyflavin form of the cofactor (1.8). The prototypical group A 
member, p-hydroxybenzoate 3-hydroxylase (PHBH), has been well-studied.39 This work has led 
to an understanding of the mechanism of substrate recognition, cofactor binding and flavin 
reduction. Recently, group A members from biosynthetic pathways have received attention for 
their synthetic potential.40,41 
Sorbicillin natural products have been of interest to the synthetic community for nearly two 
decades due to their dense structural complexity and biological activity.42 The shortest linear 




sequences to these natural products have employed an oxidative dearomatization as a key synthetic 
step; however, due to the lack of a general asymmetric method for this transformation, only 
racemic syntheses have been achieved via this route.42 Recently, Sib and coworkers employed 
SorbC, a flavin-dependent monooxygenase from the sorbicillactone biosynthetic pathway,43 as key 
a synthetic step in the chemoenzymatic synthesis of sorbiquinol (1.69), bisorbicillinol (1.70) and 
trichodimerol (1.71).40 Sorbicillin (1.67) was transformed in a SorbC-mediated oxidative 
dearomatization to afford sorbicillinol (1.68) in >99.5% ee. In the presence of different organic 
cosolvents, sorbicillinol (1.68) could be selectively dimerized to afford the natural products 1.69, 
1.70, or 1.71 (Figure 1.5A).   
Halogenases: Group F flavin-dependent monooxygenases are structurally related to class A 
monooxygenases and follow the same catalytic sequence up to the formation of the C4a-
hydroperoxide (FlOOH, 1.8). Halogenases bind halide ions which are oxidized by the C4a-
hydroperoxide to form hypochlorous or hypobromous acid (Figure 1.6A, 1.72).44 As the substrate 
binding site is distant from the flavin binding site, researchers hypothesize that the acid traverses 
a tunnel to the substrate binding site where it reacts with a lysine residue to form a covalent 
chloramine adduct (1.73), in the case of chlorination.44 This electrophilic chlorine species is 
thought to undergo nucleophilic attack by an aromatic substrate (1.75). The Wheland intermediate 




Figure 1.6: Reactions of halogenases. (A) General reaction mechanism for halogenase-mediated halogenation (EAS 
= Electrophilic aromatic substitution). (B) Halogenation, Pd-catalyzed Suzuki coupling cascade for late-stage 
functionalization of indole natural product scaffolds.45 (C) Evolution of RebH variants using substrate walking from 
simple indole derivatives to pentacyclic alkaloids.46 
 Select flavin-dependent halogenases have received significant attention from the synthetic 
community for their ability to halogenate aromatic systems under mild reaction conditions with 
excellent site selectivity. For example, Durak and coworkers demonstrated the application of 
enzymatic halogenation of indole derivatives in conjunction with Pd-catalyzed cross coupling 
reactions on crude extracts of reaction mixtures to afford further functionalized products (Figure 
1.6B, see 1.78 to 1.79).45 The parent enzyme, RebH, was evolved using a substrate-walking 
directed evolution strategy to obtain variants capable of halogenating a broad range of large indole 
and carbazole substrates (Figure 1.6C, 1.80-1.83).46 Recently, Fraley and coworkers characterized 
halogenase MalA from the malbrancheamide biosynthetic pathway, which performs iterative 
halogenation of the bicyclo[2.2.2]diazaoctane core.47 These enzymes hold promise for future use 
in the selective halogenation of indoles and other electron-rich arenes. 
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The breadth of chemistry accessible with flavin-dependent biocatalysts coupled with the 
demonstrated scalability of these reactions positions this enzyme class to make major contributions 
to synthetic organic chemistry. Current applications have largely been constrained to native 
reaction mechanisms; however, with an ever-increasing understanding of the structural and 
function of these enzymes, synthetic chemists have the opportunity to employ these catalysts in 
novel reactions and integrate them into complexity-generating cascade sequences. 
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CHAPTER 2:  Substrate Scope of Biocatalytic Oxidative Dearomatization 
 
Portions adapted with permission from “Biocatalytic site- and enantioselective oxidative 
dearomatization of phenols” Nat. Chem. 2018, 10, 119–125. 
Chapter 2.1: Introduction 
Oxidative dearomatization, a method which has served as a key step in the synthesis of 
natural products and biologically relevant molecules, is a prime example of a challenging, yet 
valuable chemical transformation.1 Oxidative dearomatization of substituted arenes (see 2.7), 
planar molecules that can be assembled using well-established chemistry, affords chiral o-quinols 
(2.8, Figure 2.1B), which readily undergo carbon-carbon and carbon-heteroatom bond-forming 
reactions and can be exploited to rapidly increase structural complexity. Lead tetraacetate was 
reported in 1950 to afford [2.2.2] bicycles from phenol starting materials, the [4+2] cycloadducts 
of the dearomatized intermediates.2 In the ensuing decades, hypervalent iodide species, most 
notably PIDA and IBX, gained popularity as an attractive oxidant for this challenging 
transformation.3 During the past two decades, a number of asymmetric methods have been reported 
to afford enantioenriched o-quinols. In 2004, Porco and coworkers described the development of 
a copper-oxo sparteine oxidant which was capable of delivering the azaphilone core from phenolic 
precursors in high yields and enantioselectivities. 4 A number of hypervalent oxidants based on the 
Phox and BINOL scaffolds have been developed and reported to give high enantiomeric excesses.5 
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In all of these cases, stoichiometric quantities of the chiral oxidant are required, limiting the 
synthetic utility of the method. 
 
Figure 2.1: Small-molecule methods for asymmetric oxidative dearomatization. 
To address this limitation, catalytic, enantioselective variants of this transformation have 
been developed; the benchmark selectivity of 84% ee was recently obtained by Maruoka and 
coworkers (Figure 2.1).6 This remarkable achievement in chiral oxidant design highlights the 
challenges inherent in achieving high site- and stereoselectivity in this transformation. As the 
chiral environment is distal from the approach of the nucleophile, highly engineered oxidants are 
required to enable selectivity. Nature has overcome this challenge by controlling the positioning 
of the substrate within the active site of enzymes through specific substrate-protein interactions.7  
Flavin-dependent monooxygenases perform this challenging oxidation with perfect site- 
and stereoselectivity.7 These enzymes employ the noncovalent cofactor FADH2 (see 1.1, Figure 
1.1) which reacts with molecular oxygen to form hydroperoxyflavin, an electrophilic source of 
oxygen that can be incorporated into organic substrates bound in the active site. To harness the 
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advantages of these biocatalysts, it is important to address potential challenges, including typically 
narrow substrate scopes of wild-type enzymes, solubility conflicts between the substrate and the 
protein catalyst, and enzyme stability.8 
Our initial investigations into enzymatic oxidative dearomatization began with three flavin-
dependent monooxygenases from natural product pathways: TropB, SorbC and AzaH (Figure 2.2). 
The biochemical function of TropB was characterized by Cox and coworkers in 2012.9 The first 
oxygenase enzyme in the biosynthesis of stipitatic acid (2.14), TropB, natively converts 3-
methylorcinaldehyde (2.12) to o-quinol 2.13 (Figure 2.2). This intermediate undergoes further 
tailoring to ultimately afford the tropolone natural product stipitatic acid (2.14). SorbC, a homolog 
of TropB, was also first identified and studied by the Cox group. This enzyme mediates the 
oxidative dearomatization of sorbicillin (2.15) to sorbicillinol (2.16).10 Sorbicillinol has been 
implicated as a key intermediate in the biosynthesis of a large number of sorbicillin natural 
products, including sorbicillactone A and the bisorbicillinoids.10 Interestingly, the native substrates 
of these two enzymes feature a 3-methylresorcinol core, yet SorbC and TropB demonstrate 
orthogonal site- and stereoselectivities, offering two complementary catalysts for site-selective 
oxidation.     
A third flavin-monooxygenase capable of oxidative dearomatization, AzaH, was 
discovered by Tang and coworkers in 2012.11 AzaH mediates the oxidative dearomatization and 
was proposed to catalyze the subsequent cyclization of orcinaldehyde-derivative 2.18 in the 
biosynthesis of azanigerone A (2.21, Figure 2.2).11 The stereochemical configuration at C11 and 
C13 of 2.21 and the absolute configuration of natural product were not disclosed in this initial 




   
Figure 2.2: The native reaction and biosynthetic pathway of the three flavin-dependent monooxygenases TropB,9 
SorbC10 and AzaH.11  
In order to explore the substrate promiscuity of these flavoproteins we chose to develop 
routes to phenolic and resorcinol substrate analogs varying the steric and electronic properties of 
each substituent. These compounds were then tested for reactivity with the flavin-dependent 
monooxygenases TropB, SorbC and AzaH by assessing conversion to dearomatized products. The 
site- and facial fidelity of C–O bond formation with these catalysts with non-native substrates was 
determined in preparative-scale reactions with purified proteins (in vitro reactions) and the 
enantio-enrichment of each product was assessed by comparison to racemic standards. 
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Chapter 2.2: Substrate Synthesis 
 
Figure 2.3: Retrosynthetic analysis of substrate classes for biocatalytic oxidative dearomatization.  
A small library of phenolic substrates was designed to explore the steric and electronic 
requirements for substrate turnover (Figure 2.3). SorbC and TropB native substrate analogs such 
as 2.22 and 2.25 could be accessed by acylation of the isomeric dimethylresorcinol cores. As 
dimethyl resorcinols 2.23 and 2.26 were prohibitively expensive, we chose to trace these 
intermediates back to inexpensive, singly methylated 1,3-diphenols (2.24 and 2.27). We 
envisioned generating substrates with varying alkyl groups at the C3 position through acylation of 
the dialkylated resorcinols (2.29). The variable C3 group could be incorporated through lithiation 
of 2.30 followed by alkylation with the desired alkyl halide. C6-substituted compounds (see 2.31) 
could be generated through a Pd-catalyzed cross-coupling of aryl bromide 2.32 with either boronic 
acids or alkynes. A four-step route to aryl bromide 2.32 from benzaldehyde 2.33 had been 
previously reported by Porco.3b 
The native substrates of TropB (2.12) and SorbC (2.15) were chosen as our first synthetic 
targets. This would allow us to establish conditions for our proposed divergent routes, generate 
significant quantities of the key intermediates 2.23 and 2.26 and enable positive controls for our 
enzymatic reactions. Vilsmeier-Haack formylation of 2.23 proceeded in high yield.3b Methyl ether 
deprotection of the resulting benzaldehyde was initially low yielding, potentially due to loss of 
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material as the boron complex, but a work up procedure that included basifying the reaction 
mixture with 1 M NaOH to a pH of 10 followed by acidification was found to afford nearly 
quantitative yields reproducibly. This two-step sequence from 2.23 gave access to the TropB native 
substrate.  
Resorcinol 2.26 underwent Friedel-Crafts acylation to afford substrate class 2.25.12 
McOmie acylation conditions13 afforded the corresponding benzyl ketones with unprotected 
phenolic groups; unfortunately, the same transformation was low yielding with more sterically 
hindered substrates such as 2.23. A protecting group strategy was used to access compounds 2.25a-
d (see Figure 2.4). 6,7-bicycle 2.43 was accessed via Wittig olefination, reduction and acid-
promoted Friedel-Crafts cyclization. This route was also employed to access the corresponding 
tetralone. Acylation of resorcinol 2.27 followed by thermal Fries-rearrangement,14 reduction and 
Vilsmeier-Haack formylation afforded benzaldehyde 2.49.  Suzuki cross-coupling of aryl 
bromides 2.32 and 2.50 afforded the biphenyls 2.51 and 2.53 in good yield. This aryl bromide was 
also leveraged as a key intermediate in the synthesis of azaphilone precursors. Sonogashira cross-
coupling with the appropriate alkyne, followed by an AuCl3 catalyzed cyclization to the pyrillium 
and subsequent hydration to the ketone afforded a number of dicarbonyl substrates (see Figure 
5.4).3b 
Chapter 2.3: Reactivity Profile 
Genes encoding tropB and sorbC were cloned into a pET151 vector. The plasmids were then 
transformed into BL21 (DE3) E. coli cells. The gene encoding azaH in a modified pET28 vector 
was a generous gift from the Tang lab at UCLA. Expression and purification conditions were 




Figure 2.4: Synthetic routes to resorcinol substrates for biocatalytic oxidative dearomatization. 
With our desired proteins in hand, we next optimized reaction conditions using TropB with 
the native substrate 2.12. Initial conditions for the flavin-dependent monooxygenase-mediated 
oxidative dearomatization were modeled on Cox’s report.15 KPi buffer at pH 8.0 was found to be 
optimal for conversion to product at one hour. A temperature screen showed that 30 °C provided 
highest turnover within one hour with no side product formation as observed by UPLC-PDA. The 
use of super-stoichiometric amounts of NAPDH employed in Cox’s report,15 however, was 
24 
 
undesirable, due to the high cost and instability of this cofactor. To address this limitation, a well-
established NADPH recycling system was used in our studies.16  
Under these optimized conditions, fifty substrates were incubated with each of the three 
FAD-dependent monooxygenases (Figure 2.5). Reactions were analyzed by UPLC-PDA. Standard 
curves of the starting material were obtained and used to determine total turnover numbers (TTN) 
for each substrate-enzyme pair. Thirty-five of these substrates showed partial or full conversion 
by at least one enzyme at 0.1 mol% catalyst loading. 
 
Figure 2.5: Workflow for analytical-scale oxidative dearomatization. Synthetic genes are cloned into the desired 
vector, transformed into a competent E. coli strain which is then grown in 0.5 or 1 L cultures. Overexpression is 
induced and cells are harvested and lysed. After Ni-affinity purification of the crude lysate the protein solution is 
used in small scale reactions. 
TropB catalyzed the oxidation of several substrates to singly hydroxylated products, with 
TTNs ranging from 84 to ≥ 1000 (Table 2.1).18 Among these substrates were aryl bromides (2.50, 
2.55) and resorcinols with electron donating (see 2.59) and withdrawing groups (2.53). Branched 
or straight chain ketones (see 22a-e) were cleanly oxidized as well as a biphenyl substrate (2.53). 
We have found the C1-carbonyl motif, and C2- and C4-hydroxyl groups were critical for substrate 
conversion. As one might predict from examining the structure of the native substrate, increasing 
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steric bulk at the C1 position resulted in a decrease in TTN; the largest substituent that was 
accepted at this position was an isobutyl ketone. The substitution of an alternative electron-
withdrawing group such as a nitrone or nitro group was tolerated, however, esters and acids were 
not converted. Two attributes have been proposed to be at play for the role of the requisite electron-
withdrawing group. First, we proposed this group is needed to lower the pKa of the substrate. 
Attabey Rodrìguez Benìtez has found that the pKa of the native substrate 2.12 is 7.2.17 It is 
therefore likely that the anionic form of the substrate binds in the enzyme active site. The second 
feature of this functional group could be the role of the extended  system affording a lower 
energetic barrier to dearomatization. Current computational and experimental work is ongoing in 
an attempt to decouple these two features; however, we propose that it is likely the two 
characteristics are both critical for the design of a productive substrate. 
A surprisingly large number of substrates featuring alternative substitution at the C5- and 
C6-position were also tolerated. Good conversion was observed with the C6-phenyl 2.53, whereas, 
the C5-phenyl substrate 2.51 was not accepted, indicating the hydrophobic pocket occupied 
presumably by the C6-methyl group of the native substrate can accommodate significant steric 
bulk. However, the rotation from the active conformation required to put the C5-substituent in this 
C6-pocket is either too unfavored to allow for binding or alternatively places the carbon to be 
oxidized, C3, too far from the hydroperoxy group. Interestingly, although the substitution of the 
methyl group from the C6- to C5-position is tolerated with an aldehyde at C1 (see 2.58), and the 
butyl ketone 2.22d was also efficiently converted, both alterations are not tolerated when present 
in a single substrate (see 2.25b).  
AzaH was also able to efficiently hydroxylate phenols with significant structural 
differences from the native substrate 2.18 (Table 2.1). The -hydroxy carbonyl is not critical to  
26 
 
Table 2.1: Turnover numbers (TN) at 1 h, based on consumption of starting material as measured by absorbance at 
270 nm. Conditions: 2.5 mM substrate, 2.5 M flavin-dependent monooxygenase, 5 mM G6P, 1 mM NADP+, 1 
unit/mL G6PDH, 50 mM KPi buffer, 30 °C, 1 h. 
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substrate recognition as derivatives featuring a methyl group (2.12) or hydrogen atom (2.50, 2.63, 
2.25d) at this position undergo oxidation by AzaH. Lipophilic-substituted carbonyls at the C1-
position were also tolerated (2.25a-d). Interestingly, C5-bromides gave much higher conversions 
then their C5-methyl group or hydrogen atom analogs (see 2.50 vs. 2.53 and 2.67 vs. 2.79).  Clearly 
the bromide is playing an important role in electrostatic interactions in the active site, but 
rationalization of this result will most likely require docking studies of these unnatural substrates 
with a homology model or crystal structure of the protein.  
Only substrates with a straight-chain group extending from the carbonyl of at least 4 
carbons showed significant turnover with SorbC (Table 2.1). This result could be evidence that 
this hydrophobic substituent is critical for substrate binding. Interestingly, when a hydrogen atom 
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Figure 2.6: Trends in reactivity of the three enzymes TropB, SorbC and AzaH with five substrate classes. Red arrow 
indicates high conversion, grey arrow indicates decreasing conversion with increasing steric bulk and yellow equal 









rather than methyl group is present at C6 (see 2.22c-e), the site of hydroxylation in the native 
substrate, a product with an absorption spectrum of a triphenol is formed. Hydroxylation at C6 
followed by deprotonation and rearomatization would account for this result. Similar results are 
seen in TropB reactions with C3-proto substrates (see 2.61). The high fidelity for C6-hydroxylation 
by SorbC and C4-hydroxylation by TropB with unnatural substrates has encouraged our interest 
in developing these enzymes as synthetically relevant catalysts. 
Chapter 2.4: Preparative-scale Reactions 
Several substrates were chosen for scale-up reactions to determine the enantioselectivity 
of the transformation mediated by the three enzymes (Figure 2.7). Gratifyingly, comparable 
conversions were observed on 10 mg-scale as in our analytical scale assays without alteration of 
the reaction conditions. Choice of reaction vessel, however, did prove to be critical to obtaining 
high conversion. Crystallizing dishes were employed in our initial reactions to maximize surface 
area of the air-buffer interface, as oxygen is required as the stoichiometric oxidant. We later found 
that an Erlenmeyer flask could also be employed, if shaken at a low rate (typically 100 rpm) to 
allow for efficient gas exchange.  
The o-quinol products were found to rapidly dimerize through a Diels-Alder cycloaddition 
and other decomposition pathways upon concentration of the reaction mixture in organic solvent. 
To mitigate this byproduct formation, crude reaction mixtures were diluted with two volumes of 
acetone and centrifuged to precipitate large biomolecules. The filtrate was then concentrated and 
directly purified by reverse-phase preparative HPLC to afford analytically pure o-quinol products 
which could be characterized by NMR and mass spectrometry. Racemic standards of the C3-
hydroxylated products could be accessed through an IBX-mediated oxidative dearomatization. 
Porco’s conditions afforded the desired product in almost all cases (Figure 2.7).3b After purification 
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by preparative HPLC sufficient material was obtained for the substrates shown in Figure 2.7 to 
allow for analysis by chiral HPLC or SFC. A notable exception was the 5-nitro substituted 
substrate 2.86 which returned only starting material or, under more forcing thermal conditions, 
nonspecific decomposition. 
 Although the stereocenter forged by TropB is later ablated in the subsequent enzymatic 
step, we found that the o-quinol native product is formed in >99% ee. A number of non-native 
substrates were also obtained in high enantiopurity including the 6,7-bicycle 2.84 and C6-phenyl 
2.80 (Figure 2.7). Unexpectedly, we found that ketone substrates such as methyl ketone 2.82 and 
isobutyl ketone 2.83 afforded dearomatized products which favored the ketone tautomer over the 
exocyclic enol form which was observed for all aldehyde and aldehyde-derived compounds. This 
was attributed to increased allylic strain between the C1 carbonyl substituent and the C6 methyl 
group that was relieved in the ketone tautomer. Keto-enol tautomerization was found to be 
confounding in all attempts to resolve the enantiomers of these class of products. Attempts were 
made to form the Mosher ester19 to determine the enantiopurity of the methyl ketone product, 
however, as was seen in later studies (see Chapter 5), acylation of the tertiary alcohol was 
challenging, and none of the conditions screened afforded high conversion to the desired ester 
product. However, we anticipate the ketone products are afforded in high enantiopurity based upon 
the high %ee observed with the bicyclic substrate, which would presumably bind within the active 
site in a similar manner to the ketone substrate.  
Marc Becker completed the synthesis of ±2.18, enabling us to benchmark the activity of 
AzaH with the enzyme’s native substrate. AzaH oxidized both enantiomers with apparently equal 
efficiency affording a 1:1 ratio of diasteromers, both obtained in >99% ee. Fortunately, AzaH 
turned over several substrates that were also converted by TropB, allowing for assignment of the 
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absolute configuration of the AzaH products. We found that, like TropB, AzaH afforded the R 
enantiomer of 2.13 (Figure 2.7). Based on the high %ee of the o-quinols isolated, we hypothesize 
that the binding mode of these nonnative substrates affords the same facial selectivity as the native 
substrate. This has been supported by docking studies and QM/MM calculations performed by 
Sarah Tweedy in the Brooks Lab.17 
C5-hydroxylated products (see 2.87) are constitutively locked as the cyclohexadiene 
tautomer and thus prone to undergo Diels-Alder cycloaddition with dienophiles at or below room 
temperature. SorbC products were therefore acylated in situ to mitigate undesired dimerization. 
The acylation products were stable on silica and isolable. Fortunately, Corey’s Pb(OAc)4 
conditions20 for the racemic synthesis of acylated 2.87 afforded the acylated dienones 
reproducibly. SorbC was found to afford the C5-hydroxylated products in 96 to >99% ee. 
Sorbicillinol, the native product, was obtained in excellent enantiopurity. Substrates with shorter 
akyl substituents on the C1 ketone (see 2.91) and longer aliphatic groups at C3 gave the lowest 
enantiomeric excesses seen to date in the enzymatic oxidative dearomatization. Based on these 
data we hypothesized that the C1 hydrophobic group was critical in substrate recognition and 
binding. We leveraged this insight to enable a substrate engineering approach to overcome the 




Figure 2.7: Yields and enantiomeric excesses of products obtained from preparative scale enzymatic reactions. 
Conditions: 2.5 mM substrate (10 mg, in DMSO), 2.5 mM flavin-dependent monooxygenase, 5 mM G6P, 1 mM 
NADP+, 1 unit/mL G6PDH, 50 mM Kpi buffer, 30 °C, 1 h.    
Chapter 2.5: Conclusions 
 The substrate scope, site- and stereoselectivity of three wild-type flavin-dependent 
monooxygenases was explored. First, a library of phenolic compounds was designed based on the 
native substrates of the three enzymes, TropB, SorbC and AzaH. TTNs were determined for each 
enzyme-substrate pair. In all productive reactions a single hydroxylated product was detected by 
UPLC and LC-MS. Preparative in vitro reactions were performed, allowing for structural 
characterization of the enzymatic products and determination of % ee. High enantioselectivities 
were observed in all reactions. Attabey Rodrìguez Benìtez and Sarah Tweedy have performed 
structural, biochemical and computational studies to elucidate the mechanisms controlling 
substrate specificity and reactivity of TropB.17 Work is on-going to understand the stereoelectronic 
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effects which govern substrate selectivity of AzaH, a homolog which is capable of turning over 
more electron poor substrates than either TropB or SorbC. Substrate selection and binding by 
SorbC is further discussed in Chapter 3.  
 One challenging limitation we have encountered in our exploration of the synthetic utility 
of the FDMOs TropB, SorbC, and AzaH, is the requirement for an electron-withdrawing group at 
C1. As the biosynthetic routes to the substrates for dearomatization employ non-reducing 
polyketide synthases, there seems to be evolutionary pressure for these enzymes and their 
homologs to only recognize substrates featuring this specific oxidation pattern. To access 
enantioenriched o-quinols, which do not feature this NRPKS motif, new enzyme classes should be 
explored for the desired reactivity.  
Chapter 2.6: Experimental  
Chapter 2.6.1: Substrate Synthesis 
All reagents were used as received unless otherwise noted. Reactions were carried out under a 
nitrogen atmosphere using standard Schlenck techniques unless otherwise noted. Solvents were 
degassed and dried over aluminum columns on an MBraun solvent system (Innovative 
Technology, inc., Model PS-00-3). Reactions were monitored by thin layer chromatography using 
Millipore 60 F254 pre-coated silica TLC plates (0.25 mm) which were visualized using UV, p-
anisaldehyde, CAM, DNP, or bromocresol green stains. Flash column chromatography was 
performed using Machery-Nagel 60 μm (230-400 mesh) silica gel. All compounds purified by 
column chromatography were sufficiently pure for use in further experiments unless otherwise 
indicated. 1H and 13C NMR spectra were obtained in CDCl3 at rt (25 C), unless otherwise noted, 
on Varian 400 MHz or Varian 600 MHz spectrometers. Chemical shifts of 1H NMR spectra were 
recorded in parts per million (ppm) on the δ scale. High resolution electrospray mass spectra were 
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obtained on an Agilent UPLC-QTOF at the University of Michigan Life Sciences Institute. IR 
spectra were recorded on a Perkin-Elmer Spectrum BX FT-IR spectrometer. Melting points were 
obtained on a MEL-TEMP capillary melting point apparatus.  
 
List of reagents prepared or purified: 
2-Iodoxybenzoic Acid (IBX) was synthesized according to the procedure described by Sputore et 




2.50 mL DMF was added to a flame-dried round-bottom flask equipped with a stir bar. The vessel 
was cooled to 0 C and POCl3 (0.50 mL, 4.4 mmol, 1.1 equiv) was slowly added over the course 
of 10 min. The mixture was stirred for 30 min before 2,5-dimethylbenzene-1,3-diol (0.55 g, 4.0 
mmol in 2.50 mL DMF) was added dropwise. The mixture was warmed to rt. After 2 h, the reaction 
was quenched by the addition of ice (1.0 g) followed by 10% NaOH(aq) until a pH of 13 was 
achieved. The mixture was refluxed for 10 min before cooling to rt. Acidification to pH 3 induced 
the precipitation of a white crystalline solid which was isolated by vacuum filtration to yield 0.44 
g (66%) of the title compound. 1H NMR (400 MHz, CDCl3) δ 12.65 (s, 1H), 10.07 (s, 1H), 6.21 






1,3-Dimethoxy-2,5-dimethylbenzene (2.23)  
2,5-Dimethylbenzene-1,3-diol (1.00 g, 7.24 mmol), K2CO3 (5.14 g, 36.2 mmol, 5.0 equiv) and 
acetonitrile (14 mL) were added to a flame-dried round-bottom flask equipped with a stir bar. The 
vessel was cooled to 0 C and MeI (2.25 mL, 36.2 mmol, 5.0 equiv) was slowly added. The mixture 
was heated to 40 C and stirred for 16 h at this temperature. The mixture was then cooled to rt and 
filtered over celite. The celite was rinsed with EtOAc (5 mL). Water (20 mL) was added to the 
filtrate which was then extracted with EtOAc (3 x 15 mL). The combined organic layers were 
washed with water (15 mL) and brine (15 mL), dried over magnesium sulfate and filtered. The 
solvent was removed under reduced pressure to afford a colorless oil. Purification on silica gel 
(100% hexanes to 10% EtOAc in hexanes) afforded 0.52 g (43% yield) of resorcinol 2.23 as a 
colorless solid.  1H NMR (400 MHz, CDCl3) δ 6.35 (s, 2H), 3.79 (s, 6H), 2.32 (s, 3H), 2.04 (s, 




AlCl3 (53 mg, 0.33 mmol, 1.1 equiv) and 0.5 mL of nitroethane were added to a flame-dried vial 
equipped with a stir bar. A solution of 1,3-dimethoxy-2,5-dimethylbenzene (50 mg, 0.30 mmol, 
1.0 equiv in 0.2 mL nitroethane) was added followed by acetyl chloride (32 μL, 0.45 mmol, 1.5 
equiv). The mixture was stirred for 4 h, and then, it was quenched by the addition of water (3 mL). 
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The mixture was extracted with DCM (3 x 10 mL). The combined organic layers were washed 
with brine, dried over magnesium sulfate and filtered. The solvent was removed under reduced 
pressure to afford a dark brown oil, which was taken up in hexanes and EtOAc (1:1) and filtered 
through a silica gel plug. The crude material was transferred to a flame-dried vial, dissolved in 
DCM (3.75 mL) and cooled to -78 C. BBr3 (0.625 mL, 1 M in DCM, 4.0 equiv, 0.625 mmol) was 
added dropwise. The mixture was then warmed to rt and stirred for 16 h at which time the reaction 
mixture was quenched by the slow addition of water. The resulting solution was extracted with 
EtOAc (3 x 10 mL). The combined organic layers were washed with brine, dried over magnesium 
sulfate and concentrated under reduced pressure to afford a dark brown solid. Purification on silica 
gel (100% hexanes to 15% EtOAc in hexanes) afforded 40.5 mg (76% yield over two steps) of the 
methyl ketone as a tan crystalline solid.  1H NMR (400 MHz, CDCl3) δ 13.80 (s, 1H), 6.22 (s, 
1H), 5.17 (s, 1H), 2.62 (s, 3H), 2.53 (s, 3H), 2.09 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 204.3, 




6-Bromo-2,4-dimethoxy-3-methylbenzaldehyde (2.32)  
Concentrated HCl (1.96 mL) was added to a solution of (3-amino-2-bromo-4,6-dimethoxy-5-
methylphenyl)methylene diacetate (1.07 g, 2.86 mmol, 1.0 equiv) in 10.0 mL of THF and 0.30 mL 
of distilled water. The mixture was cooled to -5 C. Sodium nitrite (0.394 g, 5.71 mmol, 2.0 equiv) 
in 6.0 mL of distilled water was added, and the reaction was stirred at -5 C for 1 h. Urea (0.172 
g, 2.86 mmol, 1.0 equiv) was added to the resulting mixture followed by dropwise addition 
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hypophosphorous acid (3.29 mL, 50% w/w aqueous solution). The solution was stirred at 4 C for 
12 h and was then warmed to 40 C for 4 h. The reaction mixture was then cooled to rt and extracted 
with EtOAc (3 x 10 mL). The combined EtOAc extracts were washed with water, dried over 
magnesium sulfate, filtered and concentrated under reduced pressure. Purification on silica gel 
(100% hexanes to 30% EtOAc in hexanes) afforded 0.610 g (92% yield) of 2.32 as a white 
crystalline solid. 1H NMR (400 MHz, CDCl3) δ 10.28 (s, 1H), 6.93 (s, 1H), 3.90 (s, 3H), 3.81 (s, 




To a flame-dried vial was added 6-bromo-2,4-dimethoxy-3-methylbenzaldehyde (28.5 mg, 0.110 
mmol, 1.0 equiv) in 0.5 mL DCM. The solution was cooled to -78 C, and BBr3 (0.44 mL, 1 M in 
DCM, 4.0 equiv) was added dropwise. The mixture was then warmed to rt and stirred for 24 h. 
The reaction mixture was quenched by the slow addition of water (2 mL). The solution was 
extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine, dried 
over sodium sulfate and concentrated under reduced pressure to afford a tan oil. Purification on 
silica gel (10% to 20% EtOAc in hexanes) afforded 21.0 mg (83% yield) of the title compound as 
a colorless solid. 1H NMR (400 MHz, CDCl3) δ 12.67 (s, 1H), 10.11 (s, 1H), 6.68 (s, 1H), 5.50 (s, 






2,4-Dihydroxy-3-methylbenzaldehyde (1.00 g, 6.57 mmol, 1.0 equiv) and 17 mL of MeOH were 
added to a flame-dried round-bottom flask equipped with a stir bar. 1.52 g NBS (1.3 equiv) was 
added, and the mixture was allowed to stir at rt for 4 h. The solution was concentrated and extracted 
with EtOAc (3 x 15 mL). The combined organic layers were washed with brine, dried over sodium 
sulfate, filtered and concentrated under reduced pressure to afford an orange oil. Purification on 
silica gel (100% hexanes to 10% EtOAc in hexanes) afforded 1.45 g (96% yield) of the title 
compound as a colorless yellow solid.  1H NMR (600 MHz, (CD3)2SO) δ 11.37 (s, 1H), 9.74 (s, 
1H), 7.80 (s, 1H), 2.70 (s, 3H); 13C NMR (150 MHz, (CD3)2SO) δ 195.1, 160.3, 159.4, 135.1, 
116.1, 113.5, 102.1, 9.2; HR-ESI-MS: m/z calculated for C8H7BrO3 [M-H]
-. 228.9506, found: 




3,5-Dihydroxy-4-methylbenzoic acid (2.00 g, 11.9 mmol, 1.0 equiv), K2CO3 (9.90 g, 71.4 mmol, 
6.0 equiv) and 30 mL acetone were added to a flame-dried round-bottomed flask equipped with a 
stir bar. The vessel was cooled to 0 C and MeI (4.4 mL, 71 mmol, 6.0 equiv) was slowly added. 
The mixture was then heated to 40 C and stirred until complete consumption of the starting 
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material was observed by TLC. The mixture was then filtered, and the residue rinsed with EtOAc. 
The mixture was extracted with EtOAc (3 x 100 mL) and washed with 50 mL water followed by 
50 mL brine. The combined organic layers were dried over magnesium sulfate and filtered. The 
solvent was removed under reduced pressure to afford a colorless crystalline solid, which was 
recrystallized from EtOH to afford 1.90 g (76% yield) of ester 2.39. 1H NMR (400 MHz, CDCl3) 





3,5-Dimethoxy-4-methylbenzoate (1.50 g, 7.13 mmol, 1.0 equiv) and 8 mL of DCM were added 
to a flame-dried round-bottom flask equipped with a stir bar. The reaction vessel was cooled to 0 
C and DIBAL-H (15.7 mL,1 M in hexanes, 2.2 equiv) was added dropwise. The mixture was 
allowed to stir for 1 h and was then quenched with 1 M HCl(aq) (20 mL). The mixture was extracted 
with EtOAc. The combined EtOAc extracts were washed with water, dried over magnesium 
sulfate, filtered and concentrated under reduced pressure. Purification on silica gel (100% DCM 
to 10% MeOH in DCM) afforded 1.32 g (99%) of the benzyl alcohol 2.93 as a colorless oil. 1H 
NMR (400 MHz, CDCl3) δ 6.54 (s, 2H), 4.64 (s, 2H), 3.81 (s, 6H), 2.06 (s, 3H). All spectra 






A solution of (3,5-dimethoxy-4-methylphenyl)methanol (1.00 g, 5.50 mmols, 1.0 equiv) in 40 mL 
of EtOAc was added to a flame-dried round-bottom flask equipped with a stir bar. To this mixture 
was added IBX (4.62 g, 16.5 mmol, 3.0 equiv). The mixture was heated to 80 C and stirred for 5 
h at this temperature. The mixture was then cooled to rt, washed with water, dried over magnesium 
sulfate, filtered and concentrated under reduced pressure. Purification on silica gel (100% hexanes 
to 15% EtOAc in hexanes) afforded 1.0 g (99% yield) of 2.39 as a crystalline white solid. 1H NMR 
(400 MHz, CDCl3) δ 9.89 (s, 1H), 7.04 (s, 2H), 3.88 (s, 6H), 2.14 (s, 3H). All spectra obtained 
were consistent with literature values.25 
 
 
(E)-4-(3,5-dimethoxy-4-methylphenyl)but-3-enoic acid (2.41) 
(2-Carboxypropyl)triphenylphosphonium bromide (0.852 g, 4.73 mmols, 1.2 equiv) in 3.0 mL of 
DCM was added to a flame-dried round-bottom flask equipped with a stir bar. The solution was 
cooled to 0 C and KOtBu (1.32 g, 11.8 mmol, 2.5 equiv) was added in a single portion. The 
mixture was allowed to stir for 1 h before the addition of (3,5-dimethoxy-4-
methylphenyl)methanol (2.36 g, 1.83 mmol, 1.0 equiv). The resulting mixture was allowed to stir 
at rt for 8 h. The reaction was quenched by the addition of water (3 mL) and acidified to a pH of 1 
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with 1 M HCl. The mixture was extracted with DCM (3 x 10 mL). The combined organic layers 
were washed with brine, dried over magnesium sulfate, filtered, and concentrated under reduced 
pressure. Purification on silica gel (100% DCM to 10% MeOH in DCM) afforded 1.10 g (93% 
yield) of the acid 2.41 as a crystalline yellow solid. 1H NMR (600 MHz, CDCl3) δ 6.55 (s, 1H), 
6.43 (d, J = 15.7 Hz, 1H), 6.19 (m, 1H), 3.84 (s, 6H), 2.57 (m, 4H), 2.10 (s, 3H); 13C NMR (150 
MHz, CDCl3) δ 179.4, 158.3, 135.7, 131.6, 127.2, 113.9, 101.6, 55.7, 33.8, 27.9, 8.2; HR-ESI-
MS: m/z calculated for C14H17O4 [M-H]
-: 249.1132, found: 249.1130; IR (thin film): 2997, 2937, 
1706, 1529 cm-1; MP: 117.0-119.3 C. 
 
 
5-(3,5-dimethoxy-4-methylphenyl)pentanoic acid (2.94) 
(E)-4-(3,5-dimethoxy-4-methylphenyl)but-3-enoic acid (1.10 g, 4.39 mmol, 1.0 equiv), Pd/C 10 
wt% (0.467 g, 0.439 mmol, 0.1 equiv) and MeOH (20 mL) were added to a round-bottom flask. 
The flask was sparged with N2 for 30 min then equipped with a H2 filled balloon and sparged again 
for 30 min. The reaction was stirred under a H2 atmosphere for 24 h. The mixture was then filtered 
through celite and concentrated under reduced pressure. Purification on silica gel (100% DCM to 
10% MeOH in DCM) afforded 1.02 g (92% yield) of acid 2.94 as a white solid. 1H NMR (400 
MHz, CDCl3) δ 1H NMR δ 6.37 (s, 2H), 3.82 (s, 6H), 2.62 (t, J = 7.2 Hz, 2H), 2.41 (t, J = 6.6 Hz, 
2H), 2.06 (s, 3H), 1.71 (m, 4H); 13C NMR (150 MHz, CDCl3) δ 179.9, 158.2, 140.5, 105.1, 103.8, 
55.7, 36.1, 33.9, 30.9, 24.3, 7.9; HR-ESI-MS: m/z calculated for C14H19O4 [M-H]
-; 251.1289, 






5-(3,5-dimethoxy-4-methylphenyl)pentanoic acid (1.02 g, 4.04 mmol, 1.0 equiv) and 
polyphosphoric acid (10.0 mL) were added to a flame-dried round-bottom flask equipped with a 
stir bar. The mixture was heated to 60 °C and stirred for 2 h. The reaction was then quenched by 
the addition of water (10 mL) and extracted with EtOAc (3 x 15 mL). The combined organic layers 
were dried over magnesium sulfate, filtered and concentrated under reduced pressure. Purification 
on silica gel (100% hexanes to 15% EtOAc in hexanes) afforded 0.745 g (81% yield) of 4.42 as a 
colorless solid. 1H NMR (600 MHz, CDCl3) δ 6.40 (s, 2H), 3.84 (s, 3H), 3.75 (s, 3H), 2.73 (m, 
2H), 2.60 (m, 2H), 2.10 (s, 3H), 1.77 (m, 4H); 13C NMR (150 MHz, CDCl3) δ 196.1, 161.9, 160.2, 
145.7, 119.7, 119.4, 105.6, 60.9, 55.7, 55.6, 40.7, 31.3, 23.0, 8.2; HR-ESI-MS: m/z calculated for 
C14H17O3 [M-H]




2,4-dimethoxy-3-methyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-one (50.0 mg, 0.213 mmol, 
1.0 equiv) was dissolved in 1.10 mL DCM. The solution was cooled to -78 C and BBr3 (0.853 
mL, 1 M in DCM, 4.0 equiv) was added dropwise. The mixture was then warmed to rt and stirred 
for 24 h. The reaction mixture was quenched by the slow addition of water (5 mL). The solution 
was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine, 
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dried over sodium sulfate and concentrated under reduced pressure to afford a brown oil. 
Purification on silica gel (10% to 20% EtOAc in hexanes) afforded 44.0 mg (99% yield) of the 
title compound as a colorless solid.  1H NMR (600 MHz, CDCl3) δ 13.49 (s, 1H), 6.22 (s, 1H), 
5.22 (s, 1H), 2.86 (m, 4H), 2.10 (s, 3H), 1.83 (m, 4H); 13C NMR (151 MHz, CDCl3) δ 208.2, 
164.2, 158.8, 144.6, 114.3, 108.9, 108.8, 41.4, 33.5, 24.6, 20.7, 7.3; HR-ESI-MS: m/z calculated 
for C12H14O3 [M-H]
-: 205.0870, found: 205.0872; IR (thin film): 2927, 1574, 1439, 1296, 1127 




13.4 mL DMF was added to a flame-dried round bottom flask equipped with a stir bar. The vessel 
was cooled to 0 C and POCl3 (3.04 mL, 32.6 mmol, 1.5 equiv) was slowly added over the course 
of 10 min. The mixture was stirred for 30 min before 2,5-dimethylbenzene-1,3-diol (3.00 g, 21.7 
mmol, 1.0 equiv in 13.4 mL DMF) was added dropwise. The mixture was then warmed to rt. After 
2 h, the reaction was quenched by the addition of ice (approx. 5 g) followed by addition of 10% 
NaOH(aq) until a pH of 13 was achieved. The mixture was then refluxed for 10 min before cooling 
to rt. Acidification to pH 3 induced the precipitation of a yellow crystalline solid which was 
isolated by vacuum filtration to yield 3.24 g (98% yield) of the title compound. 1H NMR (600 
MHz, CDCl3) δ 11.66 (d, J = 1.4 Hz, 1H), 9.69 (s, 1H), 7.29 (d, J = 8.5 Hz, 1H), 6.47 (d, J = 8.4 






AlCl3 (44.0 mg, 0.330 mmol, 1.1 equiv) and 0.5 mL of nitroethane were added to a flame-dried 
vial equipped with a stir bar. A solution of 1,3-dimethoxy-2,5-dimethylbenzene (50 mg, 0.30 
mmol, 1.0 equiv) in 0.2 mL nitroethane was added followed by butyryl chloride (46.7 μL, 0.450 
mmol,1.5 equiv). The mixture was then stirred overnight before the reaction was quenched by the 
addition of water (3 mL). The mixture was then extracted three times with EtOAc (3 x 15 mL). 
The combined organic layers were washed with brine, dried over magnesium sulfate and filtered. 
The solvent was removed under reduced pressure to afford a dark brown oil. The oil was then 
taken up in hexanes and EtOAc (1:1) and filtered through a silica gel plug. This crude material 
was transferred to an oven-dried vial, dissolved in DCM (3.75 mL) and cooled to -78 C. BBr3 
(1.20 mL, 1 M in DCM, 4.0 equiv) was added dropwise. After 20 h, the reaction mixture was 
quenched by the slow addition of water (10 mL). The solution was extracted three times with 
DCM. The combined organic layers were washed with brine and dried over magnesium sulfate. 
The solvent was removed under reduced pressure to afford a dark brown oil. Purification on silica 
gel (100% hexanes to 15% EtOAc in hexanes) afforded 38.9 mg (53% yield over two steps) of the 
title compound as a colorless solid. 1H NMR (600 MHz, CDCl3) δ 13.56 (s, 1H), 6.21 (s, 1H), 
5.70 (s, 1H), 2.89 (t, J = 8.5 Hz, 2H), 2.52 (s, 3H), 2.09 (s, 3H), 1.70 (m, 2H), 1.38 (m, 2H), 0.94 
(t, J = 8.5 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 207.7, 164.0, 158.4, 138.4, 115.4, 111.1, 109.1, 
43.7, 27.2, 24.8, 22.5, 13.9, 7.5  ; HR-ESI-MS: m/z calculated for C13H17O3 [M-H]
-: 221.1183, 






AlCl3 (44.0 mg, 0.3 mmol, 1.1 equiv) and 0.5 mL of nitroethane were added to a flame-dried vial 
equipped with a stir bar. A solution of 1,3-dimethoxy-2,5-dimethylbenzene (50 mg, 0.30 mmol, 
1.0 equiv) in 0.2 mL of nitroethane was added followed by propionyl chloride (39.3 μL, 0.450 
mmol, 1.5 equiv). The mixture was stirred overnight, and then the reaction was quenched by the 
addition of water (3 mL). The mixture was extracted with EtOAc (3 x 15 mL). The combined 
organic layers were washed with brine, dried over magnesium sulfate and filtered. The solvent was 
removed under reduced pressure to afford a dark brown oil. The oil was then taken up in hexanes 
and EtOAc (1:1) and filtered through a silica gel plug. This crude material was transferred to an 
oven-dried vial, dissolved in DCM (3.75 mL) and cooled to -78 C. BBr3 (1.20 mL, 1 M in DCM, 
4.0 equiv) was added dropwise. After 24 h, the reaction mixture was quenched by the slow addition 
of water (10 mL). The solution was extracted with EtOAc (3 x 15 mL). The combined organic 
layers were washed with brine (10 mL) and dried over magnesium sulfate. The solvent was 
removed under reduced pressure to afford a dark brown oil. Purification on silica gel (100% 
hexanes to 15% EtOAc in hexanes) afforded 44.4 mg (71% yield over two steps) of the title 
compound as a pale yellow solid.  1H NMR (400 MHz, CDCl3) δ 13.56 (s 1H), 6.21 (s, 1H), 5.39 
(s, 1H), 2.88 (t, J = 8, 2H), 2.53 (s, 3H), 2.09 (s, 3H), 1.76 (m, 2H), 0.98 (t, 3H, J = 8 Hz). All 






AlCl3 (44.0 mg, 0.330 mmol, 1.1 equiv) and 0.5 mL nitroethane were added to a flame-dried vial 
equipped with a stir bar. A solution of 1,3-dimethoxy-2,5-dimethylbenzene (50.0 mg, 0.300 mmol, 
1.0 equiv) in 0.2 mL nitroethane was then added followed by isobutyryl chloride (39.3 μL, 0.450 
mmol, 1.5 equiv). The mixture was stirred overnight before the reaction was quenched by the 
addition of water (3 mL). The mixture was extracted with EtOAc (3 x 15 mL). The combined 
organic layers were washed with brine (1 x 10 mL), dried over magnesium sulfate and filtered. 
The solvent was removed under reduced pressure to afford a dark brown oil. The oil was taken up 
in hexanes and EtOAc (1:1) and filtered through a silica gel plug. The crude material was 
transferred to an oven-dried vial, dissolved in DCM (3.75 mL) and cooled to -78 C. BBr3 (1.20 
mL, 1 M in DCM, 4.0 equiv) was added dropwise. After 4 h, the reaction mixture was quenched 
by the slow addition of water (10 mL). The solution was extracted with EtOAc (3 x 15 mL). The 
combined organic layers were washed with brine (1 x 10 mL) and dried over magnesium sulfate. 
The solvent was removed under reduced pressure to afford a dark brown oil. Purification on silica 
gel (100% hexanes to 15% EtOAc in hexanes) afforded 41.3 mg (62% yield over two steps) of the 
title compound as a tan solid. 1H NMR (400 MHz, CDCl3) δ 13.34 (s, 1H), 6.20 (s, 1H), 5.10 (s, 
1H), 2.78 (d, J = 6.6 Hz, 1H), 2.53 (s, 3H), 2.27 (m, 1H), 2.09 (s, 3H), 0.96 (d, J = 6.6 Hz, 6H).13C 
NMR (150 MHz, CDCl3) δ 207.6, 163.7, 158.6, 138.3, 115.7, 111.2, 109.3, 52.8, 25.9, 24.7, 22.7, 
7.6; HR-ESI-MS: m/z calculated for C13H17O3 [M-H]
-: 221.1183, found: 221.1185; IR (thin film): 






6-Bromo-2,4-dimethoxy-3-methylbenzaldehyde (100 mg, 0.433 mmol, 1.0 equiv), Pd(PPh)4 (50.0 
mg, 0.0430 mmol, 0.1 equiv), and K2CO3 (138 mg, 0.693 mmol, 1.6 equiv) were added to a flame-
dried vial which was then backfilled with N2. DMF (3.0 mL) was added followed by phenylboronic 
acid (79.0 mg, 0.649 mmol, 1.5 equiv), and the mixture was sparged with N2 for 15 min. The 
mixture was capped and stirred at 100 C for 10 h at which time the reaction mixture was allowed 
to cool to rt. The reaction was diluted with EtOAc (10 mL) and washed with water (3 x 10 mL) 
and brine (1 x 10 mL). The organic layer was dried over magnesium sulfate and concentrated under 
reduced pressure to afford a brown oil. Purification on silica gel (10% EtOAc in hexanes) afforded 
81.3 mg (73% yield) of biphenyl 2.52 as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 9.91 (s, 
1H), 7.40 (m, 3H), 7.32 (m, 2H), 6.60 (s, 1H), 3.89 (s, 3H), 2.19 (s, 3H); 13C NMR (151 MHz, 
CDCl3) δ 190.3, 161.9, 160.6, 146.4, 139.4, 129.6, 128.1, 127.8, 121.1, 120.1, 108.6, 62.3, 55.8, 
8.4; HR-ESI-MS: m/z calculated for C16H17O3 [M+Na]
+: 279.0992, found: 279.0994; IR (thin 




3,5-dimethoxy-4-methyl-[1,1'-biphenyl]-2-carbaldehyde (83.1 mg, 0.317 mmol, 1.0 equiv) in 
DCM (4.0 mL) was cooled to -78 C, and BBr3 (1.27 mL, 1 M in DCM, 4.0 equiv) was added 
47 
 
dropwise. The mixture was then warmed to rt and stirred for 24 h. The reaction mixture was 
quenched by the slow addition of water (10 mL). The solution was extracted with EtOAc (3 x 15 
mL). The combined organic layers were washed with brine, dried over sodium sulfate and 
concentrated under reduced pressure to afford a brown oil. Purification on silica gel (10% to 20% 
EtOAc in hexanes) afforded 61.5 mg (85% yield) of the title compound as a white solid.  1H NMR 
(400 MHz, CDCl3) δ  12.66 (s, 1H), 9.63 (s, 1H), 7.45 (m, 3H), 7.34 (m, 2H), 6.36 (s, 1H), 5.49 
(s, 1H), 2.18 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 195.3, 163.6, 160.2, 146.8, 137.3, 129.8, 
128.3, 128.2, 112.7, 110.2, 109.5, 7.1; HR-ESI-MS: m/z calculated for C14H11O3 [M-H]
-: 





0.45 mL DMF was added to a flame-dried round-bottom flask equipped with a stir bar. The vessel 
was cooled to 0 C and POCl3 (0.081 mL, 0.86 mmol, 1.2 equiv) was slowly added. The mixture 
was stirred for 30 min before 2,4-dimethylbenzene-1,3-diol (100 mg, 0.72 mmol in 0.45 mL DMF) 
was added dropwise. The mixture was warmed to rt. After 2 h, the reaction was quenched by the 
addition of ice (approx. 250 mg) followed by 10% NaOH(aq) until a pH of 13 was achieved at which 
time a precipitate formed. A white crystalline solid was isolated by vacuum filtration to yield 45.3 
mg (41% yield) of the title compound. 1H NMR (400 MHz, CDCl3) δ 11.54 (s, 1H), 9.66 (s, 1H), 
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2.50 mL DMF was added to a flame-dried round-bottom flask equipped with a stir bar. The vessel 
was cooled to 0 C and POCl3 (0.50 mL, 4.4 mmol, 1.1 equiv) was slowly added over 10 min. The 
mixture was stirred for 30 min before 2,4,5-trimethylbenzene-1,3-diol (0.55 g, 4.0 mmol in 2.5 
mL DMF) was added dropwise. The mixture was then warmed to rt. After 2 h, the reaction was 
quenched by the addition of ice (approx. 1 g) followed by 10% NaOH(aq) until a pH of 13 was 
achieved. The mixture was refluxed for 10 min before cooling to rt. Acidification to pH 3 induced 
precipitation of a white crystalline solid, which was isolated by vacuum filtration to yield 0.44 g 
(66% yield) of the title compound. 1H NMR (400 MHz, CDCl3) δ 12.79 (s, 1H), 10.18 (s, 1H), 





To a flame-dried round-bottomed flask equipped with a stir bar was added 2.5 mL DMF. The 
vessel was cooled to 0 C and POCl3 (0.50 mL, 1.1 equiv) was slowly added over 10 min. 2-ethyl-
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5-methylbenzene-1,3-diol (0.61 g, 4.0 mmol, 1.0 equiv) as a solution in 2.50 mL DMF was added 
dropwise. The mixture was warmed to rt. After 2 h, the reaction was quenched by the addition of 
ice followed by 10% NaOH(aq) to a pH of 13. The mixture was refluxed for 10 min before being 
cooling to rt and acidified to a pH of 3. A white crystalline solid precipitated and was isolated by 
vacuum filtration to yield 0.42 g (58% yield) of the title compound. 1H NMR (600 MHz, CD3CN) 
δ 12.73 (s, 1H), 10.07 (s, 1H), 7.72 (s, 1H), 6.28 (s, 1H), 2.58 (q, J = 7.5 Hz, 2H), 2.25 (s, 3H), 
1.08 (t, J = 7.5 Hz, 3H);13C NMR (150 MHz, CD3CN) δ 194.0, 163.6, 162.1, 142.2, 115.0, 112.8, 
110.0, 17.0, 15.0, 12.6; HRMS (ESI) m/z calculated for C14H11O3 [M-H]
- 179.0714, found: 




A mixture of 1,3-diacetoxy-5-methylbenzene (50 mg, 0.24 mmol) and AlCl3 (100 mg, 0.72 mmol, 
3.0 equiv) in chlorobenzene (2.5 mL) was stirred at 90 C for 24 h. After cooling to rt, ice (3 g) 
was added to the reaction mixture. The mixture was extracted with EtOAc (3 x 10 mL). The 
combined organic layers were washed with brine (1 x 5 mL), dried over sodium sulfate and 
concentrated under reduced pressure to give crude 2,6-diacetyl-5-methylresorcinol (53 mg). 
Purification on silica gel (20% EtOAc in hexanes) afforded 43 mg (85% yield) of the diketone as 
a colorless solid. 1H NMR (600 MHz, CDCl3): δ 6.29 (s, 1H), 2.74 (s, 3H), 2.65 (s, 3H), 2.57 (s, 






10 mL DMF was added to a flame-dried round-bottomed flask equipped with a stir bar. The vessel 
was cooled to 0 C and POCl3 (0.82 mL, 8.9 mmol, 1.1 equiv) was slowly added over 10 min. 5-
methyl resorcinol (1.0 g, 8.1 mmol, 1.0 equiv) as a solution in 5.0 mL DMF was added dropwise. 
The mixture was warmed to rt. After 2 h, the reaction was quenched by the addition of ice followed 
by 10% NaOH(aq) to a pH of 13. The mixture was refluxed for 10 min before being cooling to rt 
and acidified to pH 3. A white crystalline solid precipitated and was isolated by vacuum filtration 
to yield 1.1 g (87% yield) of the aldehyde. 1H NMR (400 MHz, CDCl3) δ 12.38 (s, 1H), 10.10 (s, 





6-Bromo-2,4-dihydroxy-3-methylbenzaldehyde (2.55) (140 mg, 0.649 mmol, 1.0 equiv), 
PdCl2(PPh3)2 (46.1 mg,  0.065 mmol, 0.1 equiv) and CuI (12.4 mg, 0.065 mmol, 0.1 equiv) in 4.7 
mL anhydrous  DMF were added to a flame-dried round-bottomed flask. ± 4-Pentyn-2-ol (73.5 
L, 0.779 mmol, 1.2 equiv) and Et3N (298 L, 2.14 mmol, 3.3 equiv) were then added, and the 
mixture was sparged with N2 for 15 min. The mixture was heated at 60 C for 14 h. The reaction 
mixture was cooled to rt, diluted with water (5 mL) and acidified to a pH of 2. The mixture was 
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extracted with EtOAc (3 x 15 mL) and the combined organic layers were washed with water (10 
mL) and brine (10 mL), dried over sodium sulfate, filtered, and concentrated under reduced 
pressure to afford crude 2.95. Purification on silica gel (50% EtOAc in hexanes) provided 121 mg 
(80% yield) of alkynylbenzaldehyde 2.95 as a yellow solid. 1H NMR (400 MHz, CD3OD) δ 10.16 
(s, 1H), 6.49 (s, 1H), 3.98 (h, J = 6.1 Hz, 1H), 2.59 (d, J = 6.0 Hz, 2H), 2.01 (s, 3H), 1.29 (d, J = 
6.2 Hz, 3H); 13C NMR (150 MHz, (CD3)2SO) δ 194.9, 163.4, 162.6, 126.8, 113.3, 112.4, 111.5, 
95.4, 77.3, 65.3, 29.8, 23.3, 7.8; HR-ESI-MS: m/z calculated for C13H13O4 [M-H]
- 233.0819, 




6-Bromo-2,4-dihydroxy-3-methylbenzaldehyde (2.55) (100 mg, 0.433 mmol, 1.0 equiv), 
PdCl2(PPh3)2 (30.4 mg, 0.043 mmol, 0.1 equiv) and CuI (8.25 mg, 0.043 mmol, 0.1 equiv) in 3.1 
mL anhydrous  DMF were added to a flame-dried round-bottom flask. 1-Pentyne (85.0 L, 0.866 
mmol, 2.0 equiv) and Et3N (197 L, 1.41 mmol, 3.3 equiv) were added, and the resulting mixture 
was heated at 60 C for 14 h. The reaction mixture was cooled to rt, diluted with water (5 mL), 
and neutralized with 1.0 N aqueous HCl (2 mL). The mixture was extracted with EtOAc (3 x 15 
mL) and the combined organic layers were washed with water (10 mL), brine (10 mL), dried over 
sodium sulfate, filtered, and concentrated under reduced pressure afford 2.96. Purification on silica 
gel (15% EtOAc in hexanes) provided 93.8 mg (99% yield) of the alkynylbenzaldehyde as a yellow 
solid. 1H NMR (600 MHz, (CD3)2SO) δ 12.26 (s, 1H), 10.93 (s, 1H), 10.05 (s, 1H), 6.53 (s, 1H), 
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2.44 (t, J = 7.0 Hz, 2H), 1.94 (s, 3H), 1.56 (h, J = 7.2 Hz, 2H), 0.98 (t, J = 7.4 Hz, 3H); 13C NMR 
(150 MHz, (CD3)2SO) δ 194.6, 163.4, 162.6, 126.8, 113.3, 112.5, 111.5, 97.5, 76.4, 21.9, 21.1, 
13.8, 7.8; HR-ESI-MS (ESI) m/z calculated for C13H13O3 [M-H]
- 217.0870, found: 217.0870; IR 




2,4-dihydroxy-3-methyl-6-(pent-1-yn-1-yl)benzaldehyde (121 mg, 0.519 mmol, 1.0 equiv) and 
AgNO3 (8.8 mg, 0.052 mmol, 0.1 equiv) were added to a flame-dried round-bottom flask followed 
by DCE (5 mL) and TFA (198 L, 2.60 mmol, 5.0 equiv). The resulting mixture was stirred at rt 
for 45 min. MeCN and water (10 mL, 10:1) was added, and the mixture was stirred for 1 h. The 
mixture was concentrated under reduced pressure and the residue was diluted with EtOAc (10 
mL), washed with water (5 mL) and brine (5 mL). The organic layer was dried over sodium sulfate, 
filtered and concentrated under reduced pressure. Purification on silica gel (40% EtOAc in 
hexanes) provided 55.0 mg (42% yield) of aldehyde 25 as a colorless solid. 1H NMR (400 MHz, 
CD3OD) δ 10.16 (s, 1H), 6.49 (s, 1H), 3.99 (m, 1H), 2.60 (m, 2H), 2.01 (s, 3H), 1.29 (d, J = 8.0 Hz, 
3H) ppm. All spectra obtained were consistent with literature values.30 
 




2,4-dihydroxy-3-methyl-6-(pent-1-yn-1-yl)benzaldehyde (99.8 mg, 0.430 mmol, 1.0 equiv) and 
AgNO3 (7.3 mg, 0.043 mmol, 0.1 equiv) were added to a flame-dried round bottom flask followed 
by DCE (5 mL) and TFA (165 L, 2.15 mmol, 5.0 equiv), and the resulting mixture was stirred at 
rt for 45 min. MeCN and water (10 mL, 10:1) was added and the mixture was stirred for 1 h. The 
mixture was then concentrated, and the residue was diluted with EtOAC (10 mL), washed with 
water (5 mL) and brine (5 mL). The organic layer was dried over sodium sulfate, filtered and 
concentrated under reduced pressure. Purification on silica gel (30% EtOAc in hexanes) provided 
29.5 mg (29% yield) of the dicarbonyl as a tan solid. 1H NMR (400 MHz, CDCl3) δ 12.65 (s, 1H), 
9.86 (s, 1H), 6.19 (s, 1H), 3.89 (s, 2H), 2.51 (t, J = 7.3 Hz, 2H), 1.62 (q, J = 7.3 Hz, 2H), 0.91 (t, J 
= 7.4 Hz, 3H) ppm; 13C NMR (150 MHz, CD3CN) δ 207.5, 194.1, 163.7, 162.2, 138.4, 112.7, 
110.4, 110.0, 45.1, 44.0, 21.9, 6.4; HR-ESI-MS: m/z calcd. for C13H15O4 [M-H]
-: 235.0976, found: 




A solution of 2,4-dihydroxy-3-methylbenzaldehyde (260 mg, 1.71 mmol, 1.0 equiv) in acetic 
anhydride (210 L, 1.90 mmol, 1.1 equiv) was added to a round-bottom flask and cooled to 0 °C. 
Cu(NO3)2•3H2O (546 mg, 2.22 mmol, 1.3 equiv) was added to the solution over 5 min. The 
reaction mixture was stirred for 2 h at 0 °C. The reaction was quenched by the addition of ice (4 
g) and extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with brine (5 
mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification on 
54 
 
silica gel (30% EtOAc in hexanes) provided 211 mg (73% yield) of the nitrobenzaldehyde as a 
pale yellow solid. 1H NMR (400 MHz, CDCl3) δ 11.88 (s, 1H), 11.53 (s, 1H), 9.80 (s, 1H), 8.36 
(s, 1H), 2.19 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 194.4, 165.5, 159.3, 130.7, 127.7, 115.2, 
114.3, 7.4; IR (thin film): 2922, 1597, 1289, 1252, 1222, 1115 cm-1; HR-ESI-MS: m/z calculated 
for C8H6NO5 [M-H]




2,5-dimethylphenol (1.04 g, 8.18 mmol, 1.0 equiv), in a 1 M solution of NaOH(aq) (13 mL) was 
heated to 60 °C. CHCl3 (1.64 mL, 20.4 mmol, 2.5 equiv) was added dropwise. The mixture was 
allowed to stir for 5 h, and then the reaction was quenched by the addition of HCl (2 M, 7 mL). 
The mixture was extracted with EtOAc (3 x 30 mL). The combined organic layers were washed 
with brine (1 x 15 mL), dried over sodium sulfate, filtered and concentrated under reduced 
pressure. Purification on silica gel (100% hexanes to 30% EtOAc in hexanes) afforded 163 mg 
(13% yield) of the ortho-hydroxybenzaldehyde as a colorless solid. 1H NMR (400 MHz, CDCl3): 
δ 12.18 (s, 1H), 10.30 (s, 1H), 7.24 (d, J = 7.5 Hz, 1H), 6.61 (d, J = 7.5 Hz, 1H), 2.57 (s, 3H), 2.21 
(s, 3H). All spectra obtained were consistent with literature values.31 The structural isomer 2.68 
eluted in 50% EtOAc/hexanes. 1H NMR (400 MHz, CDCl3): 10.08 (s, 1H), 7.60 (s, 1H), 6.67 (s, 





1-(2,4-dihydroxy-3-methylphenyl)pentan-1-one (2.79)  
2-methylresorcinol (100 mg, 0.805 mmol, 1.0 equiv) and valeric acid (87.6 L, 0.805 mmol, 1.0 
equiv), were added to a flame-dried vial equipped with a stir bar. BF3•OEt2 (0.199 mL, 1.61 mmol, 
2 equiv) was added, and the reaction mixture was heated to 120 C for 4 h. The reaction was 
quenched at 0 C by the addition of water (1 mL) and extracted with EtOAc (3 x 10 mL). The 
combined organic layers were dried over magnesium sulfate, and the filtrate was concentrated 
under reduced pressure to afford a brown solid. The resulting material was refluxed in THF/water 
(1:1, 0.07 M) for 3 h. The mixture was extracted with EtOAc (3 x 25 mL). The organic layers were 
combined, dried over magnesium sulfate and concentrated under reduced pressure. Purification on 
silica gel (100% hexanes to 30% EtOAc in hexanes) afforded 122 mg (73% yield over two steps) 
of ketone 2.79 as a white solid. 1H NMR (600 MHz, CDCl3): δ 13.17 (s, 1H), 7.54 (d, J = 8.8 Hz, 
1H), 6.38 (d, J = 8.8 Hz, 1H), 5.97 (s, 1H), 2.90 (t, J = 6.0 Hz, 2H), 2.13 (s, 3H), 1.72 (m, 2H), 
1.41 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 205.8, 163.2, 160.3, 129.1, 
113.3, 111.4, 106.9, 37.8, 27.3, 22.5, 13.8, 7.3; HR-ESI-MS: m/z calculated for C12H15O3 [M-H]
-







1-(2,4-dihydroxy-3-methylphenyl)pentan-1-one (50.0 mg, 0.240 mmol, 1.0 equiv) and  2.4 mL of 
MeOH were added to a flame-dried round-bottom flask equipped with a stir bar. NBS (57.8 mg, 
0.325 mmol, 1.3 equiv) was added, and the mixture was stirred at rt for 1 h. The solution was 
concentrated and extracted with EtOAc (3 x 15 mL). The combined organic layers were washed 
with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford 
an orange oil. Purification on silica gel (100% hexanes to 15% EtOAc in hexanes) afforded 34.1 
mg (49% yield) of the aryl bromide as a pale yellow solid.  1H NMR (400 MHz, CDCl3): δ 12.94 
(s, 1H), 7.74 (s, 1H), 5.96 (s, 1H), 2.87 (t, J = 7.5 Hz, 2H), 2.17 (s, 3H), 1.68 (m, 2H), (m, 2H), 
0.94 (t, J = 7.4 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 205.8, 163.2, 160.3, 129.1, 113.3, 111.4, 
106.9, 37.8, 27.3, 22.5, 13.8, 7.3; HR-ESI-MS: m/z calculated for C12H14BrO3 [M-H]
-: 285.0132, 




2-hydroxy-3,6-dimethylbenzaldehyde (100 mg, 0.609 mmol, 1.0 equiv), and NBS (141 mg, 0.792 
mmol, 1.3 equiv) were added to a vial and stirred at rt for 3 h. The solvent was then removed under 
reduced pressure and diluted with water. The mixture was extracted with EtOAc (3 x 10 mL). The 
combined organic layers were washed with brine (1 x 15 mL), dried over sodium sulfate, filtered 
and concentrated under reduced pressure. Purification on silica gel (100% hexanes to 10% Et2O in 
hexanes) afforded 139 mg (99% yield) of the aryl bromide as a pale yellow solid. 1H NMR (400 
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MHz, CDCl3) δ; 12.20 (s, 1H), 10.18 (s, 1H), 7.37 (s, 1H), 2.49 (s, 3H), 2.05 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 195.3, 160.8, 141.1, 137.4, 126.7, 118.5, 114.0, 17.0, 14.3; IR (thin film): 
3043, 2953, 2922, 1632, 1609, 1451 cm-1; HR-ESI-MS: m/z calculated for C9H7BrO2 [M+H]
+: 




BBr3 (2.79 mL, 2.79 mmol, 1.2 equiv, 1 M in DCM) and FeCl3 (452 mg, 2.79 mmol, 1.2 equiv) in 
3 mL chlorobenzene was cooled to -15 C. 5-bromo-2-methylphenyl formate (500 mg, 2.32 mmol, 
1.0 equiv) in 1 mL chlorobenzene was added dropwise and allowed to stir at 0 C overnight. The 
reaction was warmed to rt and quenched by the addition of water. The mixture was extracted with 
EtOAc (3 x 10 mL). The combined organic layers were washed with brine (1 x 15 mL), dried over 
sodium sulfate, filtered and concentrated under reduced pressure. Purification on silica gel (100% 
hexanes to 10% Et2O in hexanes) afforded 360 mg (72% yield) of the aryl bromide as a pale yellow 
solid. 1H NMR (600 MHz, CDCl3) δ 12.16 (s, 1H), 10.19 (s, 1H), 7.08 (d, J = 7.9 Hz, 1H), 6.95 
(d, J = 7.9 Hz, 1H), 2.11 (3H); 13C NMR (100 MHz, CDCl3) δ 197.9, 162.3, 138.0, 127.1, 124.1, 
123.6, 116.8, 14.9 cm-1; IR (thin film): 2924, 2855, 1632, 1600, 1452, 1381 cm-1; HR-ESI-MS: 
m/z calculated for C8H7BrO2 [M+H]







2-hydroxy-3-methylbenzaldehyde (200 mg, 1.47 mmol, 1.0 equiv), and NBS (340 mg, 1.91 mmol, 
1.3 equiv) were added to a vial and stirred at rt for 3 h. The solvent was then removed under 
reduced pressure and diluted with water. The mixture was extracted with EtOAc (3 x 10 mL). The 
combined organic layers were washed with brine (1 x 15 mL), dried over sodium sulfate, filtered 
and concentrated under reduced pressure. Purification on silica gel (100% hexanes to 10% Et2O in 
hexanes) afforded 111 mg (35% yield) of the aryl bromide as a colorless solid. 1H NMR (600 
MHz, CDCl3) δ 11.22 (s, 1H), 9.85 (s, 1H), 7.54 (s 1H), 7.53 (s, 1H), 2.29 (s, 3H). All spectra 




2,4,5-trimethylbenzene-1,3-diol (173 mg, 1.14 mmol, 1.0 equiv) and valeric acid (124 L, 1.14 
mmol, 1.0 equiv) were added to a flame-dried vial equipped with a stir bar. BF3•OEt2 (4.89 mL, 
38.6 mmol, 10.7 equiv) was added and the reaction mixture was heated to 120 C for 4 h. The 
reaction was quenched at 0 C by the addition of water (10 mL) and extracted with EtOAc (3 x 20 
mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated 
under reduced pressure to afford a brown solid. The resulting material was refluxed in THF/water 
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(1:1, 0.07 M) for 3 h. The mixture was extracted with EtOAc (3 x 25 mL). The organic layers were 
combined, dried over magnesium sulfate and concentrated under reduced pressure. Purification on 
silica gel (100% hexanes to 30% EtOAc in hexanes) afforded 83.9 mg (31% yield over two steps) 
of the ketone as a pale yellow solid. 1H NMR (400 MHz, CDCl3): δ 11.79 (s, 1H), 5.23 (s, 1H), 
2.82 (t, J = 8.0 Hz, 2H), 2.38 (s, 3H), 2.11 (s, 3H), 2.10 (s, 3H), 1.68 (m, 2H), 1.33 (m, 2H), 0.89 
(t, J = 8.0 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 205.7, 161.5, 158.5, 132.1, 113.9, 113.4, 
101.4, 37.4, 26.6, 22.1, 14.2, 9.3; HR-ESI-MS: m/z calculated for C14H20O3 [M-H]
-: 235.1340, 




2,4-dimethylbenzene-1,3-diol (50.0 mg, 0.362 mmol, 1.0 equiv) and acetic acid (20.7 L, 0.362 
mmol, 1.0 equiv) were added to a flame-dried vial equipped with a stir bar. BF3•OEt2 (4.89 mL, 
38.6 mmol, 10.7 equiv) was added, and the reaction mixture was heated to 120 C for 4 h. The 
reaction was quenched at 0 C by the addition of water (2 mL) and extracted with EtOAc (3 x 10 
mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated 
under reduced pressure to afford a dark orange solid. The resulting material was refluxed in 
THF/water (1:1, 0.07 M) for 3 h. The mixture was extracted with EtOAc (3 x 10 mL). The organic 
layers were combined, dried over magnesium sulfate and concentrated under reduced pressure. 
Purification on silica gel (100% hexanes to 50% EtOAc in hexanes) afforded 17.5 mg (27% yield 
over two steps) of the ketone as a white solid.  1H NMR (600 MHz, CDCl3): δ 12.87 (s, 1H), 7.37 
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(s, 1H), 5.28 (s, 1H), 2.55 (s, 3H), 2.21 (s, 3H), 2.13 (s, 3H). All spectra obtained were consistent 





2,4-dimethylbenzene-1,3-diol (500 mg, 3.62 mmol, 1.0 equiv) and butyric acid (398 L, 4.34 
mmol, 1.2 equiv), were added to a flame-dried vial equipped with a stir bar. BF3•OEt2 (4.89 mL, 
38.6 mmol, 10.7 equiv) was added, and the reaction mixture was heated to 120 C for 4 h. The 
reaction was quenched at 0 C by the addition of water (10 mL) and extracted with EtOAc (3 x 20 
mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated 
under reduced pressure to afford a brown solid. The resulting material was refluxed in THF/water 
(1:1, 0.07 M) for 3 h. The mixture was extracted with EtOAc (3 x 25 mL). The organic layers were 
combined, dried over magnesium sulfate and concentrated under reduced pressure. Purification on 
silica gel (100% hexanes to 30% EtOAc in hexanes) afforded 528 mg (70% yield over two steps) 
of the propylketone as a pale yellow solid.  1H NMR (600 MHz, CDCl3) δ 13.04 (s, 1H), 7.40 (s, 
1H), 5.30 (s, 1H), 2.88 (t, J = 7.4 Hz, 2H), 2.21 (s, 3H), 2.14 (s, 3H), 1.76 (m, 2H), 1.01 (t, J = 7.4 
Hz, 3H);13C NMR (150 MHz, CDCl3): δ 207.5, 163.7, 158.4, 138.2, 115.7, 111.1, 109.1, 52.8, 
25.8, 24.8, 7.6. HR-ESI-MS: m/z calculated for C12H15O3 [M-H]
-: 207.1027, found: 207.1027; IR 





(2E,4E)-1-(2,4-dihydroxy-3,5-dimethylphenyl)hexa-2,4-dien-1-one (sorbicillin, 2.15) 
2,4-dimethylbenzene-1,3-diol (500 mg, 3.62 mmol, 1.0 equiv) and butyric acid (398 L, 4.34 
mmol, 1.2 equiv), were added to a flame-dried vial equipped with a stir bar. BF3•OEt2 (4.89 mL, 
38.6 mmol, 10.7 equiv) was added, and the reaction mixture was heated to 120 C for 4 h. The 
reaction was quenched at 0 C by the addition of water (10 mL) and extracted with EtOAc (3 x 20 
mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated 
under reduced pressure to afford a brown solid. The resulting material was refluxed in THF/water 
(1:1, 0.07 M) for 3 h. The mixture was extracted with EtOAc (3 x 25 mL). The organic layers were 
combined, dried over magnesium sulfate and concentrated under reduced pressure. Purification on 
silica gel (100% hexanes to 30% EtOAc in hexanes) afforded 528 mg (70% yield over two steps) 
of sorbicillin (2.15) as a pale yellow solid. 1H NMR (600 MHz, CDCl3) δ 13.59 (s, 1H), 7.46 (m, 
2H), 6.95 (d, J = 14.8 Hz, 1H), 6.31 (m, 2H), 5.27 (s, 1H), 2.22 (s, 3H), 2.15 (s, 3H), 1.91 (d, J = 





2,4-dimethylbenzene-1,3-diol (500 mg, 3.62 mmol, 1.0 equiv) and hexanoic acid (544 L, 3.62 
mmol, 1.0 equiv), were added to a flame-dried vial equipped with a stir bar. BF3•OEt2 (4.89 mL, 
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38.6 mmol, 10.7 equiv) was added, and the reaction mixture was heated to 120 C for 4 h. The 
reaction was quenched at 0 C by the addition of water (10 mL) and extracted with EtOAc (3 x 
20 mL). The combined organic layers were dried over magnesium sulfate, filtered and 
concentrated under reduced pressure to afford a brown solid. The resulting material was refluxed 
in THF/water (1:1, 0.07 M) for 3 h. The mixture was extracted with EtOAc (3 x 25 mL). The 
organic layers were combined, dried over magnesium sulfate and concentrated under reduced 
pressure. Purification on silica gel (100% hexanes to 30% EtOAc in hexanes) afforded 667 mg 
(78% yield over two steps) of the ketone as a pale yellow solid. 1H NMR (600 MHz, CDCl3) δ 
13.04 (s, 1H), 7.38 (s, 1H), 5.47 (s, 1H), 2.88 (t, J = 7.5 Hz, 2H), 2.21 (s, 3H), 2.13 (s, 3H), 1.72 




2-Ethyl-4-methylbenzene-1,3-diol (82.3 mg, 0.541 mmol, 1.0 equiv) and valeric acid (71.0 L, 
0.649 mmol, 1.2 equiv) were added to a flame-dried vial equipped with a stir bar. BF3•OEt2 (0.730 
mL, 4.59 mmol, 7.0 equiv) was added, and the reaction mixture was heated to 120 C for 4 h. The 
reaction was quenched at 0 C by the addition of water (1 mL) and extracted with EtOAc (3 x 10 
mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated 
under reduced pressure to afford a brown solid. The resulting material was refluxed in THF/water 
(1:1, 0.07 M) for 3 h. The mixture was extracted with EtOAc (3 x 25 mL). The organic layers were 
combined, dried over magnesium sulfate and concentrated under reduced pressure. Purification on 
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silica gel (100% hexanes to 30% EtOAc in hexanes) afforded 30.6 mg (24% yield over two steps) 
of the ketone as a pale yellow solid.  1H NMR (400 MHz, CDCl3) δ 13.01 (s, 1H), 7.39 (s, 1H), 
5.34 (s, 1H), 2.89 (t, J = 7.5 Hz, 2H), 2.67 (q, J = 7.5 Hz, 2H), 2.21 (s, 3H), 1.72 (m, 2H), 1.42 (m, 
2H), 1.15 (t, J = 7.5 Hz, 3H), 0.96 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 205.4, 
161.3, 158.2, 127.6, 120.7, 113.0, 110.2, 37.7, 27.1, 22.8, 22.5, 14.1, 13.9, 7.4. HR-ESI-MS: m/z 
calculated for C14H19O3 [M-H]
-: 235.1340, found: 235.1341; IR (thin film): 3419, 2964, 1633, 




2,4-dimethylbenzene-1,3-diol (100 mg, 0.805 mmol, 1.0 equiv) and valeric acid (87.6 L, 0.805 
mmol, 1.0 equiv) were added to a flame-dried vial equipped with a stir bar. BF3•OEt2 (1.09 mL, 
8.58 mmol, 10.7 equiv) was added, and the reaction mixture was heated to 120 C for 4 h. The 
reaction was quenched at 0 C by the addition of water (1 mL) and extracted with EtOAc (3 x 10 
mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated 
under reduced pressure to afford a brown solid. The resulting material was refluxed in THF/water 
(1:1, 0.07 M) for 3 h. The mixture was extracted with EtOAc (3 x 25 mL). The organic layers were 
combined, dried over magnesium sulfate and concentrated under reduced pressure. Purification on 
silica gel (100% hexanes to 30% EtOAc in hexanes) afforded 100 mg (62% yield over two steps) 
of the ketone as a white solid.  1H NMR (600 MHz, CDCl3) δ 13.04 (s, 1H), 7.40 (s, 1H), 5.25 (s, 
1H), 2.93 – 2.87 (t, J = 6.0 Hz, 2H), 2.21 (s, 3H), 2.13 (s, 3H), 1.71 (m, 2H), 1.45 – 1.38 (m, 2H), 
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0.96 (t, J = 7.4 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 205.3, 161.4, 158.5, 129.1, 114.3, 113.0, 
110.3, 37.7, 27.1, 22.5, 15.6, 13.9, 7.4; HR-ESI-MS: m/z calculated for C13H17O3 [M-H]
-: 




4-Ethyl-2-methylbenzene-1,3-diol (455 mg, 2.99 mmol, 1.0 equiv) and valeric acid (394 L, 3.59 
mmol, 1.2 equiv) were added to a flame-dried vial equipped with a stir bar. BF3•OEt2 (4.27 mL, 
26.2 mmol, 8.8 equiv) was added, and the reaction mixture was heated to 120 C for 4 h. The 
reaction was quenched at 0 C by the addition of water (1 mL) and extracted with EtOAc (3 x 10 
mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated 
under reduced pressure to afford a brown solid. The resulting material was refluxed in THF/water 
(1:1, 0.07 M) for 3 h. The mixture was extracted with EtOAc (3 x 25 mL). The organic layers were 
combined, dried over magnesium sulfate and concentrated under reduced pressure. Purification on 
silica gel (100% hexanes to 30% EtOAc in hexanes) afforded 257 mg (36% yield over two steps) 
of the ketone as a white solid.  1H NMR (400 MHz, CDCl3) δ 13.06 (s, 1H), 7.40 (s, 1H), 5.29 (s, 
1H), 2.94 (m, 2H), 2.59 (q, J = 7.4 Hz, 2H), 2.14 (s, 3H), 1.70 (m, 2H), 1.42 (m, 2H), 1.24 (t, J = 
7.5 Hz, 3H), 0.96 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 205.4, 161.3, 158.2, 127.6, 
120.7, 113.0, 110.2, 37.7, 27.1, 22.8, 22.5, 14.1, 13.9, 7.4; HR-ESI-MS: m/z calculated for 
C14H19O3 [M-H]
-: 235.1340, found: 235.1339; IR (thin film): 3429, 1962, 1632, 1603, 1110 cm-1; 




Synthesis of racemic product standards 
Note: full characterization of products provided for products isolated from biocatalytic reactions 
in Chapter 2.6.3. 
 
General procedure for IBX-mediated oxidative dearomatization: Adapted from reference 5. 
Substrate (20 mg, 1.0 equiv), IBX (1.2 equiv) and TBAI (0.05 equiv) were added to an oven-
dried vial. DCE (1.5 mL) and TFA (5.0 equiv) were added and the mixture was allowed to stir at 
rt until full consumption of starting material by TLC analysis. The reaction was quenched by the 
addition of water and concentrated to dryness. Preparative HPLC purification afforded the 
racemic o-quinol product.  
 
General procedure for lead tetraacetate (LTA)-mediated oxidative dearomatization: 
Adapted from reference 20. Substrate (50 mg, 1 equiv, 0.04 M) was dissolved in AcOH and 
DCM (5:1). LTA (1.2 equiv) was added and the reaction was allowed to stir at rt for 1 h. The 
reaction was quenched by the addition of water (10 mL) and the mixture was extracted with 
EtOAc (3 x 15 mL). The combined organic layers were washed with water (1 x 20 mL) and brine 
(1 x 20 mL), dried over sodium sulfate, and concentrated under reduced pressure to afford a 






The title compound was synthesized according to the general procedure for IBX-mediated 
oxidative dearomatization. Purification by preparative HPLC using a Phenomenex Kinetex 5 µm 
C18, 150 x 21.2 mm column under the following conditions: mobile phase A = deionized water + 
0.1% formic acid and B = acetonitrile + 0.1% formic acid; method = 5% to 100% B over 13 min, 
100% B for 4 min; flow rate, 15 mL/min afforded 4.4 mg (20% yield) of the title compound as a 






The title compound was synthesized according to the general procedure for IBX-mediated 
oxidative dearomatization. Purification by preparative HPLC using a Phenomenex Kinetex 5 µm 
C18, 150 x 21.2 mm column under the following conditions: mobile phase A = deionized water + 
0.1% formic acid and B = acetonitrile + 0.1% formic acid; method = 5% to 100% B over 13 min, 
100% B for 4 min; flow rate, 15 mL/min afforded 3.0 mg (14% yield) of the racemic o-quinol as 
a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.88 (s, 1H), 5.86 (s, 1H), 3.67 (s, 1H), 2.13 (s, 2H), 






The title compound was synthesized according to the general procedure for IBX-mediated 
oxidative dearomatization. Purification by preparative by preparative HPLC using a Phenomenex 
Kinetex 5 µm C18, 150 x 21.2 mm column under the following conditions: mobile phase A = 
deionized water + 0.1% formic acid and B = acetonitrile + 0.1% formic acid; method = 5% to 
100% B over 13 min, 100% B for 4 min; flow rate, 15 mL/min afforded 6.7 mg (31% yield) of the 
racemic o-quinol as a yellow oil. 1H NMR (600 MHz, CD3CN) δ 8.06 (s, 1H), 2.10 (s, 3H), 1.94 




The title compound was synthesized according to the general procedure for IBX-mediated 
oxidative dearomatization. Purification by preparative HPLC using a Phenomenex Kinetex 5 µm 
C18, 150 x 21.2 mm column under the following conditions: mobile phase A = deionized water + 
0.1% formic acid and B = acetonitrile + 0.1% formic acid; method = 5% to 70% B over 10 min, 
70% to 100% B for 10 min; flow rate, 15 mL/min afforded 3.9 mg (18% yield) of the title 
compound as a yellow oil. 1H NMR (600 MHz, CD3CN): δ 7.73 (s, 1H), 7.51 (m, 3H), 7.44 (m, 






The title compound was synthesized according to the general procedure for IBX-mediated 
oxidative dearomatization. Purification by preparative HPLC using a Phenomenex Kinetex 5 µm 
C18, 150 x 21.2 mm column under the following conditions: mobile phase A = deionized water + 
0.1% formic acid and B = acetonitrile + 0.1% formic acid; method = 5% to 70% B over 10 min, 
70% to 100% B for 10 min; flow rate, 15 mL/min afforded 3.6 mg (26% yield) of the title 
compound as a yellow oil. 1H NMR (600 MHz, CDCl3) δ 5.76 (s, 1H), 3.66 (s, 1H), 2.72 (m, 2H), 





The title compound was synthesized according to the general procedure for IBX-mediated 
oxidative dearomatization. Purification by preparative HPLC using a Phenomenex Kinetex 5 µm 
C18, 150 x 21.2 mm column under the following conditions: mobile phase A = deionized water + 
0.1% formic acid and B = acetonitrile + 0.1% formic acid; method = 5% to 70% B over 15 min, 
70% to 100% B for 10 min; flow rate, 15 mL/min afforded 2.6 mg (11% yield) of the title 
compound as a yellow oil. 1H NMR (600 MHz, CD3CN) δ 3.91 (s, 1H), 3.74 (d, J = 21.3 Hz, 1H), 






The title compound was synthesized according to the general procedure for IBX-mediated 
oxidative dearomatization. Purification by preparative HPLC using a Phenomenex Kinetex 5 µm 
C18, 150 x 21.2 mm column under the following conditions: mobile phase A = deionized water + 
0.1% formic acid and B = acetonitrile + 0.1% formic acid; method = 5% to 70% B over 15 min, 
70% to 100% B for 10 min; flow rate, 15 mL/min afforded 2.8 mg (12% yield) of the title 
compound as a dark orange oil. 1H NMR (600 MHz, CD3CN) δ 3.90 (s, 1H), 3.75 (d, J = 18 Hz, 
1H), 3.25 (d, J = 18 Hz, 1H), 2.62 (t, J = 7.2, 2H), 1.98 (s, 3H), 1.60 (m, 2H), 1.56 (s, 3H), 1.47 




The title compound was synthesized according to the general procedure for IBX-mediated 
oxidative dearomatization Purification by preparative HPLC using a Phenomenex Kinetex 5 µm 
C18, 150 x 21.2 mm column under the following conditions: mobile phase A = deionized water + 
0.1% formic acid and B = acetonitrile + 0.1% formic acid; method = 5% to 100% B over 13 min, 
100% B for 4 min; flow rate, 15 mL/min afforded 2.9 mg (13% yield) of the title compound as a 
dark orange oil as a mixture of the keto-enol tautomers. 1H NMR (400 MHz, CD3CN) δ 8.10 (s, 
1H), 5.54 (s, 1H), 3.75 (d, J = 22.2 Hz, 1H), 3.26 (d, J = 22.1 Hz, 1H), 2.46 (s, 3H), 2.34 (s, 3H), 






The title compound was prepared according to the general procedure for IBX-mediated oxidative 
dearomatization. Purification by preparative HPLC using a Phenomenex Kinetex 5 µm C18, 150 
x 21.2 mm column under the following conditions: mobile phase A = deionized water + 0.1% 
formic acid and B = acetonitrile + 0.1% formic acid; method = 5% to 100% B over 13 min, 100% 
B for 4 min; flow rate, 15 mL/min afforded 6.3 mg (55% yield) of the beta-hydroxyazaphilone as 
a dark red oil.  1H NMR (400 MHz, CDCl3) δ 8.04 (s, 1H), 6.40 (s, 1H), 5.48 (d, J = 1.1 Hz, 1H), 
4.12 – 4.07 (m, 1H), 2.61 (dd, J = 14.6, 4.6 Hz, 1H), 2.53 (dd, J = 14.6, 8.2 Hz, 1H), 1.49 (s, 3H), 




The title compound was prepared according to the general procedure for IBX-mediated oxidative 
dearomatization. Purification by preparative HPLC using a Phenomenex Kinetex 5 µm C18, 150 
x 21.2 mm column under the following conditions: mobile phase A = deionized water + 0.1% 
formic acid and B = acetonitrile + 0.1% formic acid; method = 5% to 100% B over 13 min, 100% 
B for 4 min; flow rate, 15 mL/min afforded 14 mg (71% yield) of the azaphilone as a dark orange 
oil. 1H NMR (700 MHz, CDCl3): δ 7.90 (s, 1H), 6.12 (s, 1H), 5.52 (s, 1H), 2.73 (s, 1H), 2.41 (t, J 







The title compound was prepared according to the general procedure for LTA-mediated oxidative 
dearomatization. Purification on silica gel (20% to 50% EtOAc in hexanes) afforded 12 mg (20% 
yield) of the o-quinol as a yellow oil. 1H NMR (700 MHz, CDCl3) δ 11.83 (s, 1H), 7.46 (dd, J = 
14.7, 10.6 Hz, 1H), 7.25 (s, 1H), 6.66 (d, J = 14.8 Hz, 1H), 6.35 (m, 2H), 2.15 (s, 3H), 1.93 (d, J = 
6.4 Hz, 3H), 1.86 (s, 3H), 1.49 (s, 3H). All spectra obtained were consistent with literature values.13 
 
 
4-hydroxy-1,5-dimethyl-6-oxo-3-pentanoylcyclohexa-2,4-dien-1-yl acetate, (±)-2.89 
The title compound was prepared according to the general procedure for LTA-mediated oxidative 
dearomatization. Purification on silica gel (30% to 50% EtOAc in hexanes) afforded 14 mg (23% 
yield) of the o-quinol as a yellow oil. 1H NMR (700 MHz, CDCl3) δ 11.53 (s, 1H), 7.29 (s, 1H), 
2.81 (t, J = 7.3, 2H), 2.14 (s, 3H), 1.84 (s, 3H), 1.65 (m, 2H), 1.48 (s, 3H), 1.36 (m, 2H), 0.94 (t, J 





5-ethyl-4-hydroxy-1-methyl-6-oxo-3-pentanoylcyclohexa-2,4-dien-1-yl acetate, (±)-2.88 
The title compound was prepared according to the general procedure for LTA-mediated oxidative 
dearomatization. Purification on silica gel (20% to 40% EtOAc in hexanes) afforded 5.2 mg (8.0% 
yield) of the o-quinol as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 11.48 (s, 1H), 7.28 (s, 1H), 
2.82 (t, J = 8.6 Hz, 2H), 2.40 (m, 2H), 2.15 (s, 3H), 1.65 (p, J = 7.5 Hz, 2H), 1.49 (s, 3H), 1.38 (h, 
J = 7.6 Hz, 3H), 1.00 (t, J = 0.97 (t, 3H).  
 
 
3-hexanoyl-4-hydroxy-1,5-dimethyl-6-oxocyclohexa-2,4-dien-1-yl acetate, (±)-2.99 
The title compound was prepared according to the general procedure for LTA-mediated oxidative 
dearomatization. Purification on silica gel (20% to 40% EtOAc in hexanes) afforded 6.2 mg (10% 
yield) of the o-quinol as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 11.53 (s, 1H), 7.29 (s, 1H), 
2.81 (td, J = 7.3, 3.1 Hz, 2H), 2.13 (s, 3H), 1.83 (s, 3H), 1.65 (p, J = 7.3 Hz, 2H), 1.48 (s, 3H), 1.35 
(m, 4H), 0.90 (t, J = 6.9 Hz, 3H). All spectra obtained were consistent with literature values.13 
 
 
1-ethyl-4-hydroxy-5-methyl-6-oxo-3-pentanoylcyclohexa-2,4-dien-1-yl acetate, (±)-2.89 
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The title compound was prepared according to the general procedure for LTA-mediated oxidative 
dearomatization. Purification on silica gel (20% to 40% EtOAc in hexanes) afforded 11 mg (17% 
yield) of the o-quinol as a yellow oil. 1H NMR (700 MHz, CDCl3) δ 11.50 (d, J = 1.1 Hz, 1H), 
7.28 (s, 1H), 2.81 (t, J = 8 Hz, H), 2.15 (s, 3H), 1.88 (m, 2H), 1.82 (s, 3H), 1.64 (m, 2H), 1.37 (m, 
2H), 0.94 (overlapping t, 6H). 
 
 
3-butyryl-4-hydroxy-1,5-dimethyl-6-oxocyclohexa-2,4-dien-1-yl acetate, (±)-2.91 
The title compound was prepared according to the general procedure for LTA-mediated oxidative 
dearomatization. Purification on silica gel (20% to 40% EtOAc in hexanes) afforded 11 mg (18% 
yield) of the o-quinol as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 11.53 (t, J = 1.2 Hz, 1H), 





Chapter 2.6.2: Plasmids and Proteins 
Plasmids: Genes encoding tropB (DAA64700.1) and sorbC (XP_002567552) were codon-
optimized for overexpression in E. coli and synthesized by GeneArt (Thermofisher). The 
synthesized sequences were cloned by GeneArt into pET151 vectors conferring the T7 expression 
system, ampicillin resistance, and N-terminal 6xHis-tags encoded upstream from the insert genes.  
The plasmid encoding azaH (G3XMC2.1), in a modified pET28 vector to afford protein with both 
C- and N-terminal 6xHis-tags and is hereby referred to as pAZ83, was a generous gift from 
Professor Yi Tang’s lab at the University of California, Los Angeles.11 No further modifications 
to any of these plasmid constructs were necessary. 




































































































Protein overexpression and purification: Plasmids containing tropB, sorbC, and azaH were 
transformed using standard heat-shock protocols for chemically competent E. coli into BL21(DE3) 
cells. Overexpression of TropB and SorbC was achieved in 500 mL 4% glycerol (v/v) Terrific 
Broth (TB) in 2.8 L flasks. 500 mL portions of media were inoculated with 5 mL overnight culture 
prepared from a single colony in Luria Broth (LB) and 100 g/mL ampicillin (Gold 
Biotechnology).  Cultures were grown at 37 C and 250 rpm until the optical density at 600 nm 
reached 0.8. The cultures were then cooled to 20 C for 1 h and protein expression was induced 
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with 0.1 mM isopropyl--D-1-thiogalactopyranoside (IPTG, Gold Biotechnology).  Expression 
continued at 20 C overnight (approx. 18 h) at 200 rpm.  The typical yield for one 500 mL culture 
cell pellet was ~25 g. Overexpression of AzaH followed the same protocol as described above, 
except 1 L cultures were grown in 2.8 L flasks and kanamycin was used at 50 g/mL (Gold 
Biotechnology) in place of ampicillin. The typical yield for one 1 L culture cell pellet was ~30 g. 
 
General purification procedure: 25 – 30 g of cell pellet was resuspended in 100 mL of lysis 
buffer containing 50 mM Tris HCl pH 7.4, 300 mM NaCl, 10 mM imidazole, and 10% glycerol.  
Protease inhibitors were added to lysis buffer of AzaH only and consisted of 1 mM phenylmethane 
sulfonyl fluoride (v), 0.1 mg/mL benzamidine HCl, 0.5 mg/mL leupeptin, and 0.5 mg/mL 
pepstatin.  Approximatley 1 mg/mL lysozyme was added prior to incubating on a rocker held at 4 
C for 30 min.  Cells were lysed by passing the total cell lysate through an Avestin pressure 
homogenizer at 15000 psi.  The total lysate was centrifuged at 40,000 x g for 30 min and the 
supernatant was filtered through 0.45 m syringe filters.  The crude cell lysate was loaded onto a 
5 mL HisTrap HP column (General Electric) on an ÄKTA Pure FPLC system (General Electric) 
at a flow rate of 2.5 mL/min. Buffer A = the lysis buffer listed above, and Buffer B = 50 mM Tris 
HCl pH 7.4, 300 mM NaCl, 10% glycerol, and 400 mM imidazole.  The column was washed with 
25 mM imidazole (6.3% Buffer B) for 6 CV and eluted in a gradient to 100% Buffer B over 8 CV.  
Fractions containing TropB, SorbC, or AzaH were visibly yellow and pooled for desalting by 
dialysis.  TropB and SorbC were dialyzed into 50 mM Tris HCl pH 7.4 and 10% glycerol buffer, 
while AzaH was dialyzed into 50 mM Tris HCl pH 7.4, 300 mM NaCl, and 10% glycerol buffer 
due to instability upon dialysis into the TropB/SorbC storage buffer.  Average yields: 100 mg from 
1 L TropB, 100 mg from 1 L SorbC, and 20 mg from 1 L AzaH. Molecular weights including 
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6xHis-tags for each protein were estimated by the ProtParam tool on the Expasy server to be 50.8 
kDa for TropB, 49.2 kDa for SorbC, and 47.6 kDa for AzaH. These molecular weights are 
consistent with the proteins observed by SDS-PAGE analysis (Figure 2.8).  The purified proteins 








Determination of flavin incorporation and extinction coefficients (Experiments performed 
by April Lukowski): Samples of each protein were diluted to 10 µM in 1 mL using dialysis buffer 
for UV-vis analysis using a disposable poly(methyl 2-methylpropenoate) cuvette.  The absorbance 
spectrum for each protein was taken from 300 nm to 700 nm in 2 nm increments (blue traces in 
Figure 2.9).  A 20 µL aliquot of fresh 10% sodium dodecyl sulfate (w/v) was added to each 1 mL 
solution and mixed.  Samples were incubated at room temperature for 10 min before reading the 
absorbance spectra again under the same conditions (red traces in Figure 2.9).  The absorbance at 
450 nm for the denatured enzymes and the extinction coefficient of free FAD (11300 M-1 cm-1) 
was used to calculate the concentration of FAD in each protein sample using Beer’s law.  The 














Figure 2.8: Purified AzaH, TropB, and SorbC.  Approximately 5 µL of 1.25 µM each protein was loaded onto 
an MiniPROTEAN TGX Precast 4-15% SDS-PAGE gel (Bio-Rad).  The gel was stained with Quick Coomassie 
stain (Anatrace) and visualized with the Azure Gel Imaging System. The relative apparent masses are consistent 
with the predicted estimates. 
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coefficients were calculated using the concentrations of free flavin obtained and the absorbance at 
450 nm of the native enzymes. At 450 nm, the extinction coefficients of the proteins are 17490 M-
1 cm-1 for AzaH, 16180 M-1 cm-1 for TropB, and 11970 M-1 cm-1 for SorbC.  
 
Figure 2.9: Native enzyme absorbance spectra compared to denatured enzyme absorbance spectra exposing free FAD 





















Comparison of Native and Denatured AzaH
SDS-treated
Native















Comparison of Native and Denatured TropB
SDS-treated
Native




















Chapter 2.6.3: Biocatalytic Reactions 
Stock solutions: Stock solutions of each substrate (50 mM) were prepared by dissolving the 
substrate in DMSO (analytical grade). Stock solutions of NADP+ (100 mM) and glucose-6-
phosphate (G6P, 500mM) were stored at -20 °C. Aliquots of TropB (127 μM), SorbC (62 μM), 
AzaH (40 μM) and glucose-6-phosphate dehydrogenase (G6PDH, 100 U/mL) were stored at -80 
°C. 
 
Analytical-scale reactions: Each reaction contained 25 μL 100 mM potassium phosphate buffer, 
pH 8.0, 2.5 mM substrate (2.5 μL of a 50 mM stock solution in DMSO), 2.5 μM FAD-dependent 
monooxygenase, 5 mM G6P (0.5 μL, 500 mM), 1 mM NADP+ (0.5 μL, 100 mM), 1 U/mL G6P-
DH (0.5 μL, 100 U/mL), and  Milli-Q water to a final volume of 50 μL. The reaction was carried 
out at 30 °C for 1 h and quenched by addition of 75 µL acetonitrile with 25 mM 
pentamethylbenzene as an internal standard. Precipitated biomolecules were pelleted by 
centrifugation (16,000 x g, 12 min). The supernatant was analyzed by UPLC-DAD and conversion 
obtained by comparison to calibration curves of each substrate.    
 
Determination of total turnover number (TTN): Total turnover number was determined by 
analyzing (# of moles of starting material consumed)/(# of moles of enzyme) under the following 
conditions: 2.5 µM FAD-dependent monooxygenase, 2.5 mM substrate, 1 mM NADP+, 0.05 U 
G6PDH, and 5 mM G6P for NADPH regeneration in 50 µL of reaction buffer (50 mM potassium 
phosphate, pH 8.0). The reaction was carried out at 30 °C for 1 h and quenched by addition of 75 
µL acetonitrile with 2.5 mM pentamethylbenzene as an internal standard. Precipitated 
biomolecules were pelleted by centrifugation (16,000 x g, 12 min). The subsequent liquid 
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chromatography PDA spectrometry (UPLC) analysis was performed on a Waters Aquity H-Class 
UPLC-PDA using a Phenomenex  Kinetex 1.7 µm C18, 2.1x150 mm column under the following 
conditions: Method A: mobile phase (A = deionized water + 0.1% formic acid, B = acetonitrile + 
0.1% formic acid), 5% to 100% B over 6 min, 100% B for 4 min; flow rate, 0.5 mL/min; Method 
B: mobile phase (A = deionized water + 0.1% formic acid, B = acetonitrile + 0.1% formic acid), 
5% to 100% B over 2 min, 100% B for 1 min; flow rate, 0.5 mL/min. Based on calibration curves 
of the starting materials, the percent conversion of the substrate to dearomatized product was 
calculated with AUCsubstrate/AUCinternal standard at 270 nm. All reactions were performed and analyzed 
in triplicate. 
 
General procedure for in vitro milligram-scale reactions: Preparative–scale enzymatic 
reactions were conducted on 10 mg of each substrate under the following conditions: 2.5 µM 
flavin-dependent monooxygenase, 2.5 mM substrate, 1 mM NADP+, 1 U/mL G6PDH, and 5 mM 
G6P for NADPH generation in reaction buffer (50 mM potassium phosphate buffer, pH 8.0). The 
reaction mixture was added to a crystallizing dish and incubated at 30 °C for 2 h. The increased 
surface area afforded by the crystalizing dish as reaction vessel allowed for higher conversions 
with some substrates due to increased oxygen concentration. After 2 h, a 50 µL aliquot was 
removed and processed in an identical manner to the analytical-scale reactions escribed above to 
determine substrate conversion. The remaining reaction mixture was diluted with acetonitrile (2 x 
total reaction volume). Precipitated biomolecules were pelleted by centrifugation (4,000 x g, 12 
min). Isolation procedure A:  The supernatant was concentrated under reduced pressure to a final 
volume of approximately 2 mL. The resulting mixture was filtered through a 0.22 µm filter and 
purified by preparative HPLC using a Phenomenex Kinetex 5 µm C18, 150 x 21.2 mm column 
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under the following conditions: mobile phase A = deionized water + 0.1% formic acid and B = 
acetonitrile + 0.1% formic acid; method = 5% to 100% B over 13 min, 100% B for 4 min; flow 
rate, 15 mL/min. Isolation procedure B: The reaction mixture was cooled to 0 °C and pyridine 
(14.0 µL, 0.173 mmol) was added followed by Ac2O (10.4 µL, 0.110 mmol). The resulting mixture 
was stirred at rt for 2 h. The reaction was then acidified to pH 2 and the mixture was extracted with 
EtOAc (3 x 70 mL). The combined organic layers were washed with brine (1 x 50 mL), dried over 
sodium sulfate and concentrated under reduced pressure. Purification on silica gel (30% hexanes 




The title compound was synthesized according to the general procedure for milligram-scale in 
vitro enzymatic oxidative dearomatization using isolation method A. Purification by preparative 
HPLC afforded 6.1 mg (56% yield) of the title compound as a dark orange oil.  1H NMR (400 
MHz, CD3CN) δ 8.09 (s, 1H), 5.81 (s, 1H), 2.15 (s, 3H), 1.47 (s, 3H). All spectra obtained were 






The title compound was synthesized according to the general procedure for milligram-scale in 
vitro enzymatic oxidative dearomatization using isolation method A. Purification by preparative 
HPLC afforded 4.2 mg (39% yield) of the title compound as a yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 7.88 (s, 1H), 5.86 (s, 1H), 3.67 (s, 1H), 2.13 (s, 2H), 1.86 (q, J = 7.1 Hz, 3H), 0.90 (m, J 
= 7.5, 1.9 Hz, 3H); 13C NMR (150 MHz, CD3CN): δ 203.3, 197.0, 169.7, 152.0, 118.4, 110.8, 
84.5, 35.3, 35.0, 18.2, 7.2, 6.9; HR-ESI-MS: m/z calculated for C10H11O4 [M-H]
-: 195.0663, 




The title compound was synthesized according to the general procedure for milligram-scale in 
vitro enzymatic oxidative dearomatization using isolation method A. Purification by preparative 
HPLC afforded 2.6 mg (24% yield) of the title compound as a yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 8.07 (s, 1H), 2.10 (s, 3H), 1.94 (s, 3H), 1.45 (s, 3H); 13C NMR (150 MHz, CD3CN): δ 
203.1, 198.1, 169.1, 145.4, 123.6, 110.8, 80.5, 28.7, 14.3, 11.1; HR-ESI-MS: m/z calculated for 
C10H11O4 [M-H]







The title compound was synthesized according to the general procedure for milligram-scale in 
vitro enzymatic oxidative dearomatization using isolation method A. Purification by preparative 
HPLC afforded 2.8 mg (26% yield) of the title compound as a yellow oil. 1H NMR (600 MHz, 
CD3CN): δ 7.73 (s, 1H), 7.51 (m, 3H), 7.44 (m, 2H), 5.85 (s, 1H), 3.95 (s, 1H), 1.60 (s, 3H); 13C 
NMR (151 MHz, CD3CN): δ 204.0, 197.3, 172.9, 154.8, 136.1, 129.5, 128.8, 127.9, 118.2, 110.1, 
81.2, 28.4; HR-ESI-MS: m/z calculated for C14H11O4 [M-H]
-: 243.0663, found: 243.0661; IR 




The title compound was synthesized according to the general procedure for milligram-scale in 
vitro enzymatic oxidative dearomatization using isolation method A. Purification by preparative 
HPLC afforded 2.8 mg (26% yield) of the title compound as a yellow oil. 1H NMR (600 MHz, 
CDCl3) δ 5.76 (s, 1H), 3.66 (s, 1H), 2.72 (m, 2H), 2.70 (m, 2H), 1.86 (m, 4H), 1.57 (s, 3H); 13C 
NMR (150 MHz, CDCl3): δ 201.6, 197.8, 192.1, 158.0, 116.0, 108.0, 80.1, 34.6, 34.4, 30.3, 23.9, 
22.8; HR-ESI-MS: m/z calculated for C12H13O4 [M-H]
-: 221.0819, found: 221.0819; IR (thin 







The title compound was synthesized according to the general procedure for milligram-scale in 
vitro enzymatic oxidative dearomatization using isolation method A. Purification by preparative 
HPLC afforded 8.0 mg (68% yield) of the title compound as a yellow oil. 1H NMR (600 MHz, 
CD3CN) δ 3.91 (s, 1H), 3.74 (d, J = 21.3 Hz, 1H), 3.24 (d, J = 21.3 Hz, 1H), 2.54 (m, 2H), 1.97 (s, 
3H), 1.56 (s, 3H), 0.99 (m, 1H), 0.96 (d, J = 6 Hz, 6H); 13C NMR (150 MHz, CD3CN): δ 204.0, 
202.5, 196.2, 154.4, 137.0, 84.2, 52.0, 44.7, 25.1, 23.8, 21.7, 20.1; HR-ESI-MS: C13H17O4 [M-




The title compound was synthesized according to the general procedure for milligram-scale in 
vitro enzymatic oxidative dearomatization using isolation method A. Purification by preparative 
HPLC afforded 7.8 mg (68% yield) of the title compound as a dark orange oil. 1H NMR (600 
MHz, CD3CN) δ 3.90 (s, 1H), 3.75 (d, J = 18 Hz, 1H), 3.25 (d, J = 18 Hz, 1H), 2.62 (t, J = 7.2, 
2H), 1.98 (s, 3H), 1.60 (m, 2H), 1.56 (s, 3H), 1.47 (m, 2H), 0.92 (t, J = 6H, 3H); 13C NMR (150 
MHz, CD3CN): δ 204.6, 202.6, 196.2, 154.3, 137.0, 84.1, 44.6, 43.0, 25.2, 25.1, 21.9, 20.1, 13.1; 
HR-ESI-MS: m/z calculated for C13H17O4 [M-H]
-: 237.1132, found: 237.1131; IR (thin film): 







The title compound was synthesized according to the general procedure for milligram-scale in 
vitro enzymatic oxidative dearomatization using isolation method A. Purification by preparative 
HPLC afforded 10.1 mg (93% yield) of the title compound as a dark orange oil as a 1:1 mixture 
of keto-enol tautomers. 1H NMR (400 MHz, CD3CN) δ 8.10 (s, 1H), 5.54 (s, 1H), 3.75 (d, J = 22.2 
Hz, 1H), 3.26 (d, J = 22.1 Hz, 1H), 2.46 (s, 3H), 2.34 (s, 3H), 2.31 (s, 3H), 2.00 (s, 3H), 1.56 (s, 
3H), 1.45 (s, 3H); 13C NMR (150 MHz, CD3CN) δ 202.6, 201.9, 196.2, 154.7, 136.9, 84.1, 44.7, 
30.4, 29.1, 25.1, 24.7, 20.1; HR-ESI-MS: m/z calculated for C10H11O4 [M-H]
-: 195.0663, found: 
195.0664; IR (thin film): 3264, 2963, 2952, 1722, 1624, 1538 cm-1. 
 
 
A) In CD3CN ratio of keto-enol tautomers = 1:1 

























B) In CD3Cl ratio of tautomers = 5:1 
Ha 
Ha    Hb 
C) In CD3CN with 10% D2O alpha-protons exchange with deuterium.  







The title compound was synthesized according to the general procedure for milligram-scale in 
vitro enzymatic oxidative dearomatization using isolation method A. Purification by preparative 
HPLC afforded 2.6 mg (24% yield) of the title compound as a yellow oil.  1H NMR (600 MHz, 
(CD3)2SO) δ 9.63 (s, 1H), 8.75 (s, 1H), 1.25 (s, 3H); 13C NMR (150 MHz, (CD3)2SO): δ 197.6, 
189.2, 186.0, 145.0, 125.2, 111.0, 83.1, 28.9; HR-ESI-MS: m/z calculated for C8H6NO6 [M-H]
-: 




The title compound was prepared according to the general procedure for milligram-scale in vitro 
enzymatic oxidative dearomatization using isolation method A. Purification by preparative HPLC 
afforded 5.4 mg (55% yield) of the title compound as a dark red oil.  1H NMR (400 MHz, CDCl3) 
δ 8.04 (s, 1H), 6.40 (s, 1H), 5.48 (d, J = 1.1 Hz, 1H), 4.12 – 4.07 (m, 1H), 2.61 (dd, J = 14.6, 4.6 
Hz, 1H), 2.53 (dd, J = 14.6, 8.2 Hz, 1H), 1.49 (s, 3H), 1.25 (d, J = 6.2 Hz, 3H) ppm; 13C NMR 
(150 MHz, CD3OD): δ 199.0, 198.6, 162.1, 154.9, 117.1, 111.2, 84.5, 66.1, 43.5, 28.0, 23.4 ppm; 
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HR-ESI-MS: m/z calcd. for C13H13O5H
+ [M+H]+: 251.0914, found: 251.0904. All spectra 




The title compound was prepared according to the general procedure for milligram-scale in vitro 
enzymatic oxidative dearomatization using isolation method A. Purification by preparative HPLC 
afforded 8.1 mg (82% yield) of the title compound as a dark orange oil. 1H NMR (700 MHz, 
CDCl3): δ 7.90 (s, 1H), 6.12 (s, 1H), 5.52 (s, 1H), 2.73 (s, 1H), 2.41 (t, J = 7.5 Hz, 2H), 1.67 (m, 
2H), 1.55 (s, 3H), 1.00 (t, J = 7.5 Hz, 3H); 13C NMR (175 MHz, CDCl3): δ 196.5, 196.0, 163.0, 
153.2, 144.4, 115.7, 108.5, 104.9, 83.5, 35.1, 28.4, 19.9, 13.4; HR-ESI-MS: m/z calculated for 
C13H13O4 [M-H]





The title compound was prepared according to the general procedure for milligram-scale in vitro 
enzymatic dearomatization using isolation method B. Purification on silica gel (20% to 50% 
EtOAc in hexanes) afforded 5.4 mg (43%) of the o-quinol as a yellow oil. 1H NMR (700 MHz, 
CDCl3) δ 11.83 (s, 1H), 7.46 (dd, J = 14.7, 10.6 Hz, 1H), 7.25 (s, 1H), 6.66 (d, J = 14.8 Hz, 1H), 
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6.35 (m, 2H), 2.15 (s, 3H), 1.93 (d, J = 6.4 Hz, 3H), 1.86 (s, 3H), 1.49 (s, 3H). All spectra obtained 
were consistent with literature values.13 
 
(S)-4-hydroxy-1,5-dimethyl-6-oxo-3-pentanoylcyclohexa-2,4-dien-1-yl acetate (2.90) 
The title compound was prepared according to the general procedure for milligram-scale in vitro 
enzymatic oxidative dearomatization using isolation method B. Purification on silica gel (30% to 
50% EtOAc in hexanes) afforded 3.0 mg (24%) of the o-quinol as a yellow oil. 1H NMR (700 
MHz, CDCl3) δ 11.53 (s, 1H), 7.29 (s, 1H), 2.81 (t, J = 7.3, 2H), 2.14 (s, 3H), 1.84 (s, 3H), 1.65 
(m, 2H), 1.48 (s, 3H), 1.36 (m, 2H), 0.94 (t, J = 6.9 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 
206.1, 194.8, 170.0, 162.1, 152.9, 124.6, 111.8, 78.0, 37.6, 26.1, 24.0, 22.1, 20.5, 13.8, 7.1; HR-
ESI-MS: m/z calculated for C15H19O5 [M-H]
-: 279.1238, found: 279.1239; IR (thin film): 3280, 
2937, 1647, 1640 cm-1. 
 
 
(S)-5-ethyl-4-hydroxy-1-methyl-6-oxo-3-pentanoylcyclohexa-2,4-dien-1-yl acetate (2.88) 
 
The title compound was prepared according to the general procedure for milligram-scale in vitro 
enzymatic oxidative dearomatization using isolation method B. Purification on silica gel (20% to 
40% EtOAc in hexanes) afforded 1.0 mg (8.0% yield) of the o-quinol as a yellow oil. 1H NMR 
(400 MHz, CDCl3) δ 11.48 (s, 1H), 7.28 (s, 1H), 2.82 (t, J = 8.6 Hz, 2H), 2.40 (m, 2H), 2.15 (s, 
3H), 1.65 (p, J = 7.5 Hz, 2H), 1.49 (s, 3H), 1.38 (h, J = 7.6 Hz, 3H), 1.00 (t, J =  0.97 (t, 3H); 13C 
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NMR (100 MHz, CDCl3): δ 205.4, 161.3, 158.2, 127.6, 120.7, 113.0, 110.2, 37.7, 27.1, 22.8, 22.5, 
14.1, 13.9, 7.4; HR-ESI-MS: m/z calculated for C16H21O5 [M-H]
-: 293.1394, found: 293.1395; 
IR (thin film): 2965, 1740, 1673, 1652, 1408 cm-1. 
 
 
(S)-3-hexanoyl-4-hydroxy-1,5-dimethyl-6-oxocyclohexa-2,4-dien-1-yl acetate (2.99) 
The title compound was prepared according to the general procedure for milligram-scale in vitro 
enzymatic oxidative dearomatization using isolation method B. Purification on silica gel (20% to 
40% EtOAc in hexanes) afforded 7.8 mg (63% yield) of the o-quinol as a yellow oil. 1H NMR 
(700 MHz, CDCl3) δ 11.53 (s, 1H), 7.29 (s, 1H), 2.81 (td, J = 7.3, 3.1 Hz, 2H), 2.13 (s, 3H), 1.83 
(s, 3H), 1.65 (p, J = 7.3 Hz, 2H), 1.48 (s, 3H), 1.35 (m, 4H), 0.90 (t, J = 6.9 Hz, 3H). All spectra 
obtained were consistent with literature values.13 
 
 
(S)-1-ethyl-4-hydroxy-5-methyl-6-oxo-3-pentanoylcyclohexa-2,4-dien-1-yl acetate (2.89) 
The title compound was prepared according to the general procedure for milligram-scale in vitro 
enzymatic oxidative dearomatization using isolation method B. Purification on silica gel (20% to 
40% EtOAc in hexanes) afforded 3.4 mg (27% yield) of the o-quinol as a yellow oil. 1H NMR 
(700 MHz, CDCl3) δ 11.50 (s, 1H), 7.28 (s, 1H), 2.81 (t, J = 8 Hz, H), 2.15 (s, 3H), 1.88 (m, 2H), 
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1.82 (s, 3H),  1.64 (m, 2H), 1.37 (m, 2H), 0.94 (overlapping t, 6H); 13C NMR (100 MHz, CDCl3): 
δ 206.1, 194.8, 170.0, 162.1, 153.0, 124.6, 111.8, 78.0, 37.9, 31.1, 24.0, 23.7, 22.4, 20.4, 13.8, 7.1; 
HR-ESI-MS: m/z calculated for C14H19O3 [M-H]
-: 235.1340, found: 235.1339; IR (thin film): 
2961, 1740, 1675, 1650, 1403 cm-1. 
 
 
(S)-3-butyryl-4-hydroxy-1,5-dimethyl-6-oxocyclohexa-2,4-dien-1-yl acetate (2.91) 
The title compound was prepared according to the general procedure for milligram-scale in vitro 
enzymatic oxidative dearomatization using isolation method B. Purification on silica gel (20% to 
40% EtOAc in hexanes) afforded 2.8 mg (22% yield) of the o-quinol as a yellow oil. 1H NMR 
(400 MHz, CDCl3) δ 11.53 (t, J = 1.2 Hz, 1H), 7.29 (s, 1H), 2.81 (m, 2H), 2.14 (s, 3H), 1.84 (s, 
3H), 1.71 (m, 2H), 1.48 (s, 3H), 0.98 (t, J = 7.4, 3H); 13C NMR (100 MHz, CDCl3): δ 205.9, 194.8, 
167.0, 162.0, 153.0, 124.6, 111.8, 78.0, 39.8, 24.0, 20.5, 17.6, 13.6, 7.1; HR-ESI-MS: m/z 
calculated for C14H17O5 [M-H]
-: 265.1081, found: 265.1081; IR (thin film): 2961, 2932, 1737, 




Chapter 2.6.4: Substrate Calibration Curves 





s b d I-0 0 4
Y = 3.613*X + 0.1263
0.9948
          







s b d I-0 7 4
Y = 6.373*X + 0.06215
0.9998
 






s b d II-1 9 8
Y = 12.13*X + 0.2222
0.9994






s b d I-0 7 9











s b d I-1 5 1
Y = 7.158*X + 0.1071
0.9995






s b d II-0 2 5











































































































          





s b d II-1 4 3










Y = 9.719*X + 0.04384
0.9999
    





s b d III-0 6 4
Y = 7.732*X + 0.1104
0.9997






s b d I-0 6 6
Y = 5.022*X + 0.08012
0.9992
          






s b d II-0 0 3
Y = 11.8*X + 0.1873
0.9965
   






s b d II-1 3 6



















































































































s b d II-1 2 9
Y = 3.971*X + 0.02777
1







s b d II-1 2 2
Y = 6.336*X + 0.1325
0.9999
 







s b d II-0 9 6
Y = 16.78*X + 0.02882
1





s b d II-1 5 6










s b d IV -0 1 7
Y = 4.593*X - 0.0005654
0.9999
        






s b d I-1 2 6






































































































Concentration (mM) Concentration (mM) 













s b d I-0 6 1
Y = 27.17*X + 0.837
0.998
 






D a ta  1
 






s b d II-1 4 2









Y = 12.18*X + 0.07741
1







s b d II-0 3 5 a
Y = 15.48*X + 0.08618
0.9996
 







s b d V -0 7 9
Y = 8.452*X + 0.2442
0.9993
            







s b d V -0 7 8
Y = 1.69*X + 0.04934
0.9993


























































































































s b d V -0 7 8
Y = 8.162*X + 0.3583
0.9979







s b d I-1 3 8




       





s b d II-0 6 1
Y = 9.314*X + 0.1136
0.9998
   





s b d II-1 2 3



















































































s b d II-1 2 5
Y = 4.506*X + 0.008982
0.9999





s b d II-1 1 0
Y = 9.907*X + 0.1114
0.9995
 





s b d III-0 5 1
Y = 9.657*X + 0.02842
0.9999






s b d II-1 1 1
Y = 11.2*X - 0.02836
0.9995
   





s b d II-1 8 3
Y = 10.96*X + 0.03165
1
 





















































































Concentration (mM) Concentration (mM) 































































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 1.725 721031 87.98 154590 
2 5.148 98519 12.02 84071 
 Retention Time Area % Area Height 
1 3.841 539715 93.46 659310 
2 5.109 37786 6.54 35891 

























































0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
 Retention Time Area % Area Height 
1 1.855 118860 56.34 6542 
2 5.086 92101 43.66 69513 
 Retention Time Area % Area Height 
1 3.881 596132 86.91 586097 




























































No enzyme control 
 
 
















































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 1.502 484359 83.13 124361 
2 5.106 98277 16.87 76056 
 Retention Time Area % Area Height 
1 3.777 1136190 92.71 1285582 









No enzyme control 
 
 





















































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 2.526 310271 76.01 47820 
2 5.151 97939 23.99 77097 
 Retention Time Area % Area Height 
1 4.449 925130 92.77 1175806 










No enzyme control 
 
 















































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 1.952 909010 90.96 166861 
2 5.085 90292 9.04 55477 
 Retention Time Area % Area Height 
1 4.115 484839 85.17 396843 










No enzyme control 
 
 






















































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.410 181356 59.21 154254 
2 4.112 43890 14.33 35524 
3 5.085 81051 26.46 56795 
 Retention Time Area % Area Height 
1 4.117 429008 84.07 500038 

































































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 0.800 418978 77.69 118420 
2 3.670 57521 10.67 67315 
3 5.095 62803 11.65 60631 
 Retention Time Area % Area Height 
1 3.676 782521 89.67 652406 











No enzyme control 
 
 
















































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.698 166835 54.48 51045 
2 4.522 61034 19.93 54287 
3 5.151 78337 25.58 66344 
 Retention Time Area % Area Height 
1 4.476 669825 88.45 706595 












No enzyme control 
 
 


























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.384 204823 63.33 54734 
2 4.347 66909 20.69 75822 
3 5.132 51715 15.99 46843 
 Retention Time Area % Area Height 
1 3.841 539715 93.46 659310 












No enzyme control 
 
 






















































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.672 83136 25.70 25063 
2 4.499 148552 45.93 132589 
3 5.087 91747 28.37 73036 
 Retention Time Area % Area Height 
1 4.497 237495 71.30 255312 












No enzyme control 
 
 



















































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.710 270021 44.33 288410 
2 4.446 247233 40.59 261165 
3 5.150 91864 15.08 75650 
 Retention Time Area % Area Height 
1 4.389 527040 97.59 592278 












No enzyme control 
 
 
















































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.471 28222 4.31 21589 
2 3.893 536506 81.92 439714 
3 5.085 90190 13.77 60686 
 Retention Time Area % Area Height 
1 3.894 638837 86.57 515355 












No enzyme control 
 
 



























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.190 89444 23.96 56539 
2 4.047 204672 54.84 140734 
3 5.090 79126 21.20 48989 
 Retention Time Area % Area Height 
1 4.076 367055 78.47 457278 













No enzyme control 
 
 



























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.029 841812 78.19 689175 
2 4.071 129334 12.01 153712 
3 5.121 105509 9.80 100119 
 Retention Time Area % Area Height 
1 4.108 703952 87.74 850433 












No enzyme control 
 
 














































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 4.213 1225257 92.16 1434429 
2 5.085 104244 7.84 105774 
 Retention Time Area % Area Height 
1 4.254 1759860 97.37 2011893 












No enzyme control 
 
 























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.547 90667 37.38 108949 
2 3.748 40487 16.69 48434 
3 5.135 111429 45.93 103871 
 Retention Time Area % Area Height 
1 3.526 700523 87.89 536023 


















































































0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
 Retention Time Area % Area Height 
1 1.862 159582 26.76 30989 
2 3.905 333733 55.96 400936 
3 5.152 103014 17.27 93779 
 Retention Time Area % Area Height 
1 3.881 596132 86.91 586097 









































No enzyme control 
 
 













































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 2.751 340680 82.70 109193 
2 5.108 71281 17.30 73345 
 Retention Time Area % Area Height 
1 4.449 925130 92.77 1175806 











The product of the AzaH reaction (rt = 1.724 min) absorbs weakly at 270 nm but can be seen 
clearly at 300 nm. 
 
 

































0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 5.50 6.00 6.50 7.00 7.50 8.00 8.50 9.00 9.50 10.00
 Retention Time Area % Area Height 
1 1.724 35678    43654 
2 4.087 387692 79.63 467090 
 5.128 99150 20.37 97478 
 Retention Time Area % Area Height 
1 4.115 484839 85.17 396843 








































































































No enzyme control 
 
 




























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.412 47614 7.15 29718 
2 4.120 511990 76.92 341787 
3 5.094 105983 15.92 54970 
 Retention Time Area % Area Height 
1 4.117 429008 84.07 500038 










No enzyme control  
 
 


















































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.661 217106 39.80 254795 
2 4.395 308640 56.58 349462 
3 5.113 19743 3.62 18314 
 Retention Time Area % Area Height 
1 4.389 527040 97.59 592278 









No enzyme control  
 
 
























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.456 36206 5.68 32252 
2 3.888 513051 80.43 620848 
3 5.080 88600 13.89 89590 
 Retention Time Area % Area Height 
1 3.892 678875 89.78 641975 








No enzyme control  
 
 



























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.185 142178 32.27 77677 
2 4.044 198204 44.99 120265 
3 5.089 100184 22.74 49523 
 Retention Time Area % Area Height 
1 4.076 367055 78.47 457278 










No enzyme control 
 
 






















































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 1.916 691128 68.43 127188 
2 3.839 221794 21.96 303367 
3 5.106 97016 9.61 102058 
 Retention Time Area % Area Height 
1 3.577 446940 81.21 535164 
















































































0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
 Retention Time Area % Area Height 
1 3.278 112683 20.08 138423 
2 4.095 356300 63.50 406913 
3 5.129 92110 16.42 78498 
 Retention Time Area % Area Height 
1 4.092 441680 80.91 508946 






























No enzyme control 
 
 























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 0.830 731105 40.71 150972 
2 4.208 966490 53.81 1108286 
3 5.124 98423 5.48 100786 
 Retention Time Area % Area Height 
1 4.182 2422938 96.79 2515618 









No enzyme control 
 
 























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.135 28843 5.24 22549 
2 4.356 430957 78.35 270100 
3 5.081 90268 16.41 52523 
 Retention Time Area % Area Height 
1 4.358 508333 85.80 311590 







No enzyme control 
 
 
























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 4.063 26667 2.99 13325 
2 4.797 779733 87.42 485933 
3 5.079 85564 9.59 48080 
 Retention Time Area % Area Height 
1 4.832 1030970 91.78 1079052 














































































0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
 Retention Time Area % Area Height 
1 3.047 30565 3.72 11190 
2 3.662 689187 83.94 468888 
3 5.081 101288 12.34 55561 
 Retention Time Area % Area Height 
1 3.655 711564 88.14 470658 




























The product of the AzaH reaction (rt = 1.923 min) absorbs weakly at 270 nm but can be 
visualized at 300 nm. 
 
 





Figure 2.41: Oxidative dearomatization of 2.72 by AzaH. PDA traces of enzymatic reaction and control reaction 


























































0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00
 Retention Time Area % Area Height 
1 1.923 3085 0.56 5193 
2 2.408 447438 80.97 597906 
3 2.613 102101 18.48 131261 
 Retention Time Area % Area Height 
1 1.923 7249 20.46 11308 
2 2.408 28184 79.54 37395 
 Retention Time Area % Area Height 
1 2.409 395329 77.95 505198 


















































































No enzyme control 
 
 
Figure 2.42: Oxidative dearomatization of 2.73 by AzaH. PDA traces of enzymatic reaction and control reaction 
































































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 1.935 1078 0.36 1675 
2 2.362 193428 65.42 270165 
3 2.614 101186 34.22 129354 
 Retention Time Area % Area Height 
1 2.362 213306 72.72 291165 







 The product of the AzaH reaction (rt = 1.960 min) absorbs weakly at 270 nm but can be 






No enzyme control 
 
 
Figure 2.43: Oxidative dearomatization of 2.74 by AzaH. PDA traces of enzymatic reaction and control reaction 














































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 2.443 860640 89.29 1223636 
2 2.613 103236 10.71 133581 
 Retention Time Area % Area Height 
1 2.444 911364 89.04 1119379 











































































































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.823 13657 4.01 6727 
2 4.504 245318 72.11 149424 
3 5.081 81230 23.88 47193 
 Retention Time Area % Area Height 
1 4.501 313207 75.59 231850 









No enzyme control 
 
 




























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.448 99988 17.77 69219 
2 4.147 388393 69.02 258431 
3 5.105 74309 13.21 42896 
 Retention Time Area % Area Height 
1 3.997 724401 87.86 667824 








No enzyme control 
 
 Retention Time Area % Area Height 
1 4.480 971633 91.20 1100819 
2 5.133 93772 8.80 88619 


























































































































No enzyme control 
 
 

















































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 4.383 55863 12.49 69790 
2 4.623 341471 76.32 386499 
3 5.129 50087 11.19 48911 
 Retention Time Area % Area Height 
1 4.620 683943 86.80 680347 








No enzyme control 
 
 































































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 4.299 29866 6.92 20712 
2 4.818 333555 77.33 256926 
3 5.090 67925 15.75 48221 
 Retention Time Area % Area Height 
1 4.845 869112 90.18 747186 








No enzyme control 
 
 






















































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 4.288 65507 12.40 72216 
2 4.791 435710 82.50 488324 
3 5.143 26915 5.10 27481 
 Retention Time Area % Area Height 
1 4.822 997907 90.39 990194 








No enzyme control 
 
 



























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 4.067 31731 4.67 33355 
2 4.627 560059 82.51 648065 
3 5.081 87010 12.82 84948 
 Retention Time Area % Area Height 
1 4.637 877248 89.55 763969 








No enzyme control 
 
 























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.929 148271 20.93 182824 
2 4.790 368151 51.98 452041 
3 5.099 191872 27.09 215767 
 Retention Time Area % Area Height 
1 4.829 1024234 91.07 985786 








No enzyme control 
 
 
























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 4.339 308173 42.32 301769 
2 4.524 336046 46.15 308969 
3 5.125 83974 11.53 66040 
 Retention Time Area % Area Height 
1 4.525 569864 87.66 517315 
































































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 4.330 149076 23.64 147864 
2 4.488 388674 61.63 363526 
3 5.125 92871 14.73 71874 
 Retention Time Area % Area Height 
1 4.476 669825 88.45 706595 









No enzyme control 
 
 






















































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.473 104135 12.96 80180 
2 3.913 604255 75.20 559715 
3 5.126 95092 11.84 70041 
 Retention Time Area % Area Height 
1 3.912 809530 89.41 736129 









No enzyme control 
 
 
























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.809 126396 46.23 78348 
2 4.515 33751 12.35 25916 
3 5.096 113236 41.42 78706 
 Retention Time Area % Area Height 
1 4.501 313207 75.59 231850 








No enzyme control 
 
 

























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.473 101663 12.64 79764 
2 3.913 602274 74.90 559609 
3 5.126 100144 12.45 69007 
 Retention Time Area % Area Height 
1 3.997 724401 87.86 667824 





With SorbC: Note the formation of a second product (rt= 3.490). The immediate product of the 
reaction is converted to B over time after quenching the reaction. The addition of 1,000 u/mL of 
catalase prevents this side product from forming. Likely the second product is the result of 
oxidation of the dearomatized product by hydrogen peroxide which is formed from 
disproportionation of the hydroperoxy flavin intermediate.  
 
 













































































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.490 115556 17.23 113576 
2 3.739 89353 13.32 87093 
3 4.471 377486 56.27 334338 
4 5.124 88436 13.18 65003 
 Retention Time Area % Area Height 
1 3.733 161363 27.72 130068 
2 4.459 336440 57.80 272397 


























































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 4.473 795018 88.96 684472 








No enzyme control 
 
 






















































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.867 664888 79.45 465219 
2 4.606 34647 4.14 25663 
3 5.097 137322 16.41 98940 
 Retention Time Area % Area Height 
1 4.620 683943 86.80 680347 






With SorbC: Note the formation of a second product (rt= 3.992). The immediate product of the 
reaction (A) is converted to B (mass = +32 of starting material) over time after quenching the 
reaction. The addition of 1,000 u/mL of catalase prevents this side product from forming. Likely 
the second product is the result of oxidation of the dearomatized product by hydrogen peroxide 
which is formed from disproportionation of the hydroperoxy flavin intermediate.  
 
 






































































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.992 66049 11.44 71240 
2 4.214 219320 37.99 212829 
3 4.845 190823 33.05 177612 
4 5.126 101193 17.53 83294 
 Retention Time Area % Area Height 
1 3.914 324746 41.41 256800 
2 4.802 428228 54.60 306790 








With SorbC and catalase 
 
 
No enzyme control 
 
 




























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 4.205 143931 55.29 110819 
2 4.824 26347 10.12 20112 
3 5.096 90024 34.58 63055 
 Retention Time Area % Area Height 
1 4.845 869112 90.18 747186 








With SorbC: Note the formation of a second product (rt= 3.763). The immediate product of the 
reaction is converted to C (mass = +32 of starting material) over time after quenching the reaction. 
The addition of 1,000 u/mL of catalase prevents this side product from forming. Likely the second 
product is the result of oxidation of the dearomatized product by hydrogen peroxide which is 
formed from disproportionation of the hydroperoxy flavin intermediate 
 
 
No enzyme control 
 
   





























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 4.121 116168 23.76 77525 
2 4.797 317027 64.85 221984 
3 5.092 55683 11.39 37959 
 Retention Time Area % Area Height 
1 4.787 874906 92.62 543140 





With SorbC: Note the formation of a second product (rt= 3.763). The immediate product of the 
reaction (A) is converted to B (mass = +32 of starting material) over time after quenching the 
reaction. The addition of 1,000 u/mL of catalase prevents this side product from forming. Likely 
the second product is the result of oxidation of the dearomatized product by hydrogen peroxide 
which is formed from disproportionation of the hydroperoxy flavin intermediate 
 
 














































































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 3.763 106922 18.07 114375 
2 3.991 219339 37.06 216484 
3 4.666 162404 27.44 149164 
4 5.127 103181 17.43 81174 
 Retention Time Area % Area Height 
1 3.976 217360 38.08 166133 
2 4.642 221882 38.87 178801 


































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 4.637 877248 89.55 763969 





With SorbC:  
 
 
No enzyme control 
 
 
























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 4.132 190388 45.50 150883 
2 4.803 135918 32.48 108578 
3 5.096 92126 22.02 67077 
 Retention Time Area % Area Height 
1 4.791 821742 91.32 508753 





Chapter 2.6.6: HPLC and SFC Traces 



























































0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00
 Retention Time Area % Area Height 
1 16.121 594177 49.82 9235 
2 19.210 598376 50.18 7181 
 Retention Time Area % Area Height 
1 17.009 2207 0.09 -47 
















































Figure 2.63: PDA traces of racemic 2.13 obtained from IBX oxidative dearomatization, and 2.13  obtained from 






























































0.00 5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00 55.00
 Retention Time Area % Area Height 
1 33.489 53482643 49.97 413483 
2 42.864 53540926 50.03 273030 
 Retention Time Area % Area Height 
1 33.695 32608 0.17 249 





























































































0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00 34.00 36.00 38.00
 Retention Time Area % Area Height 
1 28.529 33044792 49.85 465816 
2 32.165 33250255 50.15 379831 
 Retention Time Area % Area Height 
1 28.693 77788 0.99 1072 






























































2.97 from TropB reaction 
156 
 












Figure 2.66: PDA traces of racemic 2.80 obtained from IBX oxidative dearomatization, and 2.80 obtained from 




















































2.20 from AzaH reaction 
 
Figure 2.70: PDA traces of racemic 2.20 obtained from IBX oxidative dearomatization, and 2.20 obtained from AzaH-
mediated oxidative dearomatization (CHIRALPAK® AD-H, 30% iPrOH, CO2, 3.5 mL/min). Note two pairs of 















































































Figure 2.74: PDA traces of racemic 2.98 obtained from LTA oxidative dearomatization, and 2.98 obtained from 









2.89 from SorbC reaction 
(±)-2.89 
2.89 
Figure 2.75: PDA traces of racemic 2.89 obtained from LTA oxidative dearomatization, and 2.89 (>99% ee) obtained 
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2.83 keto tautomer 
2.83 keto tautomer 
Ha 
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CHAPTER 3: Positioning-group Enabled Biocatalytic Oxidative Dearomatization 
 
Portions adapted with permission from “Positioning-group enabled biocatalytic oxidative 
dearomatization” ACS Central Sci. 2019, 5, 1010-1016. 
Chapter 3.1: Introduction 
 Protein engineering is a powerful tool to alter the substrate scope of a given biocatalyst, in 
which the structure of the catalyst is altered to accommodate a targeted non-native substrate;1,2 
however, this approach requires expertise and equipment not uniformly available in synthetic 
chemistry laboratories. Classical chemical methods rely not only on tuning the catalysts, but also 
an orthogonal strategy to engineer interactions between a catalyst and substrate by altering the 
substrates to contain a functional group that possesses a high affinity for the catalyst. Using this 
Figure 3.1: (A) Classical and biocatalytic methods enabled by directing groups. S = substrate, R = chemical reagent, 
DG = directing group. (B) Roles of directing groups in biocatalytic transformations including enhanced substrate 
binding, impact on conformation and substrate positioning within active site. 
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approach, high levels of site- and stereoselectivity have been obtained in a wide variety of chemical 
transformations (Figure 3.1).3,4 
 
Figure 3.2: (A) Chemo- and biocatalytic methods for asymmetric oxidative dearomatization. (B) Sorbicillin derived 
natural products accessible by previous methodology and examples of p-quinol natural products that can be accessed 
via a directing-group strategy. 
In contrast to the widespread use of directing groups in organic synthesis with chemical 
reagents and catalysts, the analogous strategy of substrate engineering has remained under-utilized 
in biocatalysis. Reported examples of substrate engineering for the purpose of synthetic chemistry 
have been restricted to a single class of enzymes, cytochromes P450.5-12 However, we anticipate 
that substrate engineering can radically expand the utility of a range of enzyme classes in 
biocatalysis. Substrate engineering can impact various aspects of a biocatalytic reaction. For 
example, approaches to substrate engineering have included the installation of a directing group 
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to anchor a substrate through a specific protein-substrate interaction (Figure 3.2).6,8-10 Using this 
strategy, substrates with low binding affinity for a biocatalyst’s active site are transformed into 
substrates with an increased affinity for the catalyst. Both Auclair and Sherman have demonstrated 
this anchoring group approach, identifying heterocycles that can enhance the binding of non-native 
substrates with P450s, and allow for predictable hydroxylation of engineered substrates.6,9,10 
Substrate engineering can also be targeted toward inducing a conformational change upon binding 
to shift from an inactive protein conformation to a catalytically productive conformation, thus 
initiating substrate turnover.13 By contrast, we have demonstrated a strategy in which a tightly 
bound but unreactive substrate is engineered to include a functional group that poses the substrate 
within the enzyme active site for a productive reaction (Figure 3.1B). This approach addresses a 
problem distinct from substrate binding, which we have shown occurs with substrates which lack 
the positioning group but do not undergo conversion. We have applied this positioning group 
strategy to expand the synthetic utility of the flavin-dependent monooxygenase SorbC, which 
mediates oxidative dearomatization with site- and stereoselectivity which exceed existing 
chemical methods. 
Like cytochromes P450, flavin-dependent enzymes mediate a broad array of chemical 
transformations encompassing both reductive and oxidative processes.14 Within the category of 
oxidative transformations, flavin-dependent enzymes are capable of catalyzing highly selective 
hydroxylation,15 epoxidation,16 halogenation,17 and Baeyer-Villiger18 reactions among others, and 
have found application in a number of commercial processes.19 Recently, we explored the synthetic 
potential of a panel of flavin-dependent monooxygenases which mediate the highly site- and 
stereoselective oxidative dearomatization of phenolic substrates.20 While several wild-type 
biocatalysts investigated demonstrated an impressive substrate scope, an enzyme with unique site-
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selectivity, SorbC, operated on a limited range of substrates.20 The site-selectivity achieved in 
reactions with SorbC is difficult to access with chemical reagents and catalysts, often requiring 
specific substitution patterns to bias the site of hydroxylation. Controlling the stereochemical 
outcome in this transformation has also challenged chemists with state-of-the-art methods 
employing hypervalent iodine catalysts providing products in 60-84% ee (Figure 2A).21,22 In the 
biocatalytic mechanism, molecular oxygen reacts with reduced flavin adenine dinucleotide 
(FADH2, 3.5) to form C4a-hydroperoxy flavin, an electrophilic source of oxygen.
23 The site- and 
stereoselectivity of hydroxylation arises from the pose of the substrate in the enzyme active site 
relative to the flavin cofactor (3.9). This strategy for stereocontrol allows for perfect selectivity in 
the native reaction. 
Our initial investigations indicated that SorbC is capable of mediating oxidative 
dearomatization with exceptional stereoselectivity, generating products such as 3.8 in >99% ee, 
solidifying SorbC as the catalyst with the highest reported site- and enantioselectivity for this 
transformation (Figure 2.5).20 However, the limited substrate scope demonstrated by SorbC 
presents a challenge in applying this biocatalyst to the synthesis of structurally diverse target 
molecules. For example, profiling the substrate promiscuity of SorbC revealed the requirement of 
an alkyl chain extending from the C1 position (see 3.24, Table 2.1). Thus, while SorbC has been 
used in the synthesis of complex molecules derived from sorbicillin (3.13), 20,24,25  it is limited to 
the synthesis of compounds containing long alkyl chains (compounds in blue, Figure 3.2B) and 
does not provide access to the full breadth of biologically active molecules that could arise from 
para-quinol precursors (see compounds in purple, Figure 3.2B). For example, the native substrate 
of SorbC, 3.13, bears a linear six-carbon chain at this position with a carbonyl at the benzylic 
position and one or two carbon-carbon double bonds. Truncation of this six-carbon chain resulted 
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in lower conversion to dearomatized products in reactions with SorbC (Figure 3.4, entries 4 and 
5). Additionally, an erosion in the enantioenrichment of the product was observed as this C1 chain 
was truncated or the C3 methyl group was extended to an ethyl substituent (see 21 and 22, 
respectively). Based on these data, we hypothesized that the six-carbon chain plays a critical role 
in substrate binding and orientation within SorbC’s active site. Herein, we demonstrate how this 
finding can be leveraged in a structure-guided substrate engineering approach to expand the 
synthetic utility of SorbC in the enantioselective oxidative dearomatization of phenolic substrates 
to enable access to a much broader array of quinol-containing natural products (see Figure 3.2B). 
Ultimately, this work will enable the syntheses of a variety of complex targets employing wild-
type SorbC in the enantiodetermining step. 
Chapter 3.2: Substrate Synthesis 
Several substrates were designed to probe the promiscuity of the FDMO SorbC towards substrates with varying C1 
functional groups, including amides and esters of different chain length and saturation. Carolyn 
Suh completed the synthesis of the key carboxylic acid intermediate 3.23 through a Kolbe-Schmitt 
carboxylation of dimethyl resorcinol 3.22.26 Alternate routes to carboxylic acid 3.23 were 
attempted but were unsuccessful. For example, Pinnick oxidation of the unprotected aldehyde 
resulted in low conversion or oxidation of the aromatic ring. Although the 




Figure 3.4: Routes to crotyl ester resorcinol compounds with varying functional groups at C2, C4 and C5.   
Kolbe-Schmitt carboxylation was typically low-yielding, this route was more direct than 
formylation followed by oxidation and so was used in the synthesis of substrates with alternative 
substitution of the ring (Figure 3.4). With carboxylic acid 3.23 in hand, we were able to access 
ester and amide derivatives via in situ acyl chloride generation followed by addition of the 
appropriate nucleophile. Alcohols and amides were chosen to give carbonyl products of the same 
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length as the native substrate (see 3.25, 3.26, and 3.29), as well as increased length (see 3.27 and 
3.30) and decreased lengths (3.28). 
We next synthesized a number of salicylic acid derivatives varying the steric bulk and 
electronics of the C3, C5, and C6 position (Figure 3.4). C3-substituted compounds were accessed 
via directed lithiation of 4-methyl resorcinol 3.32 and addition of the desired alkyl bromide. 
Methyl ether deprotection followed by Kolbe-Schmidtt carboxylation and esterification afforded 
the desired products, although in low yield due to challenging chromatography of the acids. 
Halides could be installed at the C3 position via EAS of acids such as 3.33. Alkylation of the C5 
position was achieved through Friedel-Crafts acylation with the desired acyl chloride, 
Clemmensen reduction27 of the corresponding ketone, and deprotection. These alkylated products 
then underwent Kolbe-Schmidtt carboxylation and esterification to afford crotyl esters 3.37-3.39.  
Chapter 3.3: Reactivity Profile 
Several analogs of the native substrate were evaluated in reactions containing 0.1 mol % 
SorbC.28 First, the role of the double bonds and carbonyl group in the native substrate C1 
substituent was gauged by comparing the total turnover number (TTN) of SorbC with (1) the native 
Figure 3.5: Impact of C1 substituent on SorbC activity. 
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substrate, (2) a substrate bearing a saturated C1 substituent and (3) a compound in which the 
carbonyl group was reduced to a methylene group (Figure 3.5, entries 1-3). Each of these substrates 
was dearomatized by SorbC with the native substrate (3.13) having the highest TTN, 861, and the 
further reduced compounds exhibiting decreased TTNs (656 and 500, respectively). In reactions 
with substrates possessing a truncated C1 substituent, such as a methyl ketone or aldehyde, a 
further decrease in TTN was observed (383 and 371, entries 4 and 5). With evidence supporting 
the importance of a lipophilic linear chain for achieving a productive reaction, the ketone of the 
native substrate (3.13) was replaced with groups that meet the length requirement but are 
synthetically more tractable for further elaboration toward target molecules (see Figure 3.4, entries 
6-10). This panel of amide and ester substrates were productively dearomatized by SorbC with 
TTNs ranging from 500 to 909. The amide substrate was converted to product most efficiently 
with a slightly higher TTN (909) than that observed for the native substrate, sorbicillin (3.13). This 
could be due to the increased nucleophilicity of the phenol due to the replacement of the electron-
withdrawing ketone with the less electron-withdrawing amide. Of the ester substrates tested 
(Figure 3.5, entries 7-10), crotyl ester 3.26 exhibited the greatest TTN in reactions with SorbC, 
nearly matching the reactivity observed with SorbC’s native substrate. In contrast, reactions with 
SorbC and methyl ester 3.28 afforded no detectable product. Concurrently with this work the 
(3.9) 
(3.13) 
3.13 3.28 3.28 
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Gulder group also found that a number of esters could be converted to the dearomatized products 
by SorbC.29 
To further probe the role of the lipophilic linear chain in substrate binding and reactivity, 
Attabey Rodríguez Benítez performed binding assays, and I carried out Michaelis-Menten kinetic 
analysis of SorbC with three test substrates: the native substrate (sorbicillin, 3.13), methyl ester 
3.28 and the crotyl ester 3.26.  Methyl ester 3.28 was chosen as a substrate mimic which lacked 
the long carbon chain at C1 present in 3.13 and 3.26, but with similar electronics to 3.26 in order 
to probe the role of the long chain in binding and turnover. Interestingly, despite the differences in 
reactivity, the dissociation constants for SorbC with each substrate indicated similar binding 
affinity across the three substrates (Figure 3.7). This suggested that reactivity does not correlate 
with substrate binding, and that this group does not act as an anchoring group. Additionally, steady-
state kinetic analysis of SorbC with this set of substrates revealed the KM for sorbicillin (3.13) with 
SorbC was determined to be 38.6 ± 1.7 M and crotyl ester 3.26 has a lower KM than the native 
substrate, 17.3 ± 0.7 M (Figure 3.7). For methyl ester 3.28 no reaction was observed. 
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As binding experiments suggested that the role of the C1 substituent is not important for 
increasing the concentration of substrate in the active site, we explored the influence of this group 
on substrate orientation computationally. Docking studies performed by Troy Wymore revealed 
that substrates 3.13, 3.26 and 3.28 can each achieve favorable binding interactions; however, only 
substrates with a C1 substituent of sufficient length are poised to undergo a productive reaction 
with the C4a-hydroperoxyflavin. The lowest energy poses identified through docking each of these 
three substrates (3.13, 3.26 and 3.28) with SorbC are illustrated in Figure 3.8A-C. Notably, while 
the lipophilic group of 3.13 and crotyl ester moiety of 3.26 occupy the hydrophobic substrate 
entryway (C1 pocket, Figure 3.8A and 3.8C), the unreactive substrate 3.28 adopts a flipped 
orientation (Figure 3.6B), positioning the C1 methyl ester moiety of 3.28 in the binding pocket 
occupied by the C3 substituent of the native substrate 3.13 (C3 pocket). The RMSD values from 
the lowest energy structures of each of these three substrates were then plotted against the change 
in energy from the lowest energy structures (Figure 3.8D-F). This allowed us to rapidly identify 
clusters of favorable binding poses for the three substrates. The majority of the energetically 
favorable docking solutions for the native substrate place the C1 substituent in the hydrophobic 
entryway (boxed in green) and a smaller set of energetically favorable docking solutions place the 
C3 substituent in the hydrophobic entryway (boxed in red), which correspond with unreactive 
poses (FAD-C4a−C5 distances above 5 Å). For methyl ester substrate 3.28, most energetically 
favorable docking poses position the substrate in a flipped orientation compared to the dominant 
binding mode for SorbC’s native substrate 3.13. This flipped orientation is anticipated to be 
unproductive (Figure 3.8E). Finally, crotyl ester 3.26 had numerous favorable docking solutions 
with SorbC in which the crotyl ester group occupied the hydrophobic entryway in the same fashion 
as the native substrate 3.13 (boxed in green, Figure 3.8F), and like 3.13 a number of favorable 
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poses were also obtained with the C1 substituent in the C3 binding site in an unreactive pose 
(boxed in red, Figure 3.8F).  
Taken together, these computational and experimental results indicate the necessity of the 
C1 substituent as a critical structural feature, not for lowering the Kd of a substrate, but for 
appropriately positioning the substrate within the active site for turnover. We envisioned exploiting 
this structural requirement for productive catalysis to expand the substrate scope of SorbC through 
a novel substrate engineering strategy. To execute a synthetically useful substrate engineering 
approach, the directing group must be both easily introduced prior to the biocatalytic step and 
readily removed or converted into a range of versatile handles following the targeted 
transformation. In addition to facilitating a high conversion to product, we recognized the synthetic 
advantages of the crotyl ester directing group, which could easily be installed from a carboxylic 
acid precursor and removed following the biocatalytic reaction. A number of substrates bearing a 
crotyl ester directing group were synthesized and evaluated for reactivity with SorbC. This 
substrate engineering strategy proved successful for resorcinol scaffolds with differing steric and 
electronic properties (Figure 3.9). Phenolic substrates 3.74 and 3.77 were not converted due 
perhaps to the reduced nucleophilicity of the arene. For example, hexasubstituted substrate 3.47 
was efficiently converted to dearomatized product with a TTN close to that of the native scaffold. 
Additionally, halogen substituents were tolerated at the C3 position (see 3.36 and 3.37), although 
substrate 3.76 which features only a proton at this position was not turned over. Docking studies 
indicated that the C3 pocket would have sufficient space to accommodate up to an n-propyl group. 
Substrates with increasing steric bulk at the C3 position, from a methyl group to an ethyl 
substituent and further to an n-propyl group, were efficiently turned over with only minor decrease 
in activity (see 3.28, 3.73 and 3.52), as predicted in Troy Wymore’s computational studies. 
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Substrates with additional steric bulk including a benzyl substituent at the C5 position (see 3.69) 
or an isopentyl group (see 3.68) were also tolerated. Phenolic crotyl esters and 3,5-dihydroxy crotyl 
esters were also prepared although these compounds were not found to be productive substrates in 
the enzymatic transformation (Figure 3.9). 
Chapter 3.4: Preparative-scale Reactions 
To evaluate the stereoselectivity achieved using this substrate engineering approach, the 
enantioenrichment of dearomatized products was measured. Preparative scale reactions were 
performed on 10 mg scale, employing the conditions outlined in Chapter 2.3. C5-hydroxylated 
racemic standards were synthesized using lead tetraacetate (LTA, yields shown in gray, Figure 
3.10) and resolved using chiral SFC also as described in Chapter 2.3. Gratifyingly, all enzymatic 
products examined were obtained in good enantiopurity, supporting our hypothesis that the 
lipophilic substituent at C1 is critical for proper substrate positioning. The crotyl ester with the 
native substitution pattern was obtained in a 72% isolated yield and 98% ee. The C3 and C5 ethyl 
Figure 3.8: Values given are total turnover numbers (TTNs) of each enzyme/substrate pair. Reaction conditions: 2.5 
mM substrate, 2.5 µM SorbC, 1 mM NADP+, 5 mM glucose-6-phosphate (G6P), 1 U ml–1 glucose-6-phosphate 
dehydrogenase (G6PDH), 50 mM potassium phosphate buffer, pH 8.0, 30 °C, 15% v/v DMSO 1 h. 
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products were obtained in 98% and 96% ee, respectively. Notably, the n-propyl product 3.83 was 
also obtained in 98% ee, indicating that the crotyl group is recognized in preference to the C3 alkyl 
chain which, if recognized in the same manner as the C1 substituent, would result in diminished 
facial selectivity and ultimately eroded enantiopurity of the product. This is in contrast to the 
diminished enantiopurity observed in the ketone substrate class wherein the C3 ethyl product was 
obtained in 94% ee.  
This substrate engineering strategy allowed us to expand the range of highly 
enantioenriched quinol products accessible through SorbC catalysis. To assess the utility of quinol 
products containing the crotyl ester positioning group, we explored conditions for removing the 
crotyl group as well as the innate reactivity of the ester-containing products. Removal of the crotyl 
group proved to be facile under Pd-catalyzed decrotylation conditions. By employing 7 mol % 
Pd(PPh3)4 and morpholine, the crotyl group of 3.79 was removed to unveil the carboxylic acid 
present in 3.84 (Figure 10B).30 To further explore the innate reactivity of ester-containing products, 
we sought to transform these directly into analogs of the natural product urea sorbicillinoid (4.6, 
Figure 4.3).31 Although previous reports have described ester derivatives of sorbicillinol as 
unreactive in the dimerization to afford the bisorbicillinol core,32  we have demonstrated that esters 
undergo facile in situ [4+2] cycloaddition with maleimide to afford the [2,2,2] tricycle 3.87 in 23% 
yield over two steps (Figure 3.10C). Although the dimer of the dearomatized product was observed 
by MS, attempts at isolation proved unsuccessful, due in part to low reactivity and other 
decomposition pathways available to this compound. Based on these results, we anticipate this 
positioning group-based substrate engineering strategy will expand the utility of SorbC from a 
biocatalyst that is restricted to sorbicillinol derived natural products to a breadth of natural and 
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unnatural compounds accessible through the dearomatization of structurally diverse resorcinol 
derivatives such as 3.87.  
 
Figure 3.9: Application of directing group strategy for preparative-scale oxidative dearomatization. (A) Evaluation 
of substrate scope and reaction enantioselectivities. Yields for racemic standard synthesis in grey. LTA = lead 
tetraacetate. (B) Removal of directing group through palladium-catalyzed decrotylation. (C) Elaboration of 
dearomatized product through [4+2] cycloaddition. 
Chapter 3.5: Conclusions 
Due to the high synthetic value of products obtained from the biocatalytic oxidative 
dearomatization catalyzed by SorbC, we endeavored to employ a substrate engineering strategy to 
overcome the limited product profile of this transformation. Initial investigations into the substrate 
scope of SorbC led us to hypothesize that the lipophilic carbon chain was critical for productive 
substrate binding in the active site. Further analysis of substrate binding experimentally and 
computationally revealed that the role of the C1 substituent is not in enhancing the binding affinity 
of the substrate for the protein, but rather the C1 substituent is critical for positioning the substrate 
in a reactive pose. Optimization of the positioning group led us to identify the crotyl ester as an 
ideal group to attain high TTNs on scaffolds which are otherwise not competent substrates in the 
enzymatic reaction. This ester group required for productive biocatalysis can be transformed into 
the corresponding carboxylic acid, a versatile handle for further chemical functionalization, or the 
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ester-containing dearomatized products can be used directly in subsequent complexity-generating 
transformations. Ongoing work includes exploring the generality of this positioning group 
approach to other flavin-dependent monooxygenases. By profiling the substrate scope of wild-type 
FDMOs clear trends in reactivity can allow for the identification of key functionalities that govern 
productive substrate turnover. If this functionality lends itself to a directing group strategy this 
approach can significantly broaden the types of molecular scaffolds a wild-type protein can operate 
on. 
Chapter 3.6 Experimental 
Chapter 3.6.1: Substrate Synthesis 
 
 
2,4-Dihydroxy-3,5-dimethylbenzoic acid (3.23) 
Adapted from a report by Larrosa and coworkers.26 In the glove box, NaH (60% dispersion in 
mineral oil, 1.43 g, 37.4 mmol, 4.0 equiv) was added to a vial containing 2,4-dimethylbenzene-
1,3-diol (1.29 g, 9.34 mmol, 1.0 equiv) and 2,4,6-trimethylphenol (1.27 g, 9.34 mmol, 1.0 equiv). 
The resulting mixture was heated at 100 °C for 5 min, then cooled to room temperature and ground 
into powder with a spatula. The vial containing the mixture was taken out of the glove box, purged 
with CO2, equipped with a balloon filled with CO2, and heated at 185 °C for 2 h. After this time, 
the reaction mixture was cooled to room temperature, carefully quenched with water (5 mL), 
acidified to pH 4 with aq. HCl (1 M), and extracted with EtOAc (3 x 20 mL). The organic layers 
were dried over anhydrous Na2SO4, evaporated to dryness, and purified by column 
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chromatography (10-50% EtOAc/hexanes) to yield 732 mg (43%) of salicylic acid 3.23 as a tan 
solid. 1H NMR (400 MHz, CD3OD) δ 7.44 (s, 1 H), 2.07 (s, 3 H), 2.13 (s, 3 H). All spectra obtained 
were consistent with literature values.32 
 
 
(E)-But-2-en-1-yl 2,4-dihydroxy-3,5-dimethylbenzoate (3.26) 
0.50 mL DCM was added to an oven-dried vial equipped with a stir bar containing 2,4-dihydroxy-
3,5-dimethylbenzoic acid (3.23, 50.0 mg, 0.270 mmol, 1.0 equiv). Oxalyl chloride (35 L, 0.412 
mmol, 1.5 equiv) was slowly added followed by DMF (1 drop, approx 10 L). The mixture was 
stirred for 2 h before crotyl alcohol (36 L, 0.450 mmol, 1.5 equiv mixture of cis and trans 1:19) 
was added dropwise. After 2 h, the reaction was quenched by addition of water (5 mL) and 
extracted with EtOAc (3 x 20 mL). The organic layers were dried over anhydrous Na2SO4, 
evaporated to dryness, and purified by column chromatography (0-15% EtOAc/hexanes) to yield 
41 mg (65%) of the crotyl ester as a colorless solid. None of the undesired cis isomer was observed 
by UPLC-PDA. 1H NMR (400 MHz, CD3OD) δ 7.42 (s, 1H), 5.89 (m, 1H), 5.70 (m, 1H), 4.70 (d, 
J = 6.4 Hz, 2H), 2.12 (s, 3H), 2.07 (s, 3H), 1.74 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
δ 170.3, 159.6, 159.6, 131.1, 127.9, 124.9, 115.8, 110.4, 103.6, 64.9, 16.5, 14.8, 6.8; HRMS (ESI) 
m/z calculated for C13H18O4 [M+H]
+: 237.1121, found: 237.1121; IR (thin film): 3440, 2919, 1644, 





(E)-Pent-2-en-1-yl 2,4-dihydroxy-3,5-dimethylbenzoate (3.27) 
0.50 mL DCM was added to an oven-dried vial equipped with a stir bar containing 2,4-dihydroxy-
3,5-dimethylbenzoic acid (3.23, 50.0 mg, 0.270 mmol, 1.0 equiv). Oxalyl chloride (35 L, 0.412 
mmol, 1.5 equiv) was slowly added followed by DMF (1 drop, approx 10 L). The mixture was 
stirred for 2 h before (E)-pent-2-en-1-ol (28 L, 0.270 mmol, 1.0 equiv) was added dropwise. After 
2 h, the reaction was quenched by addition of water (5 mL) and extracted with EtOAc (3 x 20 mL). 
The organic layers were dried over anhydrous Na2SO4, evaporated to dryness and purified by 
column chromatography (0-15% EtOAc/hexanes) to yield 17 mg (25%) of the pentenyl ester as a 
colorless solid. 1H NMR (400 MHz, CDCl3) δ 11.11 (s, 1H), 7.51 (s, 1H), 5.90 (m, 1H), 5.66 (m, 
1H), 5.16 (s, 1H), 4.75 (dt, J = 6.5, 1.2 Hz, 2H), 2.18 (s, 3H), 2.12 (s, 3 H), 2.09 (m, 2H), 1.03 (t, 
J = 7.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 170.2, 159.8, 158.0, 138.4, 128.6, 122.6, 114.5, 
110.0, 104.9, 65.6, 25.3, 15.3, 13.1, 7.7; HRMS (ESI) m/z calculated for C14H19O4 [M+H]
+: 




Butyl 2,4-dihydroxy-3,5-dimethylbenzoate (3.29) 
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0.50 mL DCM was added to an oven-dried vial equipped with a stir bar containing 2,4-dihydroxy-
3,5-dimethylbenzoic acid (3.23, 50.0 mg, 0.270 mmol, 1.0 equiv). Oxalyl chloride (35 L, 0.412 
mmol, 1.5 equiv) was slowly added followed by DMF (1 drop, approx 10 L). The mixture was 
stirred for 2 h before butanol (29 L, 0.270 mmol, 1.0 equiv) was added dropwise. After 2 h, the 
reaction was quenched by addition of water (5 mL) and extracted with EtOAc (3 x 20 mL). The 
organic layers were dried over anhydrous Na2SO4, evaporated to dryness, and purified by column 
chromatography (0-15% EtOAc/hexanes) to yield 10 mg (16%) of the butyl ester as a colorless 
solid. 1H NMR (400 MHz, CD3OD) δ 7.42 (s, 1H), 4.29 (t, J = 6.6 Hz, 2H), 2.13 (s, 3H), 2.07 (s, 
3H), 1.74 (m, 2H), 1.48 (h, J = 7.4 Hz, 2H), 0.99 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, CD3OD) 
δ 170.5, 159.7, 159.6, 127.8, 115.7, 110.4, 103.6, 64.2, 30.5, 18.9, 14.8, 12.6, 6.8; HRMS (ESI) 
m/z calculated for C13H19O4 [M+H]
+: 239.1278, found: 239.1275; IR (thin film): 3442, 2925, 1642, 
1610, 1403, 1288 cm-1; MP: 93-94 °C. 
 
 
Pentyl 2,4-dihydroxy-3,5-dimethylbenzoate (3.30) 
0.50 mL DCM was added to an oven-dried vial equipped with a stir bar containing 2,4-dihydroxy-
3,5-dimethylbenzoic acid (3.23, 50.0 mg, 0.270 mmol, 1.0 equiv). Oxalyl chloride (35 L, 0.412 
mmol, 1.5 equiv) was slowly added followed by DMF (1 drop, approx 10 L). The mixture was 
stirred for 2 h before pentanol (29 L, 0.270 mmol, 1.0 equiv) was added dropwise. After 2 h, the 
reaction was quenched by addition of water (5 mL) and extracted with EtOAc (3 x 20 mL). The 
organic layers were dried over anhydrous Na2SO4, evaporated to dryness and purified by column 
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chromatography (0-15% EtOAc/hexanes) to yield 50 mg (74%) of the pentyl ester as a colorless 
solid. 1H NMR (400 MHz, CDCl3) δ 11.17 (s, 1H), 7.48 (s, 1H), 5.27 (s, 1H), 4.30 (t, J = 6.7 Hz, 
2H), 2.19 (s, 3H), 2.14 (s, 3H), 1.77 (p, J = 6.9 Hz, 2H), 1.42 (m, 4H), 0.94 (m, 3H); 13C NMR 
(100 MHz, CDCl3) δ 170.6, 159.8, 158.0, 128.4, 114.6, 110.0, 104.9, 65.1, 28.4, 28.1, 22.3, 15.4, 
13.9, 7.7; HRMS (ESI) m/z calculated for C14H21O4 [M+H]
+: 253.1434, found: 253.1438; IR (thin 




0.50 mL DCM was added to an oven-dried vial equipped with a stir bar containing 2,4-dihydroxy-
3,5-dimethylbenzoic acid (3.23, 50.0 mg, 0.270 mmol, 1.0 equiv). Oxalyl chloride (35 L, 0.412 
mmol, 1.5 equiv) was slowly added followed by DMF (1 drop, approx 10 L). The mixture was 
stirred for 2 h before butyl amine (29 L, 0.270 mmol, 1.0 equiv) was added dropwise. After 2 h, 
the reaction was quenched by addition of water (5 mL) and extracted with EtOAc (3 x 20 mL). 
The organic layers were dried over anhydrous Na2SO4, evaporated to dryness and purified by 
column chromatography (0-15% EtOAc/hexanes) to yield 23 mg (34%) of the amide as a colorless 
oil. 1H NMR (400 MHz, CDCl3) δ 12.77 (s, 1H), 6.95 (s, 1H), 6.07 (s, 1H), 5.02 (s, 1H), 3.43 (q, 
J = 6.6 Hz, 2H), 2.19 (s, 3H), 2.14 (s, 3H), 1.60 (m, 2H), 1.41 (q, J = 7.5 Hz, 2H), 0.96 (t, J = 7.3 
Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 170.2, 159.7, 156.5, 123.9, 113.8, 110.8, 106.7, 39.3, 
31.6, 20.1, 15.6, 13.7, 7.6; HRMS (ESI) m/z calculated for C13H20NO3 [M+H]
+: 238.1438, found: 






4-Hexyl-2,6-dimethylbenzene-1,3-diol (Figure 3.5, Entry 3) 
A solution of 1-(2,4-dihydroxy-3,5-dimethylphenyl)hexan-1-one (115 mg, 0.692 mmol, 1.0 equiv) 
and Zn dust (452 mg, 6.92 mmol, 10 equiv) in EtOH (2.1 mL) was added to a round-bottom flask 
equipped with a stirbar and cooled to 0 °C. HCl conc. aq. (2.1 mL) was added dropwise over 15 
min. The mixture slurry was then stirred at 0 °C for 20 min before filtration. The filtrate was 
quenched by the slow addition of saturated sodium bicarbonate (1 mL) and extracted with EtOAc 
(3 x 50 mL). The combined organic layers were dried over anhydrous Na2SO4, evaporated to 
dryness and purified by column chromatography silica gel (0-20% EtOAc/hexanes) to afford 103 
mg (98% yield) of the title compound as a white solid. 1H NMR (600 MHz, CDCl3) δ 6.72 (s, 1H), 
4.55 (s, 1H), 4.53 (s, 1H), 2.49 (t, J = 8.1 Hz, 2H), 2.17 (overlapping s, 6H), 1.56 (m, 2H), 1.38 
(m, 2H), 1.32 (m, 4H), 0.89 (t, J = 6.5, 3H); 13C NMR (150 MHz, CDCl3) δ 150.6, 150.3, 128.2, 
119.6, 114.4, 109.6, 31.8, 30.2, 29.8, 29.3, 22.6, 15.4, 14.1, 8.5; HRMS (ESI) m/z calculated for 
C14H23O2 [M+H]
+: 223.1693, found: 223.1694; IR (thin film): 3512, 2923, 1611, 1468, 1377, 1191 





(E)-But-2-en-1-yl 2,4-dihydroxy-3,5,6-trimethylbenzoate (3.47) 
Adapted from a protocol developed by Giannis.34 Methyl 2,4-dihydroxy-3,5,6-trimethylbenzoate 
(180 mg, 1.20 mmol, 1.0 equiv) was dissolved in crotyl alcohol (2.4 mL) in a flame-dried vial. 
After the addition of dibutyltin oxide (71.0 mg, 0.120 mmol, 10 mol %) the mixture was heated at 
reflux for 12 h. The reaction was quenched by addition of water (5 mL) and extracted with EtOAc 
(3 x 20 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous 
Na2SO4, evaporated to dryness and purified by column chromatography (0-15% EtOAc/hexanes) 
to yield 140 mg (47%) of the crotyl ester as a colorless solid. 1H NMR (600 MHz, CDCl3) δ 11.42 
(s, 1H), 5.86 (m, 1H), 5.7 (m, 1H), 5.11 (s, 1H), 4.76 (d, J = 6.5 Hz, 2H), 2.43 (s, 3H), 2.12 
(overlapping s, 6H), 1.74 (d, J = 6.5 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 172.0, 159.5, 156.5, 
137.6, 131.8, 124.7, 114.7, 107.2, 106.3, 65.9, 18.9, 17.8, 11.8, 8.0; HRMS (ESI) m/z calculated 
for C14H19O4 [M+H]
+: 251.1278, found: 251.1277; IR (thin film): 3464, 3176, 2949, 2930, 1641, 
1611, 1188 cm-1; MP: 77-78 °C. 
 
 
(E)-But-2-en-1-yl 5-ethyl-2,4-dihydroxy-3-methylbenzoate (3.72) 
Adapted from a report by Larrosa and coworkers.26 In the glove box, NaH (60% wt/wt dispersion 
in mineral oil, 1.43 g, 37.4 mmol, 4.0 equiv) was added to a vial containing 4-ethyl-2-
methylbenzene-1,3-diol (1.29 g, 9.34 mmol, 1.0 equiv) and 4-ethyl-2-methyl resorcinol (3.40, 1.27 
g, 9.34 mmol, 1.0 equiv). The resulting mixture was heated at 100 °C for 5 min, cooled to room 
temperature and ground into powder with a spatula. The vial containing the mixture was taken out 
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of the glove box, purged with CO2 and equipped with a balloon filled with CO2 at 185 °C for 2 h. 
After this time, the reaction mixture was cooled to room temperature, carefully quenched with 
water (5 mL), acidified to pH 4 with aq. HCl (1 M), and extracted with EtOAc (3 x 20 mL). The 
organic layers were dried over anhydrous Na2SO4, evaporated to dryness and purified by column 
chromatography (30-50% EtOAc/hexanes) to yield 732 mg (43%) of salicylic acid 3.42 as a tan 
solid. DCM (10 mL) was added to an oven-dried vial equipped with a stir bar containing 5-ethyl-
2,4-dihydroxy-3-methylbenzoic acid (3.42, 400 mg, 2.04 mmol, 1.0 equiv). Oxalyl chloride (192 
L, 2.24 mmol, 1.1 equiv) was slowly added followed by DMF (1 drop, approx 10 L). The 
mixture was stirred for 2 h before crotyl alcohol (348 L, 4.08 mmol, 2.0 equiv) was added 
dropwise. After 2 h, the reaction was quenched by addition of water (5 mL) and extracted with 
EtOAc (3 x 20 mL). The organic layers were dried over anhydrous Na2SO4, evaporated to dryness 
and purified by column chromatography (0-15% EtOAc/hexanes) to yield 23 mg (34%) of the 
crotyl ester as a colorless solid. 1H NMR (600 MHz, CDCl3) δ 11.14 (s, 1H), 7.49 (s, 1H), 5.86 
(m, 1H), 5.70 (m, 1H), 5.29 (s, 1H), 4.73 (d, J = 6.5 Hz, 2H), 2.55 (q, J = 7.5 Hz, 2H), 2.13 (s, 
3H), 1.74 (m, 3H), 1.20 (t, J = 7.5 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 170.3, 159.7, 157.7, 
131.7, 127.1, 124.9, 121.0, 110.0, 104.9, 65.6, 22.7, 17.8, 14.1, 7.7; HRMS (ESI) m/z calculated 
for C14H19O4 [M+H]
+: 251.1278, found: 251.1276; IR (thin film): 3439, 2820, 1643, 1609, 1400, 
1194 cm -1; MP: 75-76 °C. 
 
 
(E)-But-2-en-1-yl 3-ethyl-2,4-dihydroxy-5-methylbenzoate (3.73) 
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Adapted from a report by Larrosa and coworkers.26 In the glove box, NaH (60% dispersion in 
mineral oil, 268 mg, 11.2 mmol, 4.0 equiv) was added to a vial containing 2-ethyl-4-
methylbenzene-1,3-diol (380 mg, 2.79 mmol, 1.0 equiv) and 2-ehtyl-4-methylresorcinol (3.39, 425 
mg, 2.79 mmol, 1.0 equiv). The resulting mixture was heated at 100 °C for 5 min, cooled to room 
temperature and ground into powder with a spatula. The vial containing the mixture was taken out 
of the glove box, purged with CO2 and equipped with a balloon filled with CO2 at 185 °C for 2 h. 
The reaction mixture was cooled to room temperature, carefully quenched with water (5 mL), 
acidified to pH 4 with aq. HCl (1 M), and extracted with EtOAc (3 x 20 mL). The organic layers 
were dried over anhydrous Na2SO4, evaporated to dryness and purified by column chromatography 
(30-50% EtOAc/hexanes) to yield 305 mg (56%) of salicylic acid 3.41 as a tan solid. 
3-ethyl-2,4-dihydroxy-5-methylbenzoic acid (3.41, 305 mg, 1.55 mmol, 1.0 equiv) was stirred in 
DCM (9 mL) in a flame-dried round-bottom flask. Oxalyl chloride (147 L, 1.71 mmol, 1.1 equiv) 
was slowly added followed by DMF (1 drop, approx 10 L). The mixture was stirred for 2 h before 
crotyl alcohol (264 L, 3.10 mmol, 2.0 equiv) was added dropwise. After 2 h, the reaction was 
quenched by addition of water (5 mL) and extracted with EtOAc (3 x 20 mL). The organic layers 
were dried over anhydrous Na2SO4, evaporated to dryness, and purified by column 
chromatography (0-15% EtOAc/hexanes) to yield 94 mg (24%) of the crotyl ester as a colorless 
solid. 1H NMR (600 MHz, CDCl3) δ 11.07 (s, 1H), 7.49 (s, 1H), 5.86 (m, 1H), 5.68 (m, 1H), 5.23 
(s, 1H), 4.72 (d, J = 6.5 Hz, 1H), 2.67 (q, J = 7.5 Hz, 2H), 2.17 (s, 3H), 1.75 (d, J = 6.5 Hz, 3H), 
1.14 (t, J = 7.5 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 170.3, 159.7, 157.6, 131.8, 128.7, 124.8, 
116.4, 114.6, 104.9, 65.5, 17.8, 16.2, 15.3, 13.2; HRMS (ESI) m/z calculated for C14H19O4 







1-Iodo-2,4-dimethoxy-3-methylbenzene (1.00 g, 3.60 mmol, 1.0 equiv) was added to a flame-dried 
round-bottom flask and dissolved in THF (25 mL). The mixture was cooled to 0 °C and nBuLi 
(1.73 mL, 4.32 mmol, 1.2 equiv, 2.5 M in hexanes) was slowly added. The mixture was stirred at 
0 °C for 30 min, before 1-bromo-3-methylbutane (1.29 mL, 10.8 mmol, 3.0 equiv) was added. The 
mixture was then warmed to rt and stirred for 30 min at which time the reaction mixture was 
quenched by the slow addition of water and diluted with EtOAc (10 mL). The resulting layers were 
separated, and the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic 
layers were washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced 
pressure to afford a brown oil. The crude material was transferred to a flame-dried vial, dissolved 
in DCM (45 mL) and cooled to -78 °C. BBr3 (7.20 mL, 7.20 mmol, 1 M in DCM, 2.0 equiv) was 
added dropwise. The mixture was warmed to rt and stirred for 16 h at which time the reaction 
mixture was quenched by the slow addition of water. The resulting solution was extracted with 
EtOAc (3 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous 
Na2SO4 and concentrated under reduced pressure to afford a dark brown solid. Purification on 
silica gel (100% hexanes to 15% EtOAc in hexanes) afforded 650 mg (93% yield over two steps) 
of 5.59 as a tan crystalline solid. 1H NMR (400 MHz, CDCl3) δ 6.81 (d, J = 8.1 Hz, 1H), 6.34 (d, 
J = 8.1 Hz, 1H), 4.76 (s, 1H), 4.72 (s, 1H), 2.51 (m, 2H), 2.14 (s, 3H), 1.58 (m, 1H), 1.46 (m, 2H), 
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0.94 (d, J = 6.6 Hz, 6H); 13C NMR (150 MHz, CDCl3) δ 152.5, 152.4, 126.9, 126.7, 120.4, 109.9, 
107.1, 39.2, 27.7, 27.6, 22.5, 8.2; HRMS (ESI) m/z calculated for C12H19O2 [M+H]
+: 195.1385, 




1-Iodo-2,4-dimethoxy-3-methylbenzene (1.00 g, 3.60 mmol, 1.0 equiv) was added to a flame-dried 
round-bottom flask and dissolved in THF (25 mL). The mixture was cooled to 0 °C and nBuLi 
(1.73 mL, 4.32 mmol, 1.2 equiv, 2.5 M in hexanes) was slowly added. The mixture was stirred at 
0 °C for 30 min, before benzylbromide (1.28 mL, 10.8 mmol, 3.0 equiv) was added. The mixture 
was then warmed to rt and stirred for 30 min at which time the reaction mixture was quenched by 
the slow addition of water and diluted with EtOAc (10 mL). The resulting layers were separated, 
and the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic layers were 
washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to 
afford a brown oil. The crude material was transferred to a flame-dried vial, dissolved in DCM (45 
mL) and cooled to -78 °C. BBr3 (7.20 mL, 7.20 mmol, 1 M in DCM, 2.0 equiv) was added slowly. 
The mixture was warmed to rt and stirred for 16 h at which time the reaction mixture was quenched 
by the slow addition of water. The resulting solution was extracted with EtOAc (3 x 10 mL). The 
combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated 
under reduced pressure to afford a dark brown solid. Purification on silica gel (100% hexanes to 
30% EtOAc in hexanes) afforded 563 mg (73% yield over two steps) of 5.60 as a tan crystalline 
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solid. 1H NMR (400 MHz, CDCl3) δ 7.25 (m, 5H), 6.85 (d, J = 8.2 Hz, 1H), 6.38 (d, J = 8.2 Hz, 
1H), 3.93 (s, 2H), 2.12 (s, 3H). All values obtained were consistent with literature values.33 
 
 
(E)-but-2-en-1-yl 2,4-dihydroxy-5-methyl-3-propylbenzoate (3.52) 
 
Adapted from a report by Larrosa and coworkers.26 In the glove box, NaH (60% dispersion in 
mineral oil, 1.43 g, 37.4 mmol, 4.0 equiv) was added to a vial containing 4-methyl-2-
propylbenzene-1,3-diol (1.29 g, 9.34 mmol, 1.0 equiv) and 2,4,6-trimethylphenol (1.27 g, 9.34 
mmol, 1.0 equiv). The resulting mixture was heated at 100 °C for 5 min, cooled to room 
temperature and ground into powder with a spatula. The vial containing the mixture was taken out 
of the glove box, purged with CO2 and equipped with a balloon filled with CO2 at 185 °C for 2 h. 
After this time, the reaction mixture was cooled to room temperature, carefully quenched with 
water (5 mL), acidified to pH 4 with aq. HCl (1 M), and extracted with EtOAc (3 x 20 mL). DCM 
(2.5 mL) was added to an oven-dried vial equipped with a stir bar containing 2,4-dihydroxy-5-
methyl-3-propylbenzoic acid (3.51, 92.0 mg, 0.438 mmol, 1.0 equiv). Oxalyl chloride (45.0 L, 
0.525 mmol, 1.2 equiv) was slowly added followed by DMF (1 drop, approx 10 L). The mixture 
was stirred for 2 h before crotyl alcohol (75.0 L, 0.876 mmol, 2.0 equiv) was added dropwise. 
After 2 h, the reaction was quenched by addition of water (5 mL) and extracted with EtOAc (3 x 
20 mL). The organic layers were dried over anhydrous Na2SO4, evaporated to dryness and purified 
by column chromatography (0-15% EtOAc/hexanes) to yield 78 mg (67%) of the crotyl ester as a 
colorless solid. 1H NMR (400 MHz, CDCl3) δ 11.07 (s, 1H), 7.50 (s, 1H), 5.86 (dd, J = 10.7, 4.9 
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Hz, 1H), 5.70 (m, 1H), 5.26 (s, 1H), 4.73 (d, J = 5.4 Hz, 2H), 2.63 (t, J = 6.2 Hz, 3H), 2.17 (s, 3H), 
1.76 (d, J = 6.5 Hz, 2H), 1.58 (m, 2H), 0.98 (t, J = 6.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
170.3, 159.9, 157.9, 131.8, 128.8, 124.9, 114.9, 114.6, 104.9, 65.5, 24.9, 21.9, 17.8, 15.4, 14.1; 
HRMS (ESI) m/z calculated for C15H21O4 [M+H]
+: 265.1434, found: 265.1433; IR (thin film): 
3404, 2952, 1744, 1637, 1196, 1397, 1194 cm-1; MP: 93-95 °C. 
 
 
(E)-but-2-en-1-yl 2,4-dihydroxy-5-isopentyl-3-methylbenzoate (3.68) 
Adapted from a report by Larrosa and coworkers.26 In the glove box, NaH (60% wt/wt dispersion 
in mineral oil, 381 mg, 9.92 mmol, 4.0 equiv) was added to a vial containing 4-isopentyl-2-
methylbenzene-1,3-diol (482 mg, 2.48 mmol, 1.0 equiv) and 2,4,6-trimethylphenol (338 mg, 2,48 
mmol, 1.0 equiv). The resulting mixture was heated at 100 °C for 5 min, cooled to room 
temperature and ground into powder with a spatula. The vial containing the mixture was taken out 
of the glove box, purged with CO2 and equipped with a balloon filled with CO2 at 185 °C for 2 h. 
After this time, the reaction mixture was cooled to room temperature, carefully quenched with 
water (5 mL), acidified to pH 4 with aq. HCl (1 M), and extracted with EtOAc (3 x 20 mL). The 
organic layers were dried over anhydrous Na2SO4, evaporated to dryness and purified by column 
chromatography (10-50% EtOAc/hexanes) to yield 228 mg (45%) of salicylic acid 5.64 as a tan 
solid. 5 mL DCM was added to an oven-dried vial equipped with a stir bar containing 2,4-
dihydroxy-5-isopentyl-3-methylbenzoic acid (5.64, 228 mg, 1.11 mmol, 1.0 equiv). Oxalyl 
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chloride (105 L, 1.22 mmol, 1.1 equiv) was slowly added followed by DMF (1 drop, approx 10 
L). The mixture was stirred for 2 h before crotyl alcohol (190 L, 2.22 mmol, 2.0 equiv) was 
added dropwise. After 2 h, the reaction was quenched by addition of water (5 mL) and extracted 
with EtOAc (3 x 20 mL). The organic layers were dried over anhydrous Na2SO4, evaporated to 
dryness and purified by column chromatography (0-15% EtOAc/hexanes) to yield 201 mg (62%) 
of the crotyl ester as a colorless solid. 1H NMR (600 MHz, CDCl3) δ 11.13 (s, 1H), 7.48 (s, 1H), 
5.87 (m, 1H), 5.70 (m, 1H), 5.24 (s, 1H), 4.73 (d, 2H), 2.53 (m, 2H), 2.13 (s, 3H), 1.75 (d, J = 6.6, 
Hz, 3H), 1.60 (m, 1H), 1.55 (m, 2H), 0.94 (d, J = 6.5 Hz, 6H); 13C NMR (150 MHz, CDCl3) δ 
170.3, 159.6, 157.7, 131.7, 127.8, 124.9, 119.9, 110.0, 104.9, 65.6, 39.0, 28.0, 27.6, 22.52, 17.8, 
7.7; HRMS (ESI) m/z calculated for C17H25O4 [M+H]
+: 293.1747, found: 293.1721; IR (thin film): 
3464, 3178, 2963, 1639, 1610, 1449, 1187 cm-1; MP: 52-53 °C. 
 
 
(E)-but-2-en-1-yl 3-chloro-2,4-dihydroxy-5-methylbenzoate (3.36) 
 
2 mL MeCN was added to a flame-dried vial containing 2,4-dihydroxy-5-methylbenzoic acid (45.0 
mg, 0.268 mmol, 1.0 equiv) and NCS (35.8 mg, 0.268 mmol, 1.0 equiv). The reaction was stirred 
at 40 °C for 3 h. After this time, the reaction mixture was cooled to room temperature, quenched 
with water (3 mL), and extracted with EtOAc (3 x 10 mL). The combined organic layers were 
washed with brine (5 mL), dried over anhydrous Na2SO4 and concentrated to dryness. 1.00 mL 
DCM was added to an oven-dried vial equipped with a stir bar containing 3-chloro-2,4-dihydroxy-
5-methylbenzoic acid (3.34, 65.0 mg, 0.253 mmol, 1.0 equiv). Oxalyl chloride (24 L, 0.28 mmol, 
1.1 equiv) was slowly added followed by DMF (1 drop, approx 10 L). The mixture was stirred 
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for 2 h before crotyl alcohol (43 L, 0.51 mmol, 2.0 equiv) was added dropwise. After 2 h, the 
reaction was quenched by addition of water (5 mL) and extracted with EtOAc (3 x 10 mL). The 
organic layers were dried over anhydrous Na2SO4, evaporated to dryness and purified by column 
chromatography (0- 10% EtOAc/hexanes) to yield 30 mg (46%) of the crotyl ester as a colorless 
solid. 1H NMR (400 MHz, CDCl3) δ 11.41 (s, 1H), 7.55 (s, 1H), 6.14 (s, 1H), 5.88 (dq, J = 13.4, 
6.6 Hz, 1H), 5.68 (dt, J = 14.7, 6.6 Hz, 1H), 4.74 (d, J = 6.5 Hz, 2H), 2.20 (s, 3H), 1.76 (d, J = 6.6 
Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 169.6, 156.7, 155.4, 132.4, 129.4, 124.4, 116.3, 107.1, 
105.6, 66.1, 17.8, 15.5; HRMS (ESI) m/z calculated for C12H14ClO4 [M+H]
+: 257.0575, found: 
257.0575; IR (thin film): 3464, 3176, 2949, 2930, 1641, 1611, 1188 cm-1. 
 
 
(E)-but-2-en-1-yl 3-bromo-2,4-dihydroxy-5-methylbenzoate (3.37) 
 
2 mL MeCN was added to a flame-dried vial containing 2,4-dihydroxy-5-methylbenzoic acid (45.0 
mg, 0.268 mmol, 1.0 equiv) and NBS (35.8 mg, 0.268 mmol, 1.0 equiv). The reaction was stirred 
at 40 °C for 3 h. After this time, the reaction mixture was cooled to room temperature, quenched 
with water (3 mL) then extracted with EtOAc (3 x 10 mL). The combined organic layers were 
washed with brine (5 mL), dried over anhydrous Na2SO4 and concentrated to dryness. 0.50 mL 
DCM was added to an oven-dried vial equipped with a stir bar containing 3-bromo-2,4-dihydroxy-
5-methylbenzoic acid (3.35, 31.3 mg, 0.155 mmol, 1.0 equiv). Oxalyl chloride (15 L, 0.17 mmol, 
1.1 equiv) was slowly added followed by DMF (1 drop, approx 10 L). The mixture was stirred 
for 2 h before crotyl alcohol (26 L, 0.31 mmol, 2.0 equiv) was added dropwise. After 2 h, the 
reaction was quenched by addition of water (5 mL) and extracted with EtOAc (3 x 10 mL). The 
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organic layers were dried over anhydrous Na2SO4, evaporated to dryness and purified by column 
chromatography (0-15% EtOAc/hexanes) to yield 9.9 mg (21%) of the crotyl ester as a colorless 
oil. 1H NMR (400 MHz, CDCl3) δ 11.56 (s, 1H), 7.60 (s, 1H), 6.14 (s, 1H), 5.90 (m, 1H), 5.65 (m, 
1H), 4.76 (d, J = 6.6 2H), 2.23 (s, 3H), 1.77 (d, J = 6.5 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 
169.6, 157.8, 156.4, 132.4, 130.3, 124.4, 116.8, 105.8, 98.5, 66.1, 17.8, 15.8; HRMS (ESI) m/z 
calculated for C12H14BrO4 [M+H]
+: 301.0070, found: 301.0072; IR (thin film): 3464, 2957, 2923, 
2854, 1739, 1663, 1455 cm-1. 
 
(E)-but-2-en-1-yl 5-benzyl-2,4-dihydroxy-3-methylbenzoate (3.69) 
Adapted from a report by Larrosa and coworkers.26 In the glove box, NaH (60% wt/wt dispersion 
in mineral oil, 1.43 g, 37.4 mmol, 4.0 equiv) was added to a vial containing 4-benzyl-2-
methylbenzene-1,3-diol (1.29 g, 9.34 mmol, 1.0 equiv) and 2,4,6-trimethylphenol (1.27 g, 9.34 
mmol, 1.0 equiv). The resulting mixture was heated at 100 °C for 5 min, cooled to room 
temperature and ground into powder with a spatula. The vial containing the mixture was taken out 
of the glove box, purged with CO2 and equipped with a balloon filled with CO2 at 185 °C for 2 h. 
After this time, the reaction mixture was cooled to room temperature, carefully quenched with 
water (5 mL), acidified to pH 4 with aq. HCl (1 M), and extracted with EtOAc (3 x 20 mL). The 
organic layers were dried over anhydrous MgSO4, evaporated to dryness to afford a tan crystalline 
solid. 0.50 mL DCM was added to an oven-dried vial equipped with a stir bar containing 4-benzyl-
2-methylbenzene-1,3-diol (5.66, 50.0 mg, 0.270 mmol, 1.0 equiv). Oxalyl chloride (35 L, 0.412 
mmol, 1.5 equiv) was slowly added followed by DMF (1 drop, approx 10 L). The mixture was 
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stirred for 2 h before crotyl alcohol (29 L, 0.270 mmol, 1.0 equiv) was added dropwise. After 2 
h, the reaction was quenched by addition of water (5 mL) and extracted with EtOAc (3 x 20 mL). 
The organic layers were dried over anhydrous Na2SO4, evaporated to dryness, and purified by 
column chromatography (0-15% EtOAc/hexanes) to yield 23 mg (34%) of the crotyl ester as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ 11.18 (s, 1H), 7.58 (s, 1H), 7.20 (m, 5H), 5.86 (m, 
1H), 5.70 (m, 1H), 5.12 (d, J = 1.2 Hz, 2H), 4.74 (m, 2H), 3.94 (s, 1H), 2.11 (s, 3H), 1.76 (d, J = 
6.2 Hz, 2H); 13C NMR (150 MHz, CDCl3) 170.2, 160.4, 158.1, 139.4, 131.8, 129.1, 128.8, 128.4, 
126.6, 124.8, 117.8, 111.0, 105.1, 65.6, 36.4, 17.8, 7.8; HRMS (ESI) m/z calculated for C19H21O4 





2,4-dimethoxy-1-methylbenzene (874 mg, 5.74 mmol, 1.0 equiv) was added to a flame-dried 
round-bottom flask and dissolved in THF (12 mL). The mixture was cooled to 0 °C and nBuLi 
(3.44 mL, 8.61 mmol, 1.5 equiv, 2.5 M in hexanes) was slowly added. The mixture was stirred at 
0 °C for 30 min, before 1-bromopropane (1.60 mL, 17.2 mmol, 3.0 equiv) was added. The mixture 
was then warmed to rt and stirred for 30 min at which time the reaction mixture was quenched by 
the slow addition of water (10 mL) and diluted with EtOAc (10 mL). The resulting layers were 
separated, and the aqueous layer was extracted with EtOAc (3 x 20 mL). The combined organic 
layers were washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced 
pressure to afford a brown oil. The crude material was transferred to a flame-dried vial, dissolved 
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in DCM (70 mL) and cooled to -78 °C. BBr3 (11.5 mL, 11.5 mmol, 1 M in DCM, 2.0 equiv) was 
added slowly. The mixture was then warmed to rt and stirred for 16 h at which time the reaction 
mixture was quenched by the slow addition of water. The resulting solution was extracted with 
EtOAc (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous 
Na2SO4 and concentrated under reduced pressure to afford a dark brown solid. Purification on 
silica gel (100% hexanes to 30% EtOAc in hexanes) afforded 897 mg (94% yield over two steps) 
of 3.52 as a tan crystalline solid. 1H NMR (400 MHz, CDCl3) δ 6.81 (d, J = 8.0 Hz, 1H), 6.32 (d, 
J = 8.0 Hz, 1H), 4.67 (s, 1H), 4.63 (s, 1H), 2.62 (t, J = 8.4, 2H), 2.17 (s, 3H), 1.59 (h, J = 7.4 Hz, 
2H), 0.99 (t, J = 7.4 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 152.7, 152.6, 127.8, 115.1, 114.7, 
107.1, 25.4, 22.3, 15.5, 14.2; HRMS (ESI) m/z calculated for C10H15O2 [M+H]
+: 167.1067, found: 
167.1066; IR (thin film): 3345, 2955, 1600, 1455, 1188 cm-1; MP: 95-97 °C. 
 
General procedure for lead tetraacetate (LTA)-mediated oxidative dearomatization: 
Adapted from a protocol developed by Nicolau.32 Substrate (50 mg, 1 equiv) was dissolved in 
AcOH and DCM (5:1, 0.04 M). LTA (1.2 equiv) was added and the reaction was allowed to stir at 
rt for 1 h. The reaction was quenched by addition of water (10 mL) and the mixture was extracted 
with EtOAc (3 x 15 mL). The combined organic layers were washed with water (1 x 20 mL), brine 
(1 x 20 mL), dried over sodium sulfate, and concentrated under reduced pressure to afford a yellow 
oil. Purification on silica gel afforded the O-acylated o-quinol product. Full characterization given 








The title compound was prepared according to the general procedure for LTA-mediated oxidative 
dearomatization. Purification on silica gel (20- 40% EtOAc in hexanes) afforded 10 mg (16% 
yield) of the o-quinol as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 10.82 (s, 1H), 7.38 (s, 1H), 
5.90 (dd, J = 15.0, 7.0 Hz, 1H), 5.66 (m, 1H), 4.71 (d, J = 6.8 Hz, 2H), 2.12 (s, 3H), 1.87 (s, 3H), 




carboxylate (±3.81)  
The title compound was prepared according to the general procedure for LTA-mediated oxidative 
dearomatization. Purification on silica gel (20-40% EtOAc in hexanes) afforded 4.9 mg (8.0% 
yield) of the o-quinol as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 10.78 (s, 1H), 7.37 (s, 1H), 
5.88 (dd, J = 14.9, 6.9 Hz, 1H), 5.63 (m, 1H), 4.71 (d, J = 6.9 Hz, 2H), 2.12 (s, 3H), 1.85 (s, 3H), 









The title compound was prepared according to the general procedure for LTA-mediated oxidative 
dearomatization. Purification on silica gel (20-40% EtOAc in hexanes) afforded 1.8 mg (3.0% 
yield) of the o-quinol as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 10.77 (s, 1H), 7.37 (s, 1H), 
5.89 (m, 1H), 5.64 (m, 1H), 4.71 (d, J = 3.5 Hz, 2H), 2.41 (q, J = 6.7 Hz, 2H), 2.12 (s, 3H), 1.77 





The title compound was prepared according to the general procedure for LTA-mediated oxidative 
dearomatization. Purification on silica gel (20-40% EtOAc in hexanes) afforded 10 mg (16% yield) 
of the o-quinol as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 10.75 (s, 1H), 7.36 (s, 1H), 5.88 (m, 
1H), 5.60 (m, 1H), 4.70 (t, J = 7.4 Hz, 2H), 2.36 (m, 2H), 2.10 (s, 3H), 1.75 (d, J = 6.7 Hz, 3H), 







The title compound was prepared according to the general procedure for LTA-mediated oxidative 
dearomatization. Purification on silica gel (20-40% EtOAc in hexanes) afforded 3.3 mg (6% yield) 
of the o-quinol as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 10.96 (s, 1H), 5.87 (m, 1H), 5.64 
(dt, J = 15.1, 7.0 Hz, 1H), 4.74 (t, J = 6.7 Hz, 2H), 2.20 (s, 3H), 2.14 (s, 3H), 1.85 (s, 3H), 1.75 (d, 
J = 6.5 Hz, 3H), 1.44 (s, 3H). 
Chapter 3.6.2: Biocatalytic Reactions 
Stock solutions: Stock solutions of each substrate (50 mM) were prepared by dissolving the 
substrate in DMSO (analytical grade). Stock solutions of NADP+ (100 mM) and glucose-6-
phosphate (G6P, 500mM) were stored at –20 °C. Aliquots of SorbC (62 μM) and glucose-6-
phosphate dehydrogenase (G6PDH, 100 U/mL) were stored at –80 °C. Analytical-scale 
reactions: Each reaction contained 25 μL 100 mM potassium phosphate buffer, pH 8.0, 2.5 mM 
substrate (2.5 μL of a 50 mM stock solution in DMSO), 2.5 μM SobC, 5 mM G6P (0.5 μL, 500 
mM), 1 mM NADP+ (0.5 μL, 100 mM), 1 U/mL G6P-DH (0.5 μL, 100 U/mL), and Milli-Q water 
to a final volume of 50 μL. The reaction was carried out at 30 °C for 1 h and quenched by addition 
of 75 µL acetonitrile with 25 mM pentamethylbenzene as an internal standard. Precipitated 
biomolecules were pelleted by centrifugation (16,000 x g, 12 min). The supernatant was analyzed 
by UPLC-DAD and conversion obtained by comparison to calibration curves of each substrate. 
Determination of total turnover number (TTN): Total turnover number was determined by 
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analyzing (# of moles of starting material consumed)/(# of moles of enzyme) under the following 
conditions: 2.5 µM SorbC, 2.5 mM substrate, 1 mM NADP+, 0.05 U G6PDH, and 5 mM G6P for 
NADPH regeneration in 50 µL of reaction buffer (50 mM potassium phosphate, pH 8.0). The 
reaction was carried out at 30 °C for 1 h and quenched by addition of 75 µL acetonitrile with 2.5 
mM pentamethylbenzene as an internal standard. Precipitated biomolecules were pelleted by 
centrifugation (16,000 x g, 12 min). The subsequent liquid chromatography PDA spectrometry 
(UPLC) analysis was performed on a Waters Aquity H-Class UPLC-PDA using a Phenomenex 
Kinetex 1.7 µm C18, 2.1x150 mm column under the following conditions: Method A: mobile 
phase (A = deionized water + 0.1% formic acid, B = acetonitrile + 0.1% formic acid), 5% to 100% 
B over 1.5 min, 100% B for 1.0 min; flow rate, 0.5 mL/min; Method B: mobile phase (A = 
deionized water + 0.1% formic acid, B = acetonitrile + 0.1% formic acid), 5% to 100% B over 2 
min, 100% B for 1 min; flow rate, 0.5 mL/min. Based on calibration curves of the starting 
materials, the percent conversion of the substrate to dearomatized product was calculated with 
AUCsubstrate/AUCinternal standard at 270 nm. All reactions were performed and analyzed in triplicate.  
General procedure for in vitro milligram-scale reactions: Preparative-scale enzymatic 
reactions were conducted on 10 mg of each substrate under the following conditions: 2.5 µM 
SorbC, 2.5 mM substrate, 1 mM NADP+, 1 U/mL G6PDH, and 5 mM G6P for NADPH generation 
in reaction buffer (50 mM potassium phosphate buffer, pH 8.0). The reaction mixture was added 
to a crystallizing dish and incubated at 30 °C for 2 h. The increased surface area afforded by the 
crystalizing dish as reaction vessel allowed for higher conversions with some substrates due to 
increased oxygen concentration. After 2 h, a 50 µL aliquot was removed and processed in an 
identical manner to the analytical-scale reactions described above to determine substrate 
conversion. The remaining reaction mixture was diluted with acetonitrile (2 x total reaction 
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volume). Precipitated biomolecules were pelleted by centrifugation (4,000 x g, 12 min). The 
reaction mixture was cooled to 0 °C and pyridine (14.0 µL, 0.173 mmol) was added followed by 
Ac2O (10.4 µL, 0.110 mmol). The resulting mixture was stirred at rt for 2 h. The reaction was then 
acidified to pH 2 and the mixture was extracted with EtOAc (3 x 70 mL). The combined organic 
layers were washed with brine (1 x 50 mL), dried over sodium sulfate and concentrated under 
reduced pressure. Purification on silica gel (30% hexanes to 50% EtOAc in hexanes) afforded the 
acylated o-quinol products.  
Steady-state kinetics of SorbC with 3.13 and 3.26. To determine the time at which initial rates 
could be recorded, duplicate 50 µL reactions with 10 µM 3.13 or 3.27 were performed and 
analyzed compared to an internal standard (300 µM) by UPLC. The resulting time course 
demonstrated that 1 min is the optimal time to capture the initial reaction rates for a variety of 
concentrations of 3.13 or 3.26. 
To determine the steady-state kinetic parameters of the SorbC with sorbicillin (3.13) reactions 
were conducted on 50 µL scale with substrate ranging 10 µM–200 µM in duplicate with 12.5 nM 
SorbC and 50 mM KPi pH 8.0 buffer in a 96-well plate. Reactions were initiated by addition of 
500 µM NADH (10 µL distributed by multichannel pipette). Reactions were quenched after 30 s 
by addition of 100 µL acetonitrile. 96-well plates were centrifuged at 2000 x g for 2 min, then 100 
µL of the centrifuged mixture was added to 100 µL of a dilution mix containing 450 µM in 
acetonitrile in a clean 96-well 0.22 µm filter plate. The plate was centrifuged over a clean 96-well 
plate at 2000 x g for 2 min. 2 µL each sample was injected on the TOF LC-MS. The resulting 
Michaelis-Menten curves for each substrate and standard curves used to quantify substrate are 




Steady-state kinetics of SorbC with sorbicillin (3.13) and crotyl ester 3.26. SorbC was prepared 
to a final concentration of 120 nM. To determine the steady-state kinetic parameters of SorbC with 
sorbicillin (3.13), reactions were conducted on 50 µL scale, in duplicate, under the following 
conditions: 10–250 µM substrate, 120 nM SorbC, 50 mM KPi pH 8.0 buffer in a 96-well plate. For 
crotyl ester 3.26, the substrate range was 10 µM–150 µM with all other reaction components the 
same as the sorbcillin (3.13) reactions. Reactions were initiated by the addition of 500 µM NADH 
(10 µL total volume added by multichannel pipette). Reactions were quenched after 1 min by 
addition of 150 µL acetonitrile containing 300 µM trimethoxy benzene as internal standard. 96-
well plates were centrifuged at 2000 x g for 2 min, then 100 µL of the centrifuged mixture was 
added to a 96-well 0.22 µm filter plate. The plate was centrifuged over a 96-well plate at 2000 x g 
for 2 min. Product standards were prepared in the same manner. Samples were analyzed by TOF 






Figure 3.10: A) Michaelis-Menten plot of SorbC reactions with native substrate sorbicillin (3.13). B) Standard curve 
of sorbicillin (3.13). 














The title compound was prepared according to the general procedure for milligram-scale in vitro 
enzymatic oxidative dearomatization. Purification on silica gel (20-40% EtOAc in hexanes) 
afforded 1.0 mg (8.0% yield) of the o-quinol as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 10.82 
(s, 1H), 7.38 (s, 1H), 5.90 (dd, J = 15.0, 7.0 Hz, 1H), 5.66 (m, 1H), 4.71 (d, J = 6.8 Hz, 2H), 2.12 
(s, 3H), 1.87 (s, 3H), 1.77 (d, J = 6.4 Hz, 3H), 1.46 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 195.4, 
169.8, 167.4, 160.3, 151.9, 133.9, 123.5, 118.7, 111.7, 78.0, 67.3, 23.9, 20.4, 17.8, 7.3; HRMS 
A B 
[3.26], M [3.26], M 
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(ESI) m/z calculated for C15H19O6 [M+H]
+: 295.1176, found: 295.1180; IR (thin film): 3426, 2923, 
1736, 1699, 1659, 1396, 1194 cm-1; [α]D





The title compound was prepared according to the general procedure for milligram-scale in vitro 
enzymatic oxidative dearomatization. Purification on silica gel (20-40% EtOAc in hexanes) 
afforded 8.0 mg (59% yield) of the o-quinol as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 10.96 
(s, 1H), 5.87 (m, 1H), 5.64 (dt, J = 15.1, 7.0 Hz, 1H), 4.74 (t, J = 6.7 Hz, 2H), 2.20 (s, 3H), 2.14 
(s, 3H), 1.85 (s, 3H), 1.75 (d, J = 6.5 Hz, 3H), 1.44 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 195.2, 
169.7, 169.1, 164.4, 161.4, 133.9, 123.5, 116.3, 109.7, 81.9, 67.4, 24.9, 20.5, 17.8, 17.1, 7.4; 
HRMS (ESI) m/z calculated for C16H21O6 [M+H]
+: 309.1333, found: 309.1332; IR (thin film): 
3165, 2963, 1737, 1698, 1654, 1396, 1235 cm-1; [α]D










carboxylate (3.81)  
The title compound was prepared according to the general procedure for milligram-scale in vitro 
enzymatic oxidative dearomatization. Purification on silica gel (20-40% EtOAc in hexanes) 
afforded 1.0 mg (8.0% yield) of the o-quinol as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 10.78 
(s, 1H), 7.37 (s, 1H), 5.88 (dd, J = 14.9, 6.9 Hz, 1H), 5.63 (m, 1H), 4.71 (d, J = 6.9 Hz, 2H), 2.12 
(s, 3H), 1.85 (s, 3H), 1.84 (m, 2H), 1.76 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.5 Hz, 3H); 13C NMR 
(150 MHz, CDCl3) δ 195.4, 169.9, 167.3, 160.3, 151.3, 133.8, 123.5, 119.6, 112.4, 80.9, 67.3, 
32.0, 20.5, 17.8, 7.5, 7.1; HRMS (ESI) m/z calculated for C16H21O6 [M+H]
+: 309.1333, found: 
309.1335; IR (thin film): 3165, 2963, 1736, 1659, 1654, 1396, 1233 cm-1; [α]D






The title compound was prepared according to the general procedure for milligram-scale in vitro 
enzymatic oxidative dearomatization. Purification on silica gel (20-40% EtOAc in hexanes) 
afforded 3.8 mg (28% yield) of the o-quinol as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 10.77 
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(s, 1H), 7.37 (s, 1H), 5.89 (m, 1H), 5.64 (m, 1H), 4.71 (d, J = 3.5 Hz, 2H), 2.41 (q, J = 6.7 Hz, 
2H), 2.12 (s, 3H), 1.77 (d, J = 6.5 Hz, 3H), 1.45 (s, 3H), 1.00 (t, J = 7.4 Hz, 3H); 13C NMR (150 
MHz, CDCl3) δ 194.8, 169.8, 167.5, 159.9, 152.0, 133.8, 123.5, 118.8, 117.7, 78.0, 67.3, 23.8, 
20.5, 17.8, 15.5, 12.6; HRMS (ESI) m/z calculated for C16H21O6 [M+H]
+: 309.1333, found: 
309.1337; IR (thin film): 3162, 2928, 1738, 1697, 1652, 1369, 1235 cm-1; [α]D






The title compound was prepared according to the general procedure for milligram-scale in vitro 
enzymatic oxidative dearomatization. Purification on silica gel (20-40% EtOAc in hexanes) 
afforded 4.1 mg (35% yield) of the o-quinol as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 10.75 
(s, 1H), 7.36 (s, 1H), 5.88 (m, 1H), 5.60 (m, 1H), 4.70 (t, J = 7.4 Hz, 2H), 2.36 (m, 2H), 2.10 (s, 
3H), 1.75 (d, J = 6.7 Hz, 3H), 1.43 (m, 5H), 0.88 (t, J = 7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) 
δ 195.0, 169.8, 167.5, 160.2, 152.0, 133.8, 123.5, 118.7, 116.2, 78.0, 67.3, 24.0, 23.9, 21.3, 20.4, 
17.8, 13.9; HRMS (ESI) m/z calculated for C17H23O6 [M+H]
+: 323.1489, found: 323.1494; IR 
(thin film): 3167, 2960, 2925, 1738, 1697, 1654, 1369, 1236 cm-1; [α]D




                 
(S)-3-acetoxy-6-hydroxy-3,5-dimethyl-4-oxocyclohexa-1,5-diene-1-carboxylic acid (3.84) 
o-quinol 3.79 (37.3 mg, 0.127 mmol, 1.0 equiv) and Pd(PPh3)4 (10.3 mg, 0.07 equiv, 0.0088 mmol) 
were added to a flame-dried vial equipped with a stir bar and dissolved in anhydrous THF (2.5 
mL). Morpholine (33.0 L, 0.381 mmol, 3.0 equiv) is then added and the reaction is stirred at rt. 
After 2 h, the reaction was quenched by addition of 1 M HCl, aq (1 mL) and extracted with EtOAc 
(3 x 5 mL). The organic layers were dried over anhydrous Na2SO4, evaporated to dryness and 
purified by column chromatography (30-100% EtOAc/hexanes) to yield 18 mg (60%) of the acid 
as a colorless solid. 1H NMR (600 MHz, CD3OD) δ 7.55 (s, 1H), 2.07 (s, 3H), 1.78 (s, 3H), 1.44 
(s, 3H); 13C NMR (300 MHz, CD3OD) 169.3, 169.3,152.5, 119.3, 110.0, 110.0, 77.4, 56.03, 22.9, 
18.8, 5.77; HRMS (ESI) m/z calculated for C11H13O6 [M+H]
+: 241.0707, found: 241.0706; IR 





The title compound was prepared according to the general procedure for milligram-scale in vitro 
enzymatic oxidative dearomatization, followed by addition of maleimde (25 mM in DMSO, 5 
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equiv). Purification on silica gel (20-100% EtOAc in hexanes) afforded 10.3 mg (23% yield) of 
the cycloadduct as a yellow oil. 1H NMR (600 MHz, CDCl3) δ 11.60 (s, 1H), 8.20 (s, 1H), 5.83 
(dq, J = 13.4, 6.5 Hz, 1H), 5.59 (dd, J = 14.7, 7.4 Hz, 1H), 4.67 (dd, J = 12.6, 6.4 Hz, 1H), 4.60 
(m, 1H), 3.87 (d, J = 3.3 Hz, 1H), 3.76 (dd, J = 8.5, 3.2 Hz, 1H), 2.94 (d, J = 8.4 Hz, 1H), 1.74 (d, 
J = 6.6 Hz, 3H), 1.58 (s, 3H), 1.31 (s, 3H); 13C NMR (300 MHz, CDCl3) δ 207.8, 176.6, 173.7, 
168.6, 168.5, 132.0, 124.2, 100.0, 71.9, 65.9, 54.2, 47.0, 42.1, 41.3, 24.5, 17.8, 9.5. HRMS (ESI) 
m/z calculated for [M+Na]+ C17H19NO7Na [M+Na]
+: 372.1054, found: 372.1048; IR (thin film): 
2928, 1737, 1705, 1622, 1412, 1378 cm-1; [α]D
25 +62 (c 0.1, MeCN) 
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Chapter 3.6.3: Substrate Calibration Curves 
 


















Chapter 3.6.4: UPLC Traces of Biocatalytic Reactions 
 
at 270 nm 
  
 Retention Time Area % Area Height 
1 2.506 11046 4.40 5286 
2 2.681 132681 52.79 102077 
3 2.950 107590 42.81 72312 
 
NEC Table 1 Entry 3 at 270 nm 
  
 Retention Time Area % Area Height 
1 2.686 159130 59.40 127839 
2 2.955 108773 40.60 74266 
 




















































































































SorbC 3.25 at 270 nm 
  
 Retention Time Area % Area Height 
1 2.291 164448 42.80 140660 
2 2.577 109187 28.42 35115 
3 2.951 110552 28.78 75766 
 
 
NEC 3.25 at 270 nm 
  
 Retention Time Area % Area Height 
1 2.516 707887 87.49 484263 
2 2.955 101262 12.51 71033 
 


























































































































SorbC and 3.26 at 240 nm 
 
 Retention Time Area % Area Height 
1 2.374 284975 16.57 383174 
2 2.706 423835 24.64 513156 
3 2.984 1011156 58.79 868048 
 
SorbC and 3.26 at 270 nm 
 






























































0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00
 Retention Time Area % Area Height 
1 2.683 1423901 94.40 1076742 
2 2.951 84541 5.60 52324 


















































































































 Retention Time Area % Area Height 
1 2.839 1986512 94.81 1497370 
2 2.956 108837 5.19 55981 
 















































0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00
 Retention Time Area % Area Height 
1 2.440 205923 12.80 151877 
2 2.765 326172 20.27 272984 





















































































 Retention Time Area % Area Height 
1 2.752 988494 90.71 753607 
2 2.955 101253 9.29 66180 
 
















































0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00
 Retention Time Area % Area Height 
1 2.413 301350 19.65 261174 
2 2.752 220513 14.38 182022 






































































































































0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00
 Retention Time Area % Area Height 
1 2.441 77178 10.25 58829 
2 2.558 230373 30.59 158864 
3 2.763 344260 45.71 261422 
4 2.952 101360 13.46 69715 
 Retention Time Area % Area Height 
1 2.767 1150031 91.91 850716 
2 2.956 101217 8.09 69189 




















































































SorbC and 3.47 at 240 nm 
 
 Retention Time Area % Area Height 
1 2.560 113288 15.76 117345 
2 2.758 437320 60.85 511516 
3 2.965 168037 23.38 132927 
 
 


















































0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00
 Retention Time Area % Area Height 
1 2.747 1490565 93.12 1152913 
2 2.948 110155 6.88 58135 






















































































SorbC and 3.72 at 270 nm 
  
 Retention Time Area % Area Height 
1 2.447 153081 17.24 120344 
2 2.553 83030 9.35 65133 
3 2.753 549538 61.90 428628 
4 2.951 102195 11.51 69156 
 
NEC of 3.27 at 270 nm 
  
 Retention Time Area % Area Height 
1 2.752 1794595 94.76 1416054 
2 2.951 99228 5.24 45478 
 





























































































































SorbC and 3.73 at 270 nm 
 
  
 Retention Time Area % Area Height 
1 2.527 120391 12.95 94531 
2 2.823 708205 76.19 558891 




NEC 3.73 at 270 nm 
   
 Retention Time Area % Area Height 
1 2.824 1609098 94.60 1231662 
2 2.950 91833 5.40 49450 
 






























































































































NEC 3.52 at 270 nm 
 



















































0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00
 Retention Time Area % Area Height 
1 2.249 60565 10.20 47548 
2 2.719 509107 85.75 565565 

















































































SorbC and 3.84 at 270 nm 
  
 Retention Time Area % Area Height 
1 2.364 39944 2.99 29879 
2 2.900 97083 7.28 78987 
3 2.968 1196964 89.73 846065 
 
 
NEC 3.84 at 270 nm 
  
 Retention Time Area % Area Height 
1 2.899 153450 10.44 123568 
2 2.967 1315706 89.56 941069 
 


























































































































SorbC and 3.36 at 270 nm 
 
 Retention Time Area % Area Height 
1 2.286 666717 32.64 816017 
2 2.713 269327 13.18 314630 

















































0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00
 Retention Time Area % Area Height 
1 2.708 1388407 95.55 1036838 
2 2.950 64677 4.45 44282 





























































































SorbC and 3.37 at 270 nm 
 
 
 Retention Time Area % Area Height 
1 2.633 90558 5.29 62617 
2 2.822 1530254 89.33 1211491 
3 2.950 92228 5.38 61719 
 
 
NEC of 3.37 at 270 nm 
 
 Retention Time Area % Area Height 
1 2.823 1690490 94.21 1347865 
2 2.952 103864 5.79 30952 
 

































































































































SorbC and 3.69 at 270 nm 
 
 Retention Time Area % Area Height 
1 2.255 34471 2.93 29745 
2 2.820 1041179 88.62 1327825 
3 2.955 99200 8.44 101574 
 
NEC of 3.69 at 270 nm 
 
 Retention Time Area % Area Height 
1 2.817 1265846 95.17 997950 
2 2.950 64266 4.83 45787 
 



























































































































Figure 3.27. With a subset of substrates, in addition to the expected product a second peak with the same m/z was 
observed (See Figure 3.29). This byproduct, formed in SorbC reactions, was not found in reactions with IBX or LTA. 
Attempts to isolate and characterize the material corresponding to the peak marked with an asterisk either directly 
from enzymatic reactions or following acylation did not produce meaningful quantities of material. Preparative HPLC 
of the crude reaction mixture did allow for isolation of the material, as judged by UPLC-PDA analysis of the resulting 
fractions; however, this material accounted for little of the mass balance of the reaction mixture (<0.1 mg isolated 









































































































































































































MS/MS SorbC rxn P MS/MS SorbC rxn * 
MS/MS IBX peak 1 






Figure 3.28: (A) LC-MS trace comparing reaction of 3.26 with SorbC and IBX. (B) MS/MS spectra comparing the 
products of the SorbC reaction and the IBX reaction. Note the second IBX product does not correspond to the more 
nonpolar SorbC product. 
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Chapter 3.6.5: Determination of Enantiomeric Excess 


















Figure 3.29: SFC-UV-Vis trace of Pd(OAc)4-generated ±3.79 and SorbC-generated 3.79. 
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Pb(OAc)4 generated 3.80 
 
 
























































SorbC generated 3.83. 
Figure 3.33: SFC-UV-Vis trace of Pb(OAc)4 and SorbC generated 3.83. 
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CHAPTER 4:  Large-scale Reaction and One-pot Platform Development 
Portions adapted with permission from “Whole-cell biocatalysis platform for gram-scale oxidative 
dearomatization of phenols" Chem Biol Drug Des. 2018, 93, 1207 – 1213 and “Biocatalytic site- 
and enantioselective oxidative dearomatization” Nat. Chem. 2018, 10, 119–125. 
Chapter 4.1: Introduction 
 The selectivity advantages of biocatalytic transformations are well established and generally 
appreciated by the synthetic community.1 However, in order for biocatalytic methods to become 
routine in traditional synthetic laboratories, more transformations with robust scalabitliy and well-
understood substrate scopes must be made available.2 Our exploration of FDMO-mediated 
oxidative dearomatization aimed to fill that gap in biocatalytic methods.3 A second challenge 
inherit to the wide-spread adoption of biocatalysis is catalyst availability.1 Protein expression in 
genetically tractable and fast-growing hosts, such as E. coli or Saccharomyces cerevisiae, requires 
only inexpensive media and an incubator for protein production; however, purification of the 
desired protein from this matrix involves several time-intensive steps, specialized equipment and 
expensive reagents and materials.4 In order to overcome this limitation and to enable multi-gram 
scale biocatalytic oxidative dearomatization, we envisioned a reaction platform employing whole 
E. coli cells expressing FDMOs as the catalyst source.  
Chapter 4.2: Whole-cell Platform  
Substrate 4.1, which was fully converted in vitro by TropB in our initial assays was 
chosen as the model substrate for reaction development using whole E. coli cells. Two methods 
were used to prepare the cell pellet for use in whole cell (WC) reactions: flash- freezing or 
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lyophilization. For the former, the crude cell pellet was flash frozen in liquid nitrogen in small 
aliquots. This method greatly alleviated difficulties in weighing out wet cell pellet for accurate 
quantification of our WC reactions. For the preparation of lyophilized cells, the crude cell pellet 
was aliquoted into 1 g portions and re-suspended in an excipient solution (0.5 L, 10% w/v 
excipient in Milli- Q water) and pelleted in several 50 mL Falcon tubes. The tubes were then 
covered with a KimWipe® and lyophilized for 48–72 h. To identify the ideal preparation method 
for lyophilized cell pellet for use in our WC reactions, we added various excipients to cells prior 
to lyophilization based upon a survey of common excipients used in the literature.5,6,7 We then 
compared the activity of each preparation in 1 g scale reactions with the non-native substrate 4.1 
(Figure 4.1). The results of these experiments indicated that enzyme activity was maintained in 
lyophilized cells, and only improved nominally by the addition of 10 wt % sucrose or PEG 4000 
(Figure 4.1, entries 3 and 4, respectively). Omission of co-solvent in whole-cell reactions with 
TropB resulted in low conversions of starting material, which we hypothesized was due to poor 
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substrate solubility in the 
 
Figure 4.2: Set-up for gram-scale whole-cell oxidative dearomatization. After the reaction is complete, the mixture is 
filtered and the filtrate is extracted with (3:1) EtOAc and iPrOH. 
aqueous reaction environment, and issues in transporting the charged compound across the cell 
membrane. To resolve this issue, we tested the effect of both water- miscible and immiscible 
cosolvents on the WC reaction (Table 4.1). The addition of 10% v/v toluene drastically improved 
conversion to o-quinol 4.2, with full conversion in 2 h under the described conditions. 
Additionally, we screened reactions with a reduced amount of wet cell pellet and noted complete 
conversion with cell loading as low as 20 weight equivalents. These optimized conditions were 
applied to gram-scale reactions, further demonstrating the appeal of this method for synthetic 
applications. 
Using our optimized WC biocatalysis platform, the overall yield of usable biocatalyst from 
each protein expression was significantly higher than what was obtained following protein 
purification for in vitro reactions. In this case, more than 20 WC preparative-scale (100 mg) 
reactions could be carried out for every liter of TropB expression cell culture. In comparison, from 
1 L of expression culture, the quantity of purified protein was sufficient for 2–3 reactions on the 
same scale. We suspect this was due to a loss of protein and activity over the course of the 
purification procedure. Reactions carried out with crude cell lysate gave diminished conversions 
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relative to both in vitro and WC reactions, indicating that some enzyme stabilization may have 
been provided by the cellular environment. The WC biocatalyst also required significantly less 
time to prepare, saving 5–6 h for each batch of catalyst. Therefore, our WC platform demonstrated 
superior efficiency over in vitro reactions in both preparation time and scalability of the reaction. 
Chapter 4.3: Complex Molecule Synthesis 
 To rapidly build molecular complexity from enzymatically generated o-quinols, we sought 
to leverage the reactivity of these compounds in cascade reactions by performing subsequent in 
situ enzymatic or chemical transformations. We anticipated that various natural product scaffolds 
could be accessed in one pot using biocatalytic dearomatization-initiated cascades.8 Toward this 
goal, we explored the synthesis of the tropolone (4.6), azaphilone (4.13) and sorbicillinoid (4.10) 
cores (Figure 4.3).  
Tropolones, seven-membered aromatic -hydroxy ketones, are synthesized by a wide 
variety of organisms and are found in a number of biologically active natural products.9,10 The 
biosynthesis of this motif remained a long-standing puzzle in the community until 2012 when Cox 
and coworkers elucidated the fungal two-enzyme cascade which affords the tropolone 
stipitaldehyde (4.6).11,12  O-quinol 4.4 produced by TropB was found to undergo ring-expansion 
by the α-ketoglutarate-dependent non-heme iron (NHI) TropC.11 NHI dioxygenases perform a 
wide variety of transformations, employing an Fe(IV)oxo intermediate to extract H-atoms from C-
H bonds of substrates.13,14 The resulting radical can undergo rebound hydroxylation, halogenation, 
or rearrangement and dehydration to form the final product. The mechanism for ring-expansion by 
TropC is the subject of ongoing study in our group by Tyler Doyon and Kevin Skinner. 
The interesting biological activity of tropolone-containing natural products has sparked the 
development of numerous synthetic approaches, including Buchner reaction and subsequent 
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rearrangement,15 [5+2]16 and [4+3]17 cycloadditions, as well as construction of saturated 7-
membered rings followed by iterative elimination.18 These methods require specific arrangement 
of functionalization to enable the required ring-expansion or elimination, limiting the number of 
substituted tropolones which can be readily accessed. To address this limitation, we envisioned 
developing a biocatalytic cascade employing TropB and TropC, or homologs thereof, to enable 
access to highly elaborated tropolones from resorcinol starting materials. As a proof of concept for 
this reaction platform we sought to complete the chemoenzymatic synthesis of stipitaldehyde (4.6).  
The one-pot cascade of TropB dearomatization of aldehyde 4.3 to o-quinol 4.4 and ring 
expansion by TropC proceeded in 53% conversion to afford stipitatic aldehyde (4.6). Isolation of 
the tropolone from the proteinaceous reaction mixture proved challenging, due to the apparent 
propensity of this compound to co-precipitate with protein.  
As Tyler Doyon continued to explore the general synthetic utility of the TropB/TropC 
cascade, we tuned our attention to the development of other chemoenzymatic cascades featuring 
FDMO-mediated oxidative dearomatization. As SorbC allowed access to enantioenriched 
sorbicillinol (4.8) we were intrigued by the potential to access members of the sorbicillinoid family 
of natural products (see Figure 1.6).20 These compounds, which include a variety of structurally 
distinct sorbicillinol dimers, have been the focus of synthetic efforts by several groups due to their 
promising biological activity including -TNF inhibition and antifungal properties.20,21,22,23 The 
most direct route to these compounds is biomimetic: oxidation of sorbicilin to bisorbicillinol 
followed by base-promoted dimerization and various rearrangements.21,22 However, the chemical 
syntheses using this route reported to date employ an achiral oxidant, Pb(OAc)4, in the 
dearomatization step, resulting in racemic products. 21,22 Having established SorbC as a highly 
enantioselective catalyst for the dearomatization of sorbicillin,3 we envisioned completing the 
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asymmetric synthesis of sorbicillin natural products by employing SorbC in the key oxidative step. 
We chose urea sorbicillin (4.10), a recently isolated sorbicillin from an interstitial Nigrospora 
fungus as our first target.24 
Malaeimide was a competent dienophile for reaction with sorbicillinol, affording a single 
product when heated to 50 C. Based on this result we hypothesized the natural product urea 
sorbicillinoid (4.10) could be accessed in a similar sequence of steps. Sorbicillin (4.7) could be 
elaborated to the natural product in a one pot cascade that commenced with SorbC oxidation to 
deliver sorbicillinol 4.8. The addition of bisacylated urea 4.9 led to facile [4+2] cycloaddition. 
Addition of LiOH to remove the acyl protecting groups from the urea moiety completed the first 
synthesis of urea sorbicillinoid natural product 4.10 in 21% yield over three steps. Subsequent 
reaction showed protection of the urea moiety was unnecessary for high conversion to the 
cycloadduct under the given reaction conditions. Concurrent to these studies, the Gulder group 
employed SorbC to access a number of bisorbicillinoid natural products (see Figure 1.6).25 
 
Figure 4.3: One-pot syntheses of secondary metabolites featuring biocatalytic oxidative dearomatization as a key 
synthetic step stipitaldehyde, urea sorbicillinoid and azaphilone from Nigrospora sp. YE3003. 
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The first asymmetric synthesis of azaphilone natural product 4.1326 was achieved from 
methyl ketone 4.11, which was synthesized in two steps from aryl bromide 2.55 (see Chapter 5.3). 
The azaphilone family of natural products contains over two hundred members, a number of which 
have been shown to have interesting biological activities ranging from anticancer to antifugal.27 
Initial AzaH-mediated dearomatization delivered enol 4.12, which spontaneously cyclized in 
buffer to azaphilone 4.13, isolated in 54% yield and >99% ee. This reaction served as a blueprint 
for the chemoenzymatic synthesis of more complex azaphilone natural products and natural 
product analogs (see Chapter 5).  
Chapter 4.4 Conclusions 
 In summary, we have developed a scalable and economical WC biocatalytic method for 
oxidative dearomatization of phenols. This biocatalytic method improves upon previously 
developed chemical methods in terms of environmental sustainability, as it uses water as a solvent 
and a biological catalyst as the oxidant. Compared to with in vitro reactions, WC biocatalytic 
methods can pro-vide distinct and significant advantages. With no requirement for enzyme 
purification, WC procedures reduce the overall time, cost, and specialized equipment associated 
with catalyst production. After the simple optimization of several parameters, such as cell 
preparation method and reaction cosolvent, our WC platform allowed us to perform tenfold more 
reactions per liter of cell culture when compared to purified enzyme. This improvement was 
achieved without loss of catalytic function or selectivity. Moreover, this highly scalable method 
provides a simple and accessible reaction platform, promoting use of biocatalysts in traditional 
synthetic chemistry. 
 We encountered substrate limitations in our WC reactions that were distinct from in vitro 
conditions. We hypothesized that this was due to sequestration of the substrate by the cellular 
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membrane. Crude lysate could afford a potential solution to this limitation, by removal of the 
problematic cellular material but still offering an abbreviated purification procedure relative to 
purified lysate.  
 The modularity of the above described (chemo)enzymatic cascades could allow for the 
rapid generation of a library of complex molecules. The previously demonstrated substrate 
promiscuity of the three enzymes TropB, SorbC and AzaH enables access to a variety of 
enantioenriched o-quinol intermediates which can undergo cycloadditions with a number of 
electron poor olefins, intramolecular cyclizations or subsequent enzymatic steps. The substrate 
scope of the non-heme iron-dependent enzyme TropC has been explored by Tyler Doyon, allowing 
for the generation of a number of tropolone products. 
Chapter 4.5: Experimental 
Chapter 4.5.1: Whole Cell Reactions  
Whole cell preparative-scale reactions: Whole-cell enzymatic reactions were conducted on 1 g 
of substrate under the following conditions: 20 weight equivalents of wet cell pellet, 5 mM 
substrate, 10% (v/v) toluene, 0.1 mM NADP+, 0.1 U/mL G6PDH, and 10 mM G6P for NADPH 
generation in reaction buffer (50 mM potassium phosphate buffer, pH 8.0). The reaction mixture 
was added to a 1 L Erlenmeyer flask and incubated at 30 °C for 2 h at 100 rpm. After 2 h, a 50 µL 
aliquot was removed and processed in an identical manner to the analytical-scale reactions 
described above to determine substrate conversion. The remaining reaction mixture was filtered 
through Celite, acidified to pH 2.0 and extracted with EtOAc (3 x 500 mL). The combined organic 
layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The 





Preparation of freeze-dried cells: Expression of TropB was carried out as described above. The 
resulting crude cell pellet was aliquoted into 10 mg portions and resuspended in the appropriate 
excipient solution (40 mL, 10% w/v excipient in Milli-Q water) and pelleted in an Eppendorf tube. 
The tube was then covered with a KimWipe© and lyophilized for 10 h. The resulting powder was 
then used as in typical whole-cell reactions described below. 










6-Bromo-2,4-dihydroxy-3-methylbenzaldehyde (100 mg, 0.433 mmol, 1.0 equiv), PdCl2(PPh3)2 
(30.4 mg, 0.043 mmol, 0.1 equiv) and CuI (8.2 mg, 0.043 mmol, 0.1 equiv) in 3.1 mL anhydrous 
DMF. Trimethyl(propargyl)silane (77.4 L, 0.520 mmol, 1.2 equiv) and Et3N (197 L, 1.43 mmol, 
3.3 equiv). The resulting mixture was heated at 60 C for 14 h. The reaction mixture was cooled 
to rt, diluted with water (5 mL), and neutralized with 1.0 N aqueous HCl (2 mL). The mixture was 
extracted with EtOAc (3 x 15 mL). The combined organic layers were washed with water (10 mL) 
and brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced 
pressure. Purification on silica gel (20% EtOAc in hexanes) provided 54.0 mg (67% yield) of 2-
alkynylbenzaldehyde 4.14 as a yellow solid; 1H  NMR  (600 MHz, CD3OD) δ 10.13 (3, 1H), 6.47 
(s, 1H), 2.08 (s, 3H), 2.02 (s, 3H); 13C NMR (150 MHz, CD3OD) δ 194.5, 162.8, 162.6, 127.1, 
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113.4, 111.7, 111.4, 91.7, 74.5, 5.9, 2.4; HR-ESI-MS m/z calculated for C11H9O3 [M-H]
- 




2,4-dihydroxy-3-methyl-6-(prop-1-yn-1-yl)benzaldehyde (50.0 mg, 0.263 mmol, 1.0 equiv) and 
AgNO3 (4.4 mg, 0.026 mmol, 0.1 equiv) were added to a flame-dried round-bottom flask followed 
by DCE (2.5 mL) and TFA (99.0 L, 0.148 mmol, 5.0 equiv). The resulting mixture was stirred at 
rt for 45 min. MeCN and water (5 mL, 10:1) were added and the mixture was stirred for 1 h. The 
mixture was then concentrated under reduced pressure. The residue was diluted with EtOAc (5 
mL), washed with water (2 mL) and brine (2 mL). The organic layer was then dried over sodium 
sulfate, filtered, and concentrated under reduced pressure. Purification on silica gel (30% EtOAc 
in hexanes) provided 19.2 mg (35% yield) of the aldehyde 56 as a tan solid. 1H NMR (400 MHz, 
CDCl3): 12.61 (s, 1H), 9.84 (s, 1H), 6.17 (s, 1H), 3.91 (s, 2H), 2.25 (s, 3H), 2.06 (s, 3H). All spectra 




2,4-Dihydroxy-3,6-dimethylbenzaldehyde (4.3) (10 mg, 2.5 mM, 50 mM im DMSO) was added 
to a crystalizing dish containing 5 M TropB, 16 M TropC, 5 mM G6P, 0.2 units/mL GDPDH, 
1 mM NADP+, 0.2 M FeSO4, 5 mM -ketoglutarate, 8 mM sodium ascorbate in 100 mM TES 
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buffer pH 7.0. The mixture was heated to 30 C for 17 h at which time the reaction was diluted 
with water (20 mL) and acidified to a pH of 2. Amberlite resin XAD 16N 20-60 mesh (2.5 g) was 
then added to the solution and allowed to stir at rt for 2 h. The mixture was filtered through a 
sintered glass funnel and the resin was washed with water (6 mL). The product was eluted with 
MeOH (12 mL) and the eluent concentrated. The crude residue was then purified by preparative 
HPLC using a Phenomenex Kinetex 5 µm C18, 150 x 21.2 mm column under the following 
conditions: mobile phase A = deionized water + 0.1% formic acid and B = acetonitrile + 0.1% 
formic acid; method = 5% to 100% B over 13 min, 100% B for 4 min; flow rate, 15 mL/min to 
afford 3.4 mg (31% yield) of the tropolone as an orange oil.1H NMR (600 MHz, DMSO-d6) δ 9.99 
(s, 1H), 6.72 (s, 1H), 6.67 (s, 1H), 2.55 (s, 3H), 1.22 (s, 2H). All spectra obtained were consistent 




The title compound was synthesized according to the general procedure for 10 mg-scale in vitro 
enzymatic oxidative dearomatization. Purification by preparative HPLC afforded 5.3 mg (54% 
yield) of the title compound as a dark orange oil. 1H NMR (400 MHz, CDCl3) δ 7.87 (s, 1H), 6.12 
(s, 1H), 5.51 (s, 1H), 2.19 (s, 3H), 1.55 (s, 3H). All spectra obtained were consistent with literature 
values.26 []D
25 -126 (c 0.1, MeOH); reported22 []D
20 +54.7 (c 0.08, MeOH). As predicted, the R 






Urea sorbicillinoid (4.10) 
Sorbicillin (4.7) (5 mg, 2.5 mM, 50 mM in DMSO) was added to a crystalizing dish containing 5 
M SorbC, 5 mM G6P, 0.2 units/mL GDPDH and 1 mM NADP+ in 50 mM potassium phosphate 
buffer pH 8.0. The mixture was heated to 30 C for 2 h at which time 1,3-diacetyl-2,3-dihydro-
1H-imidazol-2-on (25 equiv, 0.538 mmol, 500 mM in DMSO) was added and the reaction was 
heated to 80 C for 8 h. The reaction was acidified to pH of 4 and extracted with EtOAc (3 x 20 
mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under 
reduced pressure. The crude residue was then dissolved in THF (53 L) and LiOH (sat. aq. 25 L) 
was added. After 1 h the reaction was halted by the addition of 1 M HCl (30 L) and the mixture 
was extracted with EtOAc (3 x 2 mL). The combined organic layers were dried over sodium 
sulfate, filtered and concentrated under reduced pressure. The crude residue was then purified by 
preparative HPLC using a Phenomenex Kinetex 5 µm C18, 150 x 21.2 mm column under the 
following conditions: mobile phase A = deionized water + 0.1% formic acid and B = acetonitrile 
+ 0.1% formic acid; method = 5% to 100% B over 20 min, 100% B for 5 min, flow rate, 15 mL/min 
to afford 1.5 mg (21%) of urea sorbicillinoid as a yellow oil. 1H NMR (600 MHz, DMSO) δ 14.16 
(s, 1H), 7.20 (dd, J = 14.8, 10.8 Hz, 1H), 6.77 (s, 1H), 6.53 (s, 1H), 6.48 (J = 14.8 Hz, 1H), 6.35 
(m, 1H), 6.04 (s, 1H), 4.48 (m, 1H), 3.85 (m, 1H), 3.26 (s, 5H), 3.20 (d, J = 3.0 Hz, 1H), 3.14 (d, 
J = 5.1 Hz, 1H), 1.83 (d, J = 6.7 Hz, 3H), 1.05 (s, 3H), 1.04 (s, 3H); []D
25 +99 (c 0.1, MeOH); 
reported23 []D














Figure 4.4: PDA traces of racemic 4.13 obtained from IBX oxidative dearomatization, and 4.13 obtained from AzaH-
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CHAPTER 5:  Chemoenzymatic, Stereodivergent Synthesis of Azaphilone Natural 
Products 
 
Portions adapted with permission from “"Stereodivergent, Chemoenzymatic Synthesis of 
Azaphilone Natural Products." J. Am. Chem. Soc. 2019, 141, 18551-18559. 
Chapter 5.1: Introduction 
 Azaphilone natural products are characterized by an oxygenated pyranoquinone bicyclic 
core bearing a single tetrasubstituted carbon (Figure 5.1A).1 Isolated from fungal sources, this 
Figure 5.1: (A) Biologically active azaphilone natural products feature both the R- and S-configuration at the C7 
stereocenter.1,4,6 Biocatalytic oxidative dearomatization gives access to either enantiomer via AzaH or AfoD mediated 
oxidation. (A) Approaches to enabling biocatalytic stereodiversity. 
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large family of natural products is known to contain a diverse array of structural features that 
impart a wide range of biological properties including anticancer,2,3,4 antiviral,5 and anti-
inflammatory activities.4,6 For example, luteusin A (5.3) and rubrorotiorin (5.5) were found to 
inhibit the binding of the HIV surface glycoprotein gp120 to the human CD4 protein, making these 
natural products potential starting points for the development of therapeutic agents against the 
virus.4 In addition, monascin (5.4), a tricyclic azaphilone natural product, has been shown to down-
regulate steatohepatitis in a mouse model, indicating that these secondary metabolites have 
potential as therapeutics for non-alcoholic fatty liver disease.6 As illustrated in Figure 5.1A, 
azaphilone natural products can contain either the R- or S-configuration at the C7-position. Several 
cases of epimeric azaphilones are known, in which each C7-epimer is produced by a distinct fungal 
source.7, 8 The pharmaceutical potential of these molecules has been demonstrated through initial 
in vitro and cell-based assays of isolated natural products;9,10,11 however, to gain a more 
comprehensive understanding of the therapeutic potential of these molecules, the challenge of 
constructing the densely functionalized core and C7-configuration for exploration of this 
stereocenter’s impact on biological activity must be addressed.7,8,12 
 The first total syntheses of azaphilones were reported nearly half a century ago by Whalley 
and coworkers.11 Their 11-step synthesis of (±)-mitorubrin features a Pb(OAc)4 oxidative 
dearomatization of pyranoquinone as a key step.11 This strategy of constructing densely 
functionalized aromatic precursors which undergo metal-catalyzed cyclization followed by 
dearomatization has been widely employed to access a number of azaphilones including citrinin,13 
the epicocconone core,14 a number of chitoviridinins,15 and chlorofusin.16 Each of these syntheses 
employed either Pb(OAc)4 or IBX in the dearomatizative step, resulting in racemic syntheses of 
the targets. The limitations during this period for enantioselective oxidative dearomatizations 
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inspired a seminal contribution from the Porco group.16 They reported a copper-oxo-sparteine 
oxidant which was capable of delivering dearomatized products from benzaldehyde or 
pyranoquinone substrates in good yields and excellent enantioselectivites (see Chapter 2, Figure 
2.1).16 The asymmetric total synthesis of a number of azaphilone natural products were synthesized 
using this oxidant. This methodology requires super-stoichiometric quantities of the chiral oxidant 
and cryogenic temperatures, making this a challenging method to employ in a high-throughput 
manner to access libraries of azaphilones to screen for biological activity.  
 Our interest in exploring the biologically activity of the azaphilone family has inspired us 
to develop a general platform for the generation of enantioenriched azaphilones from densely 
functionalized arene precursors. By employing our FDMOs in the critical dearomatization step, 
we are able to generate libraries of azaphilones in a relatively high-throughput manner. We had 
established AzaH as a promiscuous catalyst for oxidative dearomatization to afford the R 
enantiomer of the azaphilone core; however, we desired a stereocomplementary catalyst to enable 
access to either C7 configuration (Figure 5.1B). This would allow us to then rank and the 
stereoisomers’ efficacy in our biological assays.  
Chapter 5.2: Characterization of AzaH Homologs 
To survey the selectivity of flavin-dependent monooxygenases related by sequence, 
Attabey Rodrìguez Benìtez constructed a sequence similarity network (SSN) of flavin-dependent 
monooxygenases (Figure 5.2A).17,18,19 SSNs are visual representations of the relatedness of protein 
sequences, which cluster based on similarity thresholds. This approach can enable the rapid and 
logical investigation of proteins likely to demonstrate similar reactivity and/or selectivity, 
dramatically reducing the time and search space required during screening, considerations critical 
to improving the compatibility of biocatalytic approaches and traditional synthetic strategies. The 
347 
 
protein family (Pfam01494) of flavin-dependent monooxygenases includes over 45,000 enzymes. 
This data set was truncated by limiting the search to edges possessing an alignment score greater 
than 110, which returned 1,211 sequences (Figure 5.2A). We noted that the enzymes we had 
previously investigated, AzaH, TropB, and SorbC, were each located in distinct groups or 
“clusters” within the network, and that a fourth tight clustering of sequences formed between the 
TropB and SorbC clusters containing an enzyme associated with asperfuranone biosynthesis, 
AfoD.20,21,22 Previous in vivo studies23 and bioinformatic analysis24 indicated that AfoD is 
responsible for oxidative dearomatization of an asperfuranone precursor with the same site-
selectivity as TropB and AzaH;22 however, the absolute configuration of asperfuranone suggests 
that AfoD carries out this transformation with the opposite facial selectivity.21  
We hypothesized that sequences with high similarity to tropB, azaH, afoD and sorbC would 
encode for enzymes that possess the ability to carry out oxidative dearomatization reactions, and 
further questioned if trends in site- and stereoselectivity could be predicted based on sequence. To 
test this hypothesis, seven sequences were selected based on proximity to either TropB, AzaH, 
AfoD or SorbC in the SSN (labeled FDMO1-7 in Figure 5.2A). Attabey Rodrìguez Benìtez and 
Sarah Ackenhusen transformed and expressed FDMO1-7. Under standard expression conditions, 
nine proteins were successfully obtained, whereas FDMO1 and FDMO3 proved insoluble under 
these conditions (Figure 5.2B). The reactivity of the nine soluble enzymes was evaluated with two 
substrates, 5.14 and 5.15. Gratifyingly, all nine enzymes showed activity with one of the two model 
substrates, eight of which displayed sufficiently high activity for product isolation from 
preparative-scale reactions (Figure 5.2B). A single product was obtained from each biocatalytic 
reaction and a strong trend in site-selectivity was clear from this data: FDMO7, the enzyme most 
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similar to SorbC, afforded C5-hydroxylated product (see 5.15), whereas the remaining enzymes 
 
Figure 5.2: A) Sequence similarity network (SSN) of FAD-dependent monooxygenases (Pfam01494) using a 
sequence alignment score of 110. B) Results of expression, activity with model substrate 5.14 or 5.16**, site- and 
stereoselectivity of enzymes chosen from the SSN in panel A. *FDMO4 demonstrated <10% conversion by UPLC 
with substrate 5.16. C) Selected clusters from a more stringent SSN generated with an alignment score of 150 and 
corresponding analysis of the multisequence alignment of each cluster. Figure by Attabey Rodrìguez Benìtez. 
more similar to TropB, AzaH and AfoD delivered C3-hydroxylated products (see 5.17). 
However, the trend between location on the SSN (Figure 5.2A) and stereoselectivity was not 
apparent. Increasing the alignment score from 110 to 150 produced an SSN that provided greater 
insight to the relationships between sequences in this family. Notably, previously clustered 
sequences associated with divergent selectivity, such as AfoD and FDMO5, now clearly separated 
into distinct clusters (see Figure 5.2C). Analysis of sequence alignments between each of these 
clusters revealed conserved residues at positions 118 and 237 (AfoD numbering). In general, 
catalysts that generate products with the R-configuration possess a tyrosine at position 237 and an 
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aromatic residue such as phenyalanine or tryptophan at position 118. In contrast, these conserved 
residues switch positions in biocatalysts that afford products with the S-configuration. We 
previously demonstrated that a two point coordination of the phenolate substrate by Tyr237 and an 
arginine residue is critical for positioning the substrate within the active site in the R-selective 
enzyme, TropB.23 Obtaining further structural information on these proteins will aid in 
demystifying the elements that contribute to the precise stereocontrol exhibited by these catalysts. 
Beyond the importance of Tyr position in the active site, it is clear that other mechanisms for 
stereocontrol have evolved in this class of enzymes. For example, catalysts AzaH and SorbC break 
from this Tyr control mechanism, and in the case of SorbC, we have proposed an alternative 
mechanism for control of substrate position in the active site (see Chapter 3).24 
Ultimately, this survey of sequence space surrounding known enzymes provides a greater 
understanding of the sequence features that can predict site- and stereoselectivity and has increased 
the number of biocatalysts vetted for this transformation. With catalysts capable of delivering 
enantiomeric products in hand, we chose to pursue an enantiodivergent synthetic strategy with 
AzaH and AfoD based on the robust expression and reactivity of these enzymes, in addition to the 
excellent stereoselectivity of each catalyst. Under reaction conditions to dearomatize model 
substrate 5.16 using AzaH and AfoD, enantiomeric bicycles (R)- and (S)-5.17 were accessed in 
>99% ee and 98% ee, respectively. 
Chapter 5.3: Design and Synthesis of a Common Intermediate      
With access to either enantiomer of azaphilone 5.17, we sought to complete the 
stereodivergent syntheses of two biologically active azaphilone natural products. To identify a 
common intermediate that would provide versatility in accessing an array of azaphilone natural 
products (Figure 5.1B), a number of aromatic substrates were synthesized and subjected to 
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oxidative dearomatization with stereo-complementary biocatalysts. We hypothesized that the 
orcinaldehyde motif and homobenzylic ketone group would be critical for substrate recognition. 
In addition, we desired a functional handle to enable late-stage functionalization of the eastern 
portion of the azaphilone scaffold. Interestingly, the AzaH native substrate was not converted by 
AfoD (Figure 4, 5.18). We hypothesize that the β-hydroxy group prevents the substrate from 
engaging in productive binding interactions and leads to the lack of activity of AfoD as the native 
substrate of AfoD features a hydrophobic group at this position.20 This is supported by the activity 
of the saturated substrate 5.17 with AfoD, which does not contain this polar functional group. 
     Promisingly, two alkynyl substrates that are intermediates in the synthesis of the ketone 
substrates were accepted by AzaH (5.19 and 5.20); however, neither alkyne substrate was 
converted by AfoD. A simple methyl ketone derivative (5.21) demonstrated activity with both 
enzymes as well; however, its low activity with AfoD ultimately disqualified it as the common 
substrate. The enone substrate depicted in entry 7 was efficiently dearomatized by both AfoD and 
AzaH in 83% and 95% conversion, respectively. The high conversions observed for this compound 
with both enzymes and the synthetic handle afforded by the double bond made it an ideal candidate 
for the common intermediate in our envisioned divergent synthesis of azaphilone natural products. 
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A drawback to employing this substrate was the added synthetic complication of the 
double-bond present in 5.22. A robust and concise route to 5.22 was desired to afford sufficient 
material for exploration of the late-stage chemistry. Our first-generation route employed aryl 
bromide 5.29, accessed as described by Porco25 as the key synthetic intermediate. Subsequent 
iterative Sonogashira coupling and Au-catalyzed cyclization and hydration afforded 5.22. The 
length of this sequence coupled with the low yielding final step motivated our search for an 
alternative route.  
 Inspired by the work of Franck12 and others26 we designed a second-generation route which 
featured a 1,2-addition of densely functionalized arene 5.36 to Weinreb amide 5.37. Although this 
was a much more concise route, requiring only five rather than nine steps, several transformations 
proved to be low yielding, particularly upon scale-up, and required optimization. The first 
challenge we sought to address was the large amount of competing conjugate addition during 
Weinreb amide addition. We attributed formation of this byproduct to the stability of lithiate 5.36. 
Addition of HMPA as the cosolvent afforded exclusively the 1,4-product.27 We hypothesized that 
elevating the temperature of the addition could afford improved selectivity for the desired product, 




however the same ratio of 1,2 to 1,4-addition was observed. However, overall conversion 
increased, affording a 35% yield of the enone 5.38 and a small amount of the lactone which had 
undergone base-mediated cyclization during the reaction. This initial trial conducted on 500 mg, 
was promising however multigram scale reactions typically afforded 20-25%.  
 Concurrently, we worked to optimize the final step of the sequence towards 5.22. The 
deprotection of both MOM groups proved remarkably challenging due to the presence of several 
acid-sensitive moieties in lactol 5.40. The masked aldehyde, electron-rich resorcinol and enone 
fragments were all structural liabilities during this final stage, resulting in decomposition to NMR 
and UV-Vis silent byproducts when 5.40 was subjected to protic acids under aqueous and 
anhydrous conditions. A survey of the total synthesis literature featuring late-stage MOM-
deprotections afforded several alternatives to protic acids for this deprotection.28 The strong Lewis 
acids LiBF4
28d and NbCl5
28e were both competent acids to afford the free resorcinol product when 
Figure 5.5: Second-generation synthetic route to common intermediate 5.22 through 1,2-addition and reduction. 




used in superstoichiomeric amounts with apparently clean reaction profiles as observed by UPLC-
PDA. Upon scale-up, however, we encountered reproducibility issues with LiBF4 conditions, with 
yields between 98 – 20%. Happily, NbCl5 afforded reproducible yields, however, when this 
material was subjected to our enzymatic oxidative dearomatization conditions, none of the desired 
activity was observed. 
 
 We attributed the lack of reactivity to inorganic impurities in our material. Recrystallization 
of the crude enone afforded light red crystals which were turned over with the expected efficiency 
by both FDMOs, although typically 40 to 50% of the mass was lost in this manipulation. Having 
encountered so many challenges with this second-generation route we reconsidered our strategy 
towards 5.22. Porco had reported an abbreviated route to 5.44, which Katie Rykaczewski, a 
rotation student at the time, was able to reproduce.29 This directed lithiation allowed us to eliminate 
three steps in the synthesis of the meta-functionalized resorcinol core. This improved route allowed 
for the delivery of the hundreds of milligrams required for downstream chemistry towards the 
azaphilone natural products.  




Figure 5.8: 3-step one-pot synthetic of aryl iodide 5.44. 
 
Chapter 5.4: Total Synthesis of Trichoflectin and Lunatoic Acid A 
 
Figure 5.9: Retrosynthetic analysis for trichofectin. 
Angular azaphilone, trichoflectin (5.45), was the first natural product target chosen as a 
model for route development that would enable the synthesis of more complex tricyclic 
azaphilones. First isolated by Sterner in 1998, trichoflectin exhibits moderate antimicrobial 
activity as well as the ability to inhibit DHN-melanin biosynthesis in certain fungal species.30 
Despite interest in the biological activity of this compound, no total synthesis of trichoflectin has 
been reported to date. Our proposed retrosynthesis is described in Figure 5.10. We envisioned 
constructing the butenolide ring of trichoflectin through an intramolecular Knoevenagel 
condensation following acylation of bicycle 5.46.12,14 To obtain the reported (-)-trichoflectin, the 
C7-stereocenter would be set by stereoselective oxidative dearomatization of enone 5.22 with 
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Figure 5.10: Total synthesis of (S)- and (R)-trichoflectin. Inset: Calculated and measured CD data for (S)- and (R)-
trichoflectin. *NADPH recycling system: G6P (2 equiv), NADP+ (0.4 equiv), G6PDH (1 U/mL). 
The synthesis of trichoflectin was initiated with dearomatization of 5.22 with 0.2 mol % 
AzaH which afforded azaphilone scaffold (R)-5.46 in 96% yield and >99% ee (Figure 5.24). Next, 
acylation of (R)-5.46 with the acylketene generated in situ from precursor 5.47 followed by 
Knoevenagel condensation provided (S)-trichoflectin ((S)-5.45) in 99% yield. This level of 
selectivity was unexpected as Franck and coworkers reported the isolation of both angular and 
linear tricycles when constructing the butenolide ring of a similar azaphilone scaffold, proposing 
the distribution of these products is controlled by the steric properties of the acyl group.14 However, 
in our system, the desired angular tricycle was produced exclusively. We attribute this to a 
difference in electronic properties of the extended π-system and have observed through attempts 
to reduce the C8-ketone that this position is more electrophilic than the C6-ketone. 
     Unexpectedly, the sign of the optical rotation of our synthetic (S)-5.45 was opposite to that 
which is reported for the natural product (measured +34.1, reported -121).29 To rule out the 
possibility of stereocenter inversion during the construction of the butenolide ring or that the 
enzyme performed the dearomatization on this particular substrate with unanticipated facial 
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selectivity, a CD spectrum was calculated by our collaborator Dr. Leo Joyce, currently of 
Arrowhead Pharmaceuticals, and compared to the measured spectrum of synthetic (S)-5.45. As 
depicted in Figure 5.10, the calculated CD spectrum for (R)-trichoflectin is equal and opposite to 
the measured spectrum from (S)-trichoflectin, initially suggesting that the C7-stereocenter had 
been installed as anticipated. Ultimately, with the aid and expertise of Dr. Ren Wiscons, an X-ray 
crystal structure was obtained of the AzaH-produced tricycle, unambiguously confirming the C7-
configuration of (+)-trichoflectin as S (Figure 5.10). Based on these data, we suspected that the 
natural product was misassigned. A 1976 report, which has been the basis for assignment of 
absolute configuration in the case of trichoflectin and many other azaphilone natural products, 
suggests that the optical rotation of these compounds is controlled solely by the C7-stereocenter.30 
However, we have found that the electronic properties of the azaphilone core, as well as the 
presence of other stereocenters in the compound, can have a significant impact on the optical 
rotation based on computational modeling performed by Dr. Leo Joyce. To confirm the 
configuration of the natural product as R rather than S as assigned upon isolation, Joshua Pyser 
synthesized the enantiomeric tricycle from the AfoD generated product (S)-5.45 (Figure 5.10). The 
optical rotation of (R)-5.45 was measured as -47.4, agreeing in sign with the characterization of 
the isolated natural product. Therefore, it is proposed that the structure of the natural product be 
revised to the R-configuration.  
     This revision prompted a careful inspection of the absolute configuration of structurally related 
angular tricycles. An azaphilone series called the deflectins, which are reported to possess 
inhibitory activity of bacteria and erythrocytes as well as cytotoxicity towards carcinoma cells, 
share the same tricyclic core as trichoflectin (Figure 5.12).31 Upon isolation, the absolute C7-




Figure 5.11: Total synthesis of deflectin and calculated (red) and measured (black) CD-spectra. 
To answer the question surrounding the absolute configuration of these molecules, Joshua 
Pyser completed the total synthesis of (S)-deflectin-1a (5.50, Figure 5.11). Methyl ketone 5.21 was 
dearomatized with AzaH to produce bicycle 5.48 in 95% yield and >99% ee. Acylation and 
subsequent Knoevenagel condensation with the acylketene derived from precursor 5.49 furnished 
the desired butenolide to deliver (S)-deflectin-1a in 87% yield. The spectral data for 5.50 matched 
all available reported values. A measured optical rotation of +88.4 for this S-enantiomer confirms 
the need for structural revision of the natural product from the R-configuration to S at C7. 
     With both trichoflectin and deflectin-1a in hand, we set out to construct the natural product 
lunatoic acid A (5.51), which was reported to possess the opposite configuration at C7 to the newly 
established configuration of natural trichoflectin and deflectin-1a. Isolated by Marumo, this natural 
product exhibited interesting antibacterial properties, as well as the ability to act as an antifungal 
agent by inducing chlamydospore-like cells in certain fungi.32,33 As depicted by the retrosynthesis 
in Figure 5.12, we envisioned accessing the carboxylic acid moiety of 5.51 through a cross 
metathesis with the C9,10 double bond of intermediate 5.52.27c We anticipated that the chiral 
aliphatic ester of 5.53 could be constructed through an acylation of the C7-hydroxyl group of (R)-




Figure 5.12: Retrosynthetic analysis for lunatoic acid. 
     Having established a robust method for biocatalytic dearomatization of enone 5.22, the first 
challenge we encountered en route to lunatoic acid A was the acylation of tertiary alcohol 5.46. 
While the acylation had proceeded smoothly with the ketene en route to trichoflectin and deflectin-
1a, our attempts at acylation of 5.46 using acyl chlorides or symmetric anhydrides consistently 
failed to produce chiral ester 5.52, affording only starting material or under more forcing 
conditions, complete decomposition of 5.46. Ultimately, Joshua Pyser discovered that Yamaguchi 
esterification with 5.54 (Figure 5.13) did afford the desired product, although after optimization of 
reaction conditions, a maximum 50% yield was obtained.34 Mixed anhydride 5.54 was generated 
in situ from the corresponding carboxylic acid, prepared as previously reported.35 The carboxylic 
acid moiety present in lunatoic acid A was appended as the masked methyl ester through olefin 
metathesis with methyl acrylate and Grubbs 2nd generation catalyst in 48% yield.36 Our attempts 
to perform the metathesis prior to esterification resulted in decomposition of the starting material, 
indicating that protection of the C7-hydroxyl group increases the stability of the compound to the 
reaction conditions. The expected mass of lunatoic acid A was observed by TOF-MS upon 
saponification of methyl ester 5.55 using LiOH; however, sufficient quantities of the pure 
compound for NMR studies could not be obtained. This observed instability parallels the nature 
of the free acid from culture extracts. These extracts were methylated to obtain lunatoic acid A 
methyl ester (5.55), which was fully characterized in lieu of the free acid.32 All spectral data from 
the fully synthetic 5.55 match with reported literature values, including an agreement in the sign 
359 
 
of the optical rotation and Cotton effects from the reported CD, indicating in this case that the 





190 265 340 415 490
 
Figure 5.13: Total synthesis of lunatoic acid A. Inset: calculated (red) and measured CD spectra of lunatoic acid A 
methyl ester (5.55). 
Chapter 5.5: Conclusion 
A set of complementary biocatalysts for oxidative dearomatization have been identified and 
applied to the enantiodivergent, chemoenzymatic synthesis of azaphilone natural products. 
Comparison of sequences related to characterized enzymes involved in natural product 
biosynthesis, has provided an expanded set of biocatalysts for this transformation and insight on 
the sequence features that govern site- and stereoselectivity. A focused substrate library was 
created to identify a suitable common intermediate for dearomatization by both AzaH and AfoD. 
These enzymes were then used to construct both enantiomers of scaffold 5.46 to access the desired 
natural products containing either the R-or S-configuration at C7. The AzaH-produced scaffold 
(R)-5.46 was initially used to access the natural product trichoflectin ((S)-5.45); however, it was 
discovered that this tricycle contained the opposite stereocenter from the natural product based on 
its optical rotation, CD spectral data, and X-ray crystal structure. Synthesis of the opposite 
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enantiomer of trichoflectin ((R)-5.45) was achieved using the dearomatized scaffold accessed 
through AfoD, with an optical rotation that led to the reassignment of the C7-stereocenter of 
trichoflectin to S from the original literature report of R. This prompted the construction of related 
tricycle deflectin-1a (5.49) using analogous substrates, which allowed for the reassignment of its 
C7-stereocenter. Lunatoic acid A (5.51) was then constructed from (R)-5.46 and its structure 
confirmed through CD spectra and optical rotation. We anticipate these methods will enable the 
rapid construction of libraries of natural and unnatural azaphilones. By utilizing modern tools in 
bioinformatics, we have rapidly identified homologs with desired properties, an orthogonal 
approach to protein engineering.  
 A challenge in accessing large pools of complex azaphilones from arene starting materials 
is the development of conditions for functionalizing the core which can be run in a high-throughput 
manner and, ideally, in a one-pot cascade with the oxidative dearomatization step. Toward this 
aim, new enzymatic cascades could be developed to allow for the derivatization of resorcinols into 
complex azaphilone derivatives.  
Chapter 5.6: Experimental  










Aryl bromide 5.29 (150 mg, 0.65 mmol), PdCl2(PPh3)2 (23 mg, 0.033 mmol, 0.050 equiv), CuI 
(12 mg, 0.065 mmol, 0.10 equiv) was stirred in 4.8 mL of anhydrous DMF in a flame-dried round 
bottom flask equipped with a stir bar. Et3N (0.30 mL, 2.2 mmol, 3.3 equiv) was added and the 
mixture was sparged with N2 for 15 min before methyl propargyl ether (0.11 mL, 1.3 mmol, 2.0 
equiv) was added. The resulting mixture was heated to 60 °C for 14 h. The reaction mixture was 
cooled to rt, diluted with water (2.0 mL), and acidified with 1 M HCl (4.0 mL). The mixture was 
extracted with EtOAc (3 x 10 mL) and the combined organic layers were washed with water and 
brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford a 
dark brown solid. Purification on silica gel (10-20% EtOAc in hexanes) afforded 135 mg (94% 
yield) of 5.20 as a tan solid. 1H NMR (400 MHz, CD3OD) δ 10.13 (s, 1H), 6.54 (s, 1H), 4.36 (s, 





Methyl 2,4-bis(methoxymethoxy)-3,6-dimethylbenzoate (5.35) 
Methyl atratate (13 g, 66 mmol, 1.0 equiv) in THF (650 mL) was cooled to 0 °C and NaH (60%, 
7.9 g, 200 mmol, 3.0 equiv) was added portionwise. MOMCl38 (15 mL, 200 mmol, 3.0 equiv) was 
slowly added to the resulting mixture. The solution was warmed to rt and stirred for 5 h before it 
was cooled to 0 °C and quenched with NH4Cl (500 mL, saturated aq.). The layers were separated, 
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and the aqueous layer was extracted with EtOAc (3 x 500 mL). The combined organic layers were 
washed with NaHCO3, dried over Na2SO4 and concentrated under reduced pressure to afford a 
yellow oil. Purification on silica gel (0-20% EtOAc in hexanes) afforded 15 g of the ester as a 
colorless oil (90% yield). 1H NMR (300 MHz, CDCl3): δ 6.72 (s, 1H), 5.19 (s, 2H), 4.96 (s, 2H), 
3.89 (s, 3H), 3.54 (s, 3H), 3.47 (s, 3H), 2.28 (s, 3H), 2.15 (s, 3H). All spectra obtained were 




Crotonic acid (10 g, 120 mmol, 1.0 equiv) was dissolved in oxalyl chloride (12 mL, 140 mmol, 
1.2 equiv) and stirred at 70 °C for 1 h. The resulting acyl chloride was distilled at 124 °C, then 
added to a solution of N,O-dimethylhydroxylamine hydrochloride (10 g, 100 mmol, 0.90 equiv) 
in DCM (190 mL). The mixture was cooled to 0 °C before pyridine (21 mL, 260 mmol, 2.2 equiv) 
was added slowly. The mixture was stirred at 0 °C for 30 min, then allowed to warm to rt for 30 
min before it was diluted with 1 M HCl (150 mL) and extracted Et2O (3 x 150 mL). The combined 
organic layers were washed with brine (300 mL), dried over MgSO4, and concentrated to afford a 
red oil. Purification on silica gel (60-80% Et2O in hexanes) afforded 12 g (82% yield) of the title 
compound as a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 6.98 (m, 1H), 6.41 (d, J = 15.4 Hz, 






Methyl (E)-2,4-bis(methoxymethoxy)-3-methyl-6-(2-oxopent-3-en-1-yl)benzoate (5.38) 
Diisopropylamine (9.1 mL, 65 mmol, 1.1 equiv) in THF (300 mL) was stirred at -78 °C. n-BuLi 
(2.5 M in hexane, 26 mL, 65 mmol, 1.1 equiv) was slowly added. The resulting mixture was 
warmed to 0 °C and stirred for 15 min before it was cooled to -78 °C and a solution of ester 5.36 
(15 g, 20 mmol, 1.0 equiv) in THF (50 mL) was added. The resulting mixture was stirred at -78 
°C for 15 min before a solution cooled to -78 °C of amide 5.37 (9.2 g, 71 mmol, 1.2 equiv) in THF 
(25 mL) was added by cannula. The mixture was stirred for 1 h at -78 °C and was then acidified 
with 1 M HCl (aq. 100 mL). The layers were separated, and the aqueous layer was extracted with 
EtOAc (3 x 400 mL). The combined organic layers were washed with brine (400 mL), dried over 
Na2SO4, and concentrated under reduced pressure to afford a yellow oil. Purification on silica gel 
(5-15% EtOAc in hexanes) afforded 4.5 g of an inseparable mixture of the title compound and 




NaH (170 mg, 4.50 mmol, 1.05 equiv, 60%, dispersion in mineral oil) was stirred in THF (290 
mL) at -20 °C.  Enone S7 (1.5 g, 4.3 mmol, 1.0 equiv) in THF (50 mL) was slowly added to the 
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suspension. t-BuOH (10 μL) was added and the solution was stirred for 1 h at 20 °C. The reaction 
was cooled to 0 °C and quenched with EtOAc (30 mL), followed by addition of a saturated aqueous 
solution of NH4Cl (40 mL). The mixture was then allowed to warm to rt. The layers were separated, 
and the aqueous layer extracted with EtOAc (3 x 200 mL). The combined organic layers were 
washed with brine (400 mL), dried over Na2SO4, and concentrated under reduced pressure to afford 
a white solid. Purification on silica gel (0-20% EtOAc in hexanes) afforded 1.3 g of the lactone 
5.39 as a white crystalline solid (22% yield over 2 steps). 1H NMR (400 MHz, CDCl3): δ 6.78 (s, 
1H), 6.59 (m, 1H), 6.12 (s, 1H), 5.99 (dt, J = 15.7, 1.7 Hz, 1H), 5.28 (s, 2H), 5.16 (s, 2H), 3.64 (s, 
3H), 3.49 (s, 3H), 2.27 (s, 3H), 1.89 (d, J = 6.9 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 161.0, 
159.2, 158.9, 152.2, 139.1, 131.6, 122.9, 122.3, 107.4, 105.1, 103.7, 101.6, 94.2, 57.7, 56.4, 18.3, 
9.9; HR-ESI-MS: m/z calculated for C17H21O6 [M+H]
+: 321.1333, found: 321.1335; IR (thin 




Lactone S8 (1.0 g, 2.6 mmol, 1.0 equiv) in THF (13 mL) was stirred at -78 °C. DIBALH (0.48 
mL, 2.7 mmol, 1.1 equiv) was added dropwise via syringe. The resulting solution was allowed to 
stir at -78 °C for 30 min, and then the reaction was quenched by the addition of EtOAc (1.0 mL) 
and Rochelle’s salt (saturated, 4.0 mL). The resulting mixture was stirred for 1 h at rt. The crude 
mixture was extracted with EtOAc (3 x 50 mL), and the combined organic layers were washed 
brine (20 mL), dried over Na2SO4, and concentrated under reduced pressure. Purification on silica 
gel (0-20% EtOAc in hexanes) afforded 730 mg of the lactol 5.40 as a colorless oil (89% yield). 
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1H NMR (400 MHz, CDCl3): δ 6.63 (s, 1H), 6.56 (d, J = 5.8 Hz, 1H), 6.33 (m, 1H), 5.97 (dd, J = 
15.3, 2.1 Hz, 1H), 5.78 (s, 1H), 5.16 (s, 2H), 5.01 (s, 2H), 3.60 (s, 2H), 3.45 (s, 3H), 2.15 (s, 2H), 
1.84 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 156.7, 153.0, 148.7, 129.1, 128.3, 126.0, 119.0, 
116.4, 105.8, 102.0, 99.9, 94.4, 89.0, 57.5, 56.0, 18.2, 9.9; HR-ESI-MS: m/z calculated for 
C17H23O6 [M+H]
+: 323.1489, found: 323.1489; IR (thin film): 3357, 2930, 2823, 1604, 1447 cm-
1; MP: 62-65 °C. 
  
(E)-2,4-Dihydroxy-3-methyl-6-(2-oxopent-3-en-1-yl)benzaldehyde (5.22) 
Lactol S9 (300 mg, 0.933 mmol) in MeCN and water (7:1, 0.04 M) was stirred at rt. LiBF4 (630 
mg, 6.7 mmol, 7.2 equiv) was added and the resulting mixture was stirred at 70 °C for 3 h. The 
reaction mixture was cooled to rt and quenched by the addition of water (15 mL). The mixture was 
diluted with EtOAc (30 mL) and the layers were separated. The aqueous layer was extracted with 
EtOAc (3 x 30 mL) and the combined organic layers were washed brine (40 mL), dried over 
Na2SO4, and concentrated under reduced pressure. Purification on silica gel (10-40% EtOAc in 
hexanes) afforded 200 mg (90% yield) of the title compound as a tan crystalline solid. 1H NMR 
(600 MHz, CD3OD) δ 9.77 (s, 1H), 7.06 (m, 1H), 6.25 (d, J = 1.8 Hz, 1H), 6.22 (s, 1H), 4.12 (s, 
2H), 2.00 (s, 3H), 1.92 (d, J = 5.2 Hz, 3H); 13C NMR (150 MHz, CD3OD) δ 197.5, 193.4, 163.7, 
163.0, 144.8, 138.0, 130.3, 112.3, 110.3, 109.9, 42.5, 17.0, 5.8; HR-ESI-MS: m/z calculated for 
C13H15O4 [M+H]
+: 235.0965, found: 235.0947; IR (thin film): 3231, 2928, 2824, 2409, 1614 cm-






26 (20 mg, 0.085 mmol, 1.0 equiv) and Au(OAc)3 (1.7 mg, 0.0043 mmol, 0.05 equiv) in DCE 
(0.94 mL) were added to a flame-dried vial. The mixture was stirred at rt for 30 min before IBX 
(28 mg, 0.10 mmol, 1.1 equiv), TBAI (19 mg, 0.051 mmol, 0.60 equiv), and TFA (0.094 mL, 10% 
total volume) were added. The mixture was stirred for an additional 40 min before the reaction 
was quenched with 5 drops of a saturated Na2S2O3 solution. The mixture was filtered through a 
plug of ceilte, which washed with DCM, before the solution was concentrated under reduced 
pressure. Purification by preparative TLC with 2.5% MeOH in DCM yielded 4.7 mg 5.46 (22% 
yield) of the title compound as an orange oil. 1H NMR (400 MHz, CDl3) δ 7.89 (s, 1H), 6.59 (m, 
1H), 6.10 (s, 1H), 6.01 (d, J = 15.6 Hz, 1H), 5.57 (s, 1H), 2.62 (s, 2H), 1.94 (d, J = 7.0 Hz, 3H), 




Prepared as reported previously by Fuse et al.42 1.04 g (73% yield) of the title compound was 
obtained as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 5.24 (s, 1H), 1.98 (s, 3H), 1.68 (s, 6H). 






Prepared as reported previously by Franck and coworkers.12 356 mg (26% yield over 3 steps) of 





To a solution of 5.46 (5.5 mg, 0.023 mmol, 1.0 equiv) and dioxinone 5.47 (5 mg, 0.035 mmol, 1.5 
equiv) in toluene (0.64 mL) in a flame dried vial under N2 was added mol sieves. The mixture was 
stirred at rt for 10 min and then heated to 110 °C. After 1 h, Et3N (0.0064 mL, 0.046 mmol, 2.0 
equiv) was added. The mixture was stirred for an additional hour at 110 °C before it was cooled 
to room temperature and quenched with 1 M HCl (1.0 mL). The mixture was extracted with EtOAc 
(3 x 2.0 mL). The organic layers were combined, washed with brine, dried over Na2SO4, and 
concentrated under reduced pressure. Purification by preparative HPLC yielded 7.2 mg of 5.45 
(>99% yield) as a yellow oil. 1H NMR (600 MHz, CDCl3) δ 8.82 (s, 1H), 6.63 (m, 1H), 6.06 (s, 
1H), 6.01 (d, J = 13.8 Hz, 1H), 5.35 (d, J = 1.2 Hz, 1H), 2.60 (s, 3H), 1.95 (d, J = 5.2 Hz, 3H), 1.69 
(s, 3H); 13C NMR (150 MHz, CDCl3) δ 194.5, 190.0, 168.2, 165.6, 155.2, 153.1, 144.0, 136.3, 




+: 299.0914, found: 299.0922; IR (thin film): 2921, 2827, 1721, 1614, 1503 cm -
1; [α]D +34 ° (c 0.1, CHCl3). All spectra obtained were consistent with literature values.
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To a solution of 5.48 (4.0 mg, 0.019 mmol, 1.0 equiv) and dioxinone 5.49 (6.6 mg, 0.029 mmol, 
1.5 equiv) in toluene (0.55 mL) in a flame dried vial under N2 was added mol sieves. The mixture 
was stirred at rt for 10 min and then was heated to 110 °C. After 1 h, Et3N (53 μL, 0.038 mmol, 
2.0 equiv) was added. The mixture was stirred for an additional hour at 110 °C before it was cooled 
to room temperature and quenched with 1 M HCl (1.0 mL). The mixture was extracted with EtOAc 
(3 x 2.0 mL) and the combined organic layers were washed with (5.0 mL), dried over Na2SO4, and 
concentrated under reduced pressure. Purification on silica gel (20% EtOAc in hexanes) yielded 
5.9 mg of 5.39 (87% yield) as a yellow oil. 1H NMR (599 MHz, CDCl3) δ 8.77 (s, 1H), 6.08 (s, 
1H), 5.28 (s, 1H), 3.16 (m, 1H), 2.83 (m, 1H), 2.20 (s, 3H), 1.68 (s, 3H), 1.62 (m, 2H), 1.55 (s, 
3H), 1.27 (m, 8H), 0.87 (m, 3H); 13C NMR (151 MHz, CDCl3) δ 197.3, 190.3, 168.1, 165.2, 158.7, 
153.3, 144.1, 123.6, 111.1, 108.4, 104.9, 87.6, 42.1, 31.6, 29.0, 29.0, 26.2, 23.4, 22.6, 19.4, 14.1; 
HR-ESI-MS: m/z calculated for C21H25O5 [M+H]
+: 357.1697, found: 357.1754; IR (thin film): 
2924, 1763, 1684, 1642 1540 cm-1; [α]D +88 ° (c 0.1, EtOAc). All spectra obtained were consistent 





(2S,4S)-2,4-dimethylhexanoic acid (5.56) 
Prepared as reported previously by Myers et al.43 278 mg (32% yield over 3 steps) of the title 
compound was obtained as a white crystalline solid. 1H NMR (599 MHz, CDCl3) δ 2.56 (m, 1H), 
1.72 (m, 1H), 1.39 (m, 1H), 1.32 (m, 1H), 1.17 (d, J = 7.0 Hz, 3H), 1.13 (m, 2H), 0.88 (d, J = 6.6 





To a solution of carboxylic acid 5.56 (4.5 mg, 0.031 mmol, 1.1 equiv) in THF (0.2 mL) was added 
2,4,6-trichlorobenzoyl chloride (0.0048mL, 0.031 mmol, 1.1 equiv) and Et3N (0.0043 mL, 0.031 
mmol, 1.1 equiv). The mixture was stirred at rt for 30 min before it was filtered through celite and 
concentrated. The resulting clear oil was dissolved in toluene (0.8 mL) and added to 5.46 (6.5 mg, 
0.028 mmol, 1 equiv) and DMAP (10.3 mg, 0.084 mmol, 3 equiv). This mixture was stirred at 110 
°C for 1 h before it was cooled to rt, acidified with a saturated solution of NH4Cl (1 mL), and 
extracted with EtOAc. The organic layers were washed with brine, dried over Na2SO4, and 
concentrated under reduced pressure. Purification on silica gel (10-30% EtOAc in hexanes) 
provided 5 mg (50% yield) of the title compound as an orange oil. 1H NMR (400 MHz, CDCl3) δ 
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7.88 (s, 1H), 6.55 (m, 1H), 6.07 (s, 1H), 6.00 (d, J = 15.0 Hz, 1H), 5.57 (s, 1H), 2.70 (m, 1H), 1.93 
(d, J = 6.9 Hz, 3H), 1.77 (m, 1H), 1.53 (s, 3H), 1.34 (m, 2H), 1.19 (d, J = 6.9 Hz, 3H), 1.13 (m, 
2H), 0.89 (m, 6H). 13C NMR (151 MHz, CDCl3) δ 193.20, 192.70, 176.30, 155.27, 153.38, 142.59, 
135.27, 122.37, 114.89, 108.50, 107.75, 83.76, 40.81, 36.16, 31.76, 29.44, 22.14, 19.08, 18.61, 
17.60, 11.10; HR-ESI-MS: m/z calculated for C21H27O5 [M+H]
+: 359.1853, found: 359.1858; IR 





isochromen-7-yl (2S,4S)-2,4-dimethylhexanoate (5.55)  
To a solution of 5.52 (5.5 mg, 0.015 mmol, 1 equiv) and methyl acrylate (5.4 L, 0.060 mmol, 4.0 
equiv) in degassed DCM (0.6 mL) was added a solution of Grubbs Catalyst 2nd generation (2.5 
mg, 0.0030 mmol, 0.20 equiv) in degassed DCM (0.5 mL). The mixture was stirred at 45 °C for 4 
h before it was cooled to rt and concentrated. Purification on silica gel (10-35% EtOAc in hexanes) 
afforded 2.6 mg (48% yield) of the title compound as a yellow glass. 1H NMR (400 MHz, CDCl3) 
δ 7.88 (s, 1H), 7.13 (d, J = 15.6 Hz, 1H), 6.52 (d, J = 15.6 Hz, 1H), 6.45 (s, 1H), 5.69 (s, 1H), 3.82 
(s, 3H), 2.69 (m, 1H), 1.75 (m, 1H), 1.53 (s, 3H), 1.29 (m, 2H), 1.19 (d, J = 6.8 3H), 1.13 (m, 2H), 
0.89 (m, 6H). 13C NMR (201 MHz, CDCl3) δ 192.8, 192.5, 165.8, 153.2, 153.1, 152.7, 140.7, 
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133.5, 124.0, 115.8, 114.9, 110.5, 83.8, 77.2, 77.0, 76.8, 76.7, 52.3, 40.8, 36.2, 31.8, 29.5, 21.9, 
19.1, 17.6, 11.1; HR-ESI-MS: m/z calculated for C22H27O6: 403.1751, found: 403.1728; IR (thin 
film): 2926, 2853, 1718, 1630, 1454 cm-1. [α]D -12.2 ° (c 0.1, CHCl3). All spectra obtained were 





Chapter 5.6.2: Plasmids and Proteins 
Plasmids: The plasmid encoding afoD was synthesized by GeneArt and cloned into a pET21a 
vector by Attabey Rodrìguez Benìtez. 
 
































Protein overexpression and purification: Plasmids containing azaH and afoD were transformed 
using standard heat-shock protocols into chemically competent E. coli into BL21(DE3) cells. 
Overexpression of AfoD was achieved in 500 mL 4% glycerol (v/v) Terrific Broth (TB) in 2.8 L 
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flasks. 500 mL portions of media were inoculated with 5 mL overnight culture prepared from a 
single colony in Luria Broth (LB) and 100 g/mL ampicillin (Gold Biotechnology).  Cultures were 
grown at 37 C and 250 rpm until the optical density at 600 nm reached 0.8. The cultures were 
then cooled to 18 C for 1 h and protein expression was induced with 0.1 mM isopropyl--D-1-
thiogalactopyranoside (IPTG, Gold Biotechnology). Expression continued at 20 C overnight 
(approx. 18 h) at 200 rpm. The typical yield for one 500 mL culture was ~15 g cell pellet.  
 
General purification procedure: 25-30 g of cell pellet was resuspended in 100 mL of lysis buffer 
containing 50 mM Tris HCl pH 7.4, 300 mM NaCl, 10 mM imidazole, and 10% glycerol.  Protease 
inhibitors were added to lysis buffer of AzaH only and consisted of 1 mM phenylmethane sulfonyl 
fluoride (v), 0.1 mg/mL benzamidine HCl, 0.5 mg/mL leupeptin, and 0.5 mg/mL pepstatin.  
Approximatley 1 mg/mL lysozyme was added to resuspended cells that were then incubated on a 
rocker at 4 C for 30 min.  Cells were lysed by passing the total cell lysate through an Avestin 
pressure homogenizer at 15000 psi.  The total lysate was centrifuged at 40,000 x g for 30 min and 
the supernatant was filtered through a 0.45 m filter.  The crude cell lysate was loaded onto a 5 
mL HisTrap HP column (General Electric) on an ÄKTA Pure FPLC system (General Electric) at 
a flow rate of 2.5 mL/min. Buffer A = the lysis buffer listed above, and Buffer B = 50 mM Tris 
HCl pH 7.4, 300 mM NaCl, 10% glycerol, and 400 mM imidazole.  The column was washed with 
25 mM imidazole (6.3% Buffer B) for 6 CV and eluted in a gradient to 100% Buffer B over 8 CV.  
Fractions containing AfoD or AzaH were visibly yellow and pooled for desalting on a PD10 
desalting column.  Average yields: 100 mg from 1 L AfoD, 20 mg from 1 L AzaH. Molecular 
weights including 6xHis-tags for each protein were estimated by the ProtParam tool on the Expasy 
server to be 49.0 kDa for AfoD and 47.6 kDa for AzaH. These molecular weights are consistent 
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with the mass of proteins bands observed by SDS-PAGE analysis (Figure 5.14).  The purified 
proteins were aliquoted into 0.6 mL tubes and frozen in liquid nitrogen before long-term storage 
at -80 C. 








Determination of flavin incorporation and extinction coefficients: Experiments performed 
by Attabey Rodrìguez Benìtez: Samples of each protein were diluted to 10 µM in 1 mL using 
dialysis buffer for UV-vis analysis using a disposable poly(methyl 2-methylpropenoate) cuvette.  
The absorbance spectrum for each protein was taken from 300 nm to 700 nm in 2 nm increments 
(blue traces in Figure 5.15).  A 20 µL aliquot of fresh 10% sodium dodecyl sulfate (w/v) was added 
to each 1 mL solution and mixed.  Samples were incubated at room temperature for 10 min before 
reading the absorbance spectra again under the same conditions (red traces in Figure 5.15).  The 
absorbance at 450 nm for the denatured enzymes and the extinction coefficient of free FAD (11300 
M-1 cm-1) was used to calculate the concentration of FAD in each protein sample using Beer’s law.  
The typical FAD incorporation was 82% for AzaH, 81% for AfoD. Extinction coefficients were 














Figure 5.14: Purified AzaH and AfoD.  Approximately 5 µL of 1.25 µM each protein was loaded onto an MiniPROTEAN TGX 
Precast 4-15% SDS-PAGE gel (Bio-Rad).  The gel was stained with Quick Coomassie stain (Anatrace) and visualized with the 
Azure Gel Imaging System. The relative apparent masses are consistent with the predicted estimates. 
375 
 
native enzymes. At 450 nm, the extinction coefficients of the proteins are 17490 M-1 cm-1 for 
AzaH, 6,870 M-1 cm-1 for AfoD.  
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Chapter 5.6.3: Biocatalytic Reactions  
Stock solutions: Stock solutions of each substrate (50 mM) were prepared by dissolving the 
substrate in DMSO (analytical grade). Stock solutions of NADP+ (100 mM) and glucose-6-
phosphate (G6P, 500mM) were stored at -20 °C. Aliquots of AzaH (62 μM) and AfoD (95 μM) 
and glucose-6-phosphate dehydrogenase (G6PDH, 100 U/mL) were stored at -80 °C. Analytical-
scale reactions: Each reaction contained 25 μL 100 mM potassium phosphate buffer, pH 8.0, 2.5 
mM substrate (2.5 μL of a 50 mM stock solution in DMSO), 5 μM AzaH or 20 μM AfoD, 5 mM 
G6P (0.5 μL, 500 mM), 1 mM NADP+ (0.5 μL, 100 mM), 1 U/mL G6P-DH (0.5 μL, 100 U/mL), 
and Milli-Q water to a final volume of 50 μL. The reaction was carried out at 30 °C for 1 h and 
quenched by addition of 75 µL acetonitrile with 25 mM pentamethylbenzene as an internal 
standard. Precipitated biomolecules were pelleted by centrifugation (16,000 x g, 12 min). The 
supernatant was analyzed by UPLC-DAD and conversion obtained by comparison to calibration 
curves of each substrate. The subsequent liquid chromatography PDA spectrometry (UPLC) 
analysis was performed on a Waters Aquity H-Class UPLC-PDA using a Phenomenex Kinetex 
1.7 µm C18, 2.1x150 mm column under the following conditions: Method A: mobile phase (A = 
deionized water + 0.1% formic acid, B = acetonitrile + 0.1% formic acid), 5% to 100% B over 1.5 
min, 100% B for 1.0 min; flow rate, 0.5 mL/min; Method B: mobile phase (A = deionized water 
+ 0.1% formic acid, B = acetonitrile + 0.1% formic acid), 5% to 100% B over 2 min, 100% B for 
1 min; flow rate, 0.5 mL/min. Based on calibration curves of the starting materials, the percent 
conversion of the substrate to dearomatized product was calculated with 





General procedure for in vitro preparative-scale reactions: Preparative–scale enzymatic 
reactions were conducted on 20 mg of each substrate under the following conditions: 5 µM AzaH 
or 20 µM AfoD, 2.5 mM substrate, 1 mM NADP+, 1 U/mL G6PDH, and 5 mM G6P for NADPH 
generation in reaction buffer (50 mM potassium phosphate buffer, pH 8.0). The reaction mixture 
was added to a 50 mL Erlenmeyer flask and incubated at 30 °C with 100 rpm shaking. After 2 h, 
a 50 µL aliquot was removed and processed in an identical manner to the analytical-scale reactions 
described above to determine substrate conversion. The remaining reaction mixture was diluted 
with acetone (2 x total reaction volume). Precipitated biomolecules were pelleted by centrifugation 
(4,000 x g, 12 min). Isolation procedure: The supernatant was concentrated under reduced pressure 
to a final volume of approximately 2 mL. The resulting mixture was filtered through a 0.22 µm 
filter and purified by preparative HPLC using a Phenomenex Kinetex 5 µm C18, 150 x 21.2 mm 
column under the following conditions: mobile phase A = deionized water + 0.1% formic acid and 
B = acetonitrile + 0.1% formic acid; method = 5% to 100% B over 13 min, 100% B for 4 min; 
flow rate, 15 mL/min.  
 
(R,E)-7-hydroxy-7-methyl-3-(prop-1-en-1-yl)-6H-isochromene-6,8(7H)-dione ((R)-5.46) 
The title compound was synthesized using AzaH according to the general procedure for milligram-
scale in vitro enzymatic oxidative dearomatization and isolated using the general isolation method. 
Purification by preparative HPLC afforded 9.6 mg (96% yield) of the title compound as a yellow 
oil. 1H NMR (400 MHz, CDl3) δ 7.89 (s, 1H), 6.59 (m, 1H), 6.10 (s, 1H), 6.01 (d, J = 15.6 Hz, 
1H), 5.57 (s, 1H), 2.62 (s, 2H), 1.94 (d, J = 7.0 Hz, 3H), 1.55 (s, 3H). All spectra obtained were 






The title compound was synthesized using AfoD according to the general procedure for milligram-
scale in vitro enzymatic oxidative dearomatization and isolated using the general isolation method. 
Purification by preparative HPLC afforded 4 mg (83% yield) of the title compound as a yellow 
oil. 1H NMR (400 MHz, CDl3) δ 7.89 (s, 1H), 6.59 (m, 1H), 6.10 (s, 1H), 6.01 (d, J = 15.6 Hz, 
1H), 5.57 (s, 1H), 2.62 (s, 2H), 1.94 (d, J = 7.0 Hz, 3H), 1.55 (s, 3H). All spectra obtained were 




The title compound was synthesized using AzaH according to the general procedure for milligram-
scale in vitro enzymatic oxidative dearomatization and isolated using the general isolation method. 
Purification by preparative HPLC afforded 9.5 mg (95% yield) of the title compound as a yellow 
oil. 1H NMR (400 MHz, CDCl3) δ 7.88 (s, 1H), 7.26 (s, 2H), 6.13 (s, 1H), 5.51 (s, 1H), 2.20 (s, 
3H), 1.55 (s, 3H).  
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Chapter 5.6.4: Substrate Calibration Curves 
 
 






s b d IV -0 1 7














R2 =  R
2 =  
R2 =  R2 =  
R2 =  
R2 =  























R2 =  
381 
 
















 Retention Time Area % Area Height 
1 0.563 258810 70.42 220721 
2 2.967 108693 29.58 78693 
 Retention Time Area % Area Height 
1 1.988 174634 54.03 55311 
2 2.254 41199 12.75 44106 
































































































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 2.241 292664 74.92 268642 
2 2.970 97969 25.08 66721 
Figure 5.17: Oxidative dearomatization of 5.18 by AfoD and AzaH. PDA traces of enzymatic reaction and control 
reaction. (Table 1, entry 2). SM = starting material, INT = intermediate, PRD = product, IS = internal standard. The 


























 Retention Time Area % Area Height 
1 2.110 305704 76.28 183131 








 Retention Time Area % Area Height 
1 2.426 301558 76.61 252996 
2 2.955 92051 23.39 63755 



















220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
9 Retention Time Area % Area Height 
1 2.126 111917 29.11 83638 
2 2.428 171664 44.65 146387 


















































































































 Retention Time Area % Area Height 
1 2.357 517469 65.70 351986 
2 2.652 176051 22.35 140720 




 Retention Time Area % Area Height 
1 2.647 240563 69.66 192549 





















































































































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 2.650 266100 74.22 214826 
2 2.955 92442 25.78 64989 
Figure 5.19:  Oxidative dearomatization of 5.19 by AfoD and AzaH. PDA traces of enzymatic reaction and 










 Retention Time Area % Area Height 
1 2.054 944560 91.63 354150 




 Retention Time Area % Area Height 
1 2.453 309943 76.49 222375 





 Retention Time Area % Area Height 
1 2.453 321740 77.09 237334 
2 2.953 95619 22.91 65898 















































































































































 Retention Time Area % Area Height 
1 0.572 113995 30.42 89263 
2 2.271 157150 41.94 133701 





















































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 0.565 434990 83.72 338239 




















































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 2.270 284197 77.11 250475 
2 2.955 84347 22.89 58999 









With AzaH  
  
 Retention Time Area % Area Height 
1 2.119 519413 77.67 69861 
2 2.376 60100 8.99 56370 






 Retention Time Area % Area Height 
1 2.147 398043 65.96 84339 
2 2.377 119827 19.86 97170 






































































































































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 2.378 383633 81.55 308926 
2 2.957 86811 18.45 60584 









With AzaH  
 
 Retention Time Area % Area Height 
1 1.946 59575 25.80 32920 
2 2.074 40004 17.33 21701 





 Retention Time Area % Area Height 
1 1.946 59575 25.80 32920 
2 2.074 40004 17.33 21701 

















































































































































 Retention Time Area % Area Height 
1 2.063 507851 79.50 208715 
2 2.576 130976 20.50 65081 
Figure 5.23: Oxidative dearomatization of 5.22 by AfoD and AzaH. PDA traces of enzymatic reaction and control 























































Chapter 5.6.6: Determination of Enantiomeric Excess 
 
Figure 5.24: PDA traces of racemic 5.46 obtained from a 1:1 mixture of the compound generated using AzaH and 
AfoD, (S)-25 obtained from AfoD-mediated oxidative dearomatization, (R)-5.46 obtained from AzaH-mediated 








Figure 5.25: PDA traces of racemic 5.48 obtained IBX-mediated oxidative dearomatization, (S)-5.48 obtained from 
AfoD-mediated oxidative dearomatization, (R)-5.48 obtained from AzaH-mediated oxidative dearomatization 
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CHAPTER 6: Photocatalytic Oxidative Dearomatization of Resorcinol Compounds 
 
Chapter 6.1 Introduction 
The use of lead(IV) tetraacetate for oxidative dearomatization was first reported over half 
a century ago and is still in use to this day, despite the instability of the oxidant and the 
stoichiometric quantities of lead waste that are generated.1,2 More recently, hypervalent iodide 
reagents have been employed to perform this transformation, most notably IBX,3 PIDA,4 and 
PIFA.4,5 These reagents each result in stoichiometric iodide byproducts which can be challenging 
to separate from the quinol products (Figure 6.1A).6 Recent advances in catalytic oxidative 
dearomatization have demonstrated that iodide reagents can be employed in catalytic amounts in 
conjunction with stoichiometric quantities of inexpensive oxidants, such as m-CPBA, to afford 
dearomatized products.7 This renders the method catalytic in iodide, but can limit the functional 
group tolerance of these methods, as well as producing byproducts.8 
 Nature employs flavin-dependent monooxygenases (FDMOs) to perform this challenging 
oxidation with perfect site- and stereoselectivity.9 These enzymes use the noncovalent cofactor 
FADH2 (see 6.7) which reacts with molecular oxygen to form hydroperoxyflavin (6.8), an 
electrophilic source of oxygen that can react with electron-rich arenes posed in the enzyme active 
site (Figure 6.1B).10 This environmentally benign system employs molecular oxygen as the 
stoichiometric oxidant and water as the solvent, ultimately affording a single isomer of the o-quinol 
product.9 Recently we have disclosed our computational findings which support a radical reaction 
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pathway between hydroperoxy flavin (see 6.8) and resorcinol 6.13.11 Homolysis of the peroxyl 
O−O bond followed by a single electron transfer from the electron-rich arene to the flavin radical 
was found to be more energetically favorable pathway than the two-electron mechanism that is 
commonly proposed.9 These findings inspired us to develop a small molecule-catalyzed method 
for oxidative dearomatization that mimics Nature’s approach, however alleviates the requirement 
for a biological stoichiometric reductant. We envisioned developing a catalytic method which 
employs molecular oxygen as the stoichiometric oxidant, to produce water as the sole byproduct; 
thus, improving the overall atom economy and sustainability of the transformation. 
 Upon photoexcitation, riboflavin and derivatives thereof (see Table 1) have been employed 
as oxidants in the aerobic oxidation of benzylic C-H bonds,12 cinnamic acids,13 benzylic alcohols14 
amines15, and sulfides.16 This work combined with our computational results supporting single-
electron oxidation of 6.13 by flavin through a low-barrier single electron transfer (SET)  from the 
Figure 6.1. (A) General scheme for oxidative dearomatization (OD). (B) Mechanism for I(III)-mediated OD. (C) 
Abbreviated mechanism for FMDO-mediated OD. (D) Proposed single-electron OD. 
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substrate,11 encouraged us to investigate oxidation of 6.13 by photoexcited flavin. We envisioned 
the resulting radical could then be trapped by molecular oxygen to form the desired C-O bond. 
Chapter 6.2 Reaction Development 
Irradiation of 6.13 in MeCN with 0.4 mol% riboflavin, conditions commonly employed in 
benzylic oxidation of arenes,12 returned only starting material. We hypothesized 6.13 was too 
electron poor to undergo the single electron oxidation or alternatively, the resulting radical was not 
sufficiently stable to allow for radical-cage escape.17 Porco and coworkers have shown that less 
electron-rich arenes are oxidized by a copper-oxo-sparteine catalyst when the substrate is 
deprotonated prior to introduction of the oxidant.18 Inspired by this solution to low reactivity, we 
next explored the addition of a number of organic and inorganic bases to our oxidation conditions; 
however, this strategy afforded only trace amounts of product 6.14 (Table 1, entries 1 and 2).  
Taking advantage of the solvent effect offered by moving to aqueous reaction conditions, 
wherein the pKa of resorcinol 6.13 was measured to be 7.2,10 the phenolate could be generated 
cleanly under mild conditions. We were gratified to find that in a variety of buffers at a pH of 8.0, 
Table 6.1: Optimization of photocatalytic oxidative dearomatization. 
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with 0.1 mol % FMN, 6.13 was converted to a single, dearomatized product (Table 1, entries 4, 6, 
7). Tris buffer afforded superior results, providing 95% conversion of starting material to a single 
product, compared to 60% with HEPES and 53% with potassium phosphate (KPi) buffered 
solutions. We also noted a precipitous drop in reactivity with decreasing pH (Table 1, entries 5 
and 8), supporting our hypothesis that the phenolate is the competent species for SET. However, 
increasing the pH did not afford improved reaction outcomes. Interestingly, we found FMN to be 
the superior photocatalyst to riboflavin, perhaps due to the increased solubility in our aqueous 
reaction media. Exclusion of light resulted in no conversion of the starting material and reactions 
conducted in ambient light afforded diminished yields relative to blue LED irradiation (entries 9-
11). 
The clean reaction profiles afforded by these mild, photocatalytic conditions were in sharp 
contrast to the results we obtained with model substrate 6.13 using traditional methods for 
oxidative dearomatization. Pb(OAc)4, PIDA and IBX afforded a number of byproducts including 
structural isomers, overoxidation to quinone products due to decomposition upon exposure to 
strong oxidants and challenges in separating the stoichiometric oxidant byproduct. 
Chapter 6.3 Mechanistic Studies 
The quenching rates for each of the reaction components were measured using Stern−Volmer 
analyses.19 Under both aerobic and anaerobic conditions, tris was found to quench the FMN 
excited state, with quenching rates (kq) of 2 × 108 M
−1 s−1 (see Figures 6.10 and 6.12 and Figure 
6.16). However, when the phenolate was employed as the photo quencher in pH 7.0 water the 
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quenching rate was found to be two orders of magnitude faster than the rate of tris quenching (see 
Figures 6.6 and 6.8 and Table 6.14). Under aerobic conditions, the phenolate gave a decreased rate 
due to the formation of product as evidenced in the UV-Vis spectrum (see Figure 6.15). 
To gain experimental support for the formation of radical 6.11 under the reaction 
conditions, we attempted to trap the phenoxy radical with several radical trapping reagents and 
found that in the presence of TEMPO the appropriate adduct mass was observed by MS (Figure 
6.2B). With preliminary support for the intermediacy of a radical such as 6.11 we next sought 
support for this phenoxy radical being on a productive pathway to dearomatized product. To 
generate radical 6.11 by alternative means, 6.13 was subjected to AIBN under aerobic conditions. 
Figure 6.2: A) Proposed catalytic cycle for PCOD. B) Mechanistic studies. Inset: Stern-Vollmer plots. Standard 
conditions: 0.4 mol% FMN, 50 mM tris pH 8.0 buffer, rt, blue LEDs 2h. 
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These conditions produced 10% of the dearomatized product along with a number of additional 
oxidation products, including the Baeyer-Villiger oxidation product. With evidence for the 
intermediacy of the substrate radical our attention turned to the source of hydroxyl group 
incorporated into the final product. 
 Our observation of the peroxy product by mass spectrometry and UV-Vis was support for 
the role of O2 as the oxygen atom donor. To probe the operation of a second mechanism which 
could proceed through a carbocation arising from a second PSET, we performed the reaction in 
isotopically labeled water (Figure 6.2B). As predicted, we observed no incorporation of the 
labelled water in the hydroxylated product, providing support against the intermediacy of a 
carbocation species en route to dearomatized product 6.14. It has been reported that in the presence 
of amine reductants and light, flavin containing species are capable of forming hydrogen 
peroxide.21 In order to determine if this oxidant might play a role in the photocatalytic oxidative 
dearomatization, model substrate 6.13 was subjected to the optimized reaction conditions with five 
equivalents of 18O-labeled hydrogen peroxide (Figure 6.2B). Again, no incorporation of 18O was 
observed in the dearomatized product.  
 Finally, we hypothesized that photoexcited flavin might be responsible for generating 
singlet oxygen which then could undergo nucleophilic attack by our phenolate 6.10.22 The addition 
of the strong singlet oxygen quencher sodium azide did result in a diminished yield of the product; 
however, the reaction was not sufficiently suppressed to implicate singlet oxygen as the terminal 
oxidant. 
Based on these data and previous reports of flavin mediated oxidation of arenes12-16 and 
experimental observations, we propose the following mechanism for the photocatalytic oxidative 
dearomatization (Figure 6.2A). First, photoexcitation of the flavin photocatalyst could afford 6.16, 
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which subsequently performs a single electron oxidation of phenolate 6.10. The resulting neutral 
substrate radical 6.11 could then undergo a recombination event with triplet oxygen to form 
peroxyl radical 6.18. SET from flavin semiquinone 6.17 to 6.18 would afford peroxy intermediate 
6.19, which has been observed by MS and disproportionates over time to the desired product and 
water.  
We envisioned employing this photocatalytic oxidation to access the phenoxy radical 
which could then undergo C-C or C-X bond formation by reacting with a radicalphile. However, 
the addition of electron-deficient and electron-rich olefins, metal catalysts, fluorine atom and 
trifluoromethyl radical donors each resulted in attenuation of reactivity and no new adduct masses 
by MS. We hypothesized that the inherit stability of the neutral substrate radical precluded reaction 
with low-energy species and that the addition of Lewis acids results in coordination of the 
phenolate substrate which is then unreactive in the single-electron oxidation. 
Chapter 6.4: Substrate Scope 
Having obtained support for the proposed catalytic cycle, we next investigated the substrate 
scope of this photocatalytic oxidative dearomatization. We were gratified to find several structural 
perturbations from the model substrate 6.13 were tolerated, including alternative electron-
withdrawing moieties at C1 were dearomatized cleanly (Figure 6.3), however these reactions had 
to be conducted under an oxygen atmosphere to obtain high conversions. Interestingly, we found 
that the presence of an electron-withdrawing group at C1 was critical to obtain a dearomatized 
product rather than the known C–H oxidation product.12 We hypothesize that the added resonance 
stabilization of the extended π-system in these compounds is critical to allow for sufficient radical 





Figure 6.3: Substrate table for photocatalytic oxidative dearomatization. 
Chapter 6.5 Conclusions 
In conclusion, we have developed a photocatalytic method for oxidative dearomatization 
of densely functionalized arenes using molecular oxygen as the stoichiometric oxidant. The clean 
reaction profile of this photocatalytic transformation makes it an attractive alternative to traditional 
small molecule-mediated methods. The mechanism of this transformation has been investigated 
using a number of techniques, including luminescence quenching, radical trapping reagents, and 
isotopic labeling studies. Current limitations of this method include the requirement for a carbonyl 
group ortho to the hydroxyl group. This method allows for the generation of highly substituted o-
quinols including azaphilones under mild, photocatalytic conditions. Work to expand this 
methodology to include less-electron rich arenes by tuning the redox properties of the 
photocatalyst is currently underway. A new exciting frontier for this reaction manifold could be to 
utilize this methodology to enable alternative disconnects allowing access to C–C and C–X bond 
formation products through reaction of alternative radicalphiles with the phenoxy radical.   
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Chapter 6.6: Experimental 
Chapter 6.6.1: Protocol for PCOD 
General Procedure: Stock solutions of each substrate (50 mM) were prepared by dissolving the 
substrate in DMSO (analytical grade). Stock solutions of FMN (1.0 mM) and riboflavin (1.0 mM) 
were prepared in MilliQue water and stored at -20 °C. Substrates (20 mg, 2.5 mM final 
concentration) were added to a round-bottom flask containing 50 mM tris buffer pH 8.0. The 
desired photocatalyst was then added as a solution in water (final concentration 0.1 M, 0.4 mol%). 
Reactions were stirred at rt for 2 h under an O2 atmsphere, with white light illumination from hood 
lights. After 2 h, the reaction was quenched by addition of 1 M HCl (5 mL). The reaction was 
concentrated under reduced pressure to a final volume of approximately 2 mL. The resulting 
mixture was filtered through a 0.22 µm filter and purified by preparative HPLC using a 
Phenomenex Kinetex 5 µm C18, 150 x 21.2 mm column under the following conditions: mobile 
phase A = deionized water + 0.1% formic acid and B = acetonitrile + 0.1% formic acid; method = 




Prepared according to general procedure A. 9.4 mg (45%) of the title compound isolated as a 
yellow glass. All recorded spectra agreed with previously reported values.3 1H NMR (400 MHz, 






Prepared according to general procedure A. 16.9 mg (85%) of the title compound isolated as a 
yellow glass. All recorded spectra were in agreement with previously reported values.3 1H NMR 
(600 MHz, CD3CN): δ 7.91 (s, 1H), 6.27 (s, 1H), 5.46 (s, 1H), 2.43 (t, J = 7.5 Hz, 2H), 2.15 (s, 




Prepared according to general procedure A. 13.1 mg (61%) of the title compound isolated as a 
yellow glass. All recorded spectra agreed with previously reported values.3 1H NMR (600 MHz, 




Prepared according to general procedure A. 13.4 mg (63%) of the title compound isolated as a 
yellow glass. All recorded spectra agreed with previously reported values.3 1H NMR (600 MHz, 






Prepared according to general procedure A. 16.4 mg (91%) of the title compound isolated as a 
yellow glass. 1H NMR (400 MHz, CD3CN) δ 7.41 (s, 1H), 2.63 (m, 2H), 1.91 (s, 3H), 1.65 (m, 
2H), 1.44 (s, 3H), 1.43 (m, 2H), 0.96 (t, J = 7.3 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ; 201.3, 
199.2, 188.6, 137.1, 123.7, 117.4, 80.5, 32.5, 28.9, 28.4, 22.1, 14.6, 13.1; HRMS (ESI) m/z 
calculated for C13H19O4 [M+H]




Prepared according to general procedure A. 9.2 mg (42%) of the title compound isolated as a 
yellow glass. 1H NMR (400 MHz, CD3CN) δ 7.81 (s, 1H), 7.18 (s, 1H), 1.91 (s, 1H), 1.44 (s, 1H). 
13C NMR (150 MHz, CDCl3) δ 210.2, 206.7, 198.8, 161.6, 144.7, 125.9, 110.0, 28.3, 14.6; HRMS 
(ESI) m/z calculated for C9H11O4 [M+H]







Prepared according to general procedure A. 13.1 mg (62%) of the title compound isolated as a 
yellow glass. 1H NMR (600 MHz, CD3CN) δ 7.39 (s, 1H), 5.52 (dt, J = 12.8, 6.2 Hz, 2H), 2.68 (t, 
J = 7.7 Hz, 2H), 1.91 (s, 3H), 1.64 (d, J = 6.0 Hz, 3H), 1.44 (s, 3H). 13C NMR (150 MHz, CD3CN) 
δ 201.2, 199.1, 187.7, 137.2, 129.0, 126.6, 123.8, 105.9, 80.5, 32.8, 29.0, 17.1, 14.6. HRMS (ESI) 
m/z calculated for C13H17O5 [M+H]
+: 253.1071, found: 253.1069. 
 
Chapter 6.6.2: Stern-Volmer Plots 
The Stern-Volmer luminescence quenching studies were performed in duplicate using freshly 
prepared solutions of FMN (10 M) in MilliQue water at room temperature. Samples were 
prepared in a 1.0 cm cuvette by adding 1.0 mL of the photocatalyst solution and the appropriate 
amount of the quencher solution, and diluted with MilliQue water to 1.5 mL. The solutions were 
irradiated at = 450 nm and luminescence was detected at  = 530 nm.  
 





Figure 6.5: Emission quenching of FMN in water in the presence of 0 to 2.5 mM substrate 6.13 under N2 
 
Figure 6.6: Stern-Volmer quenching experiments of FMN with 6.13 under N2. 
 
 
Figure 6.7: Emission quenching of FMN in water in the presence of 0 to 2.5 mM substrate 6.13 under air. 
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Figure 6.8: Stern-Volmer quenching experiments of FMN with 6.13 under air 
 
Figure 6.9: Emission quenching of FMN in water in the presence of 0 to 25 mM tris buffer, pH 8.0 under N2. 
 
 





Figure 6.11: Emission quenching of FMN in water in the presence of 0 to 25 mM tris buffer, pH 8.0 under air. 
 
Figure 6.12: Stern-Volmer quenching experiments of FMN with tris under air. 
 
 
Figure 6.13: Co-plot of Stern-Volmer quenching experiments of FMN with quenchers 6.13 and Tris buffer under 






= 𝟏 + 𝒌𝒒𝝉𝟎[Q]                                                   Equation (1) 
 
Figure 6.14: Summary of the luminescence quenching data for the evaluated quenchers. Rates were calculated 
according to Equation 1, where I0/I is the emission intensity ratio,  is the lifetime of the photosensitizer excited state, 
kq is the rate of quenching by quencher Q,  The lifetime of the emissive excited state of the FMN in the absence of a 






Part IV. Labeling studies 
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Figure 6.15: LC-MS trace of photocatalytic reaction in unlabeled water.  
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Figure 6.16: LC-MS trace of photocatalytic reaction in H2O18. 
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